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Abstract 
Stereotactic ablative body radiotherapy (SABR) is the standard of care for inoperable early-
stage non-small cell lung cancer (NSCLC) patients. However, thoracic tumours are 
susceptible to respiratory motion and, if unaccounted for, can potentially lead to dosimetric 
uncertainties. Respiratory gating is one method that limits treatment delivery to portions of 
the respiratory cycle, but when combined with intensity-modulated radiotherapy (IMRT), 
requires rigorous verification. The goal of this thesis is to optimize respiratory gated IMRT 
treatment planning and develop image-guided strategies to verify the dose delivery for 
future early-stage NSCLC patients.  
Retrospective treatment plans were generated for various IMRT delivery techniques, 
including fixed-beam, volumetric modulated arc therapy (VMAT), and helical 
tomotherapy. VMAT was determined the best technique for optimizing dose conformity 
and efficiency.  
A second treatment planning study that considered patients exhibiting significant tumour 
motion was conducted. Respiratory ungated and gated VMAT plans were compared. 
Significant decreases in V20Gy and V50%, predictors for radiation pneumonitis and 
irreversible fibrosis, respectively, were observed. 
The predominant uncertainty of respiratory gating lies in the ability of an external surrogate 
marker to accurately predict internal target motion. Intrafraction triggered kV imaging was 
validated in a programmable motion phantom study as a method to determine how 
correlated the internal and external motion are during ungated and gated VMAT deliveries 
and to identify potential phase shifts between the motions.  
KV projections acquired during gated VMAT delivery were used to reconstruct gated cone-
beam CT (CBCT), providing 3D tumour position verification. Image quality and target 
detectability, in the presence of MV scatter from the treatment beam to the kV detector, 
was evaluated with various imaging parameters and under real-patient breathing motion 
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conditions. No significant difference in image quality was observed for the CBCT 
acquisitions with or without the presence of MV scatter. 
This thesis explores the benefits of combining respiratory gating with IMRT/VMAT for 
the treatment of early stage NSCLC with SABR, and evaluates advanced on-board imaging 
capabilities to develop dose delivery verification protocols. The results of this thesis will 
provide the tools necessary to confidently implement a respiratory gated radiotherapy 
program aimed at improving the therapeutic ratio for early-stage NSCLC.  
 
Keywords 
lung cancer, respiratory motion, respiratory gating, intensity modulated radiation therapy 
(IMRT), volumetric modulated arc therapy (VMAT), stereotactic ablative body 
radiotherapy (SABR), flattening filter free (FFF), , intrafraction imaging, cone-beam CT 
(CBCT).  
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Chapter 1  
“The purpose of education is to replace an empty mind with an open one” 
 – Malcom Forbes 
1 Introduction  
1.1 Lung Cancer 
Cancer has recently surpassed cardiovascular disease as the leading cause of death in most 
countries1. In Canada, cancer accounted for 29.9% of all deaths compared to 19.7% from 
heart disease in 20112. More specifically, lung cancer is the leading cause of cancer death 
with a five-year survival rate of only 17% and 20,600 deaths estimated in 20152. Lung 
cancer can be further subdivided into two main groups, small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC), with 85% of all lung cancer diagnosed in the latter 
category. SCLC is a fast progressing disease and typically initiates in the centre of the 
lung3. NSCLC is subdivided into adenocarcinoma, where growth starts in the glandular 
cells in the outer part of the lung, squamous cell carcinoma, which initiates in squamous 
cells lining the bronchus, and large cell carcinoma, which can grow anywhere in the lung 
and exhibits rapid progression. Patients are classified based on the TNM staging system, 
that describes the characteristics of the tumour, node, and metastasis (Table 1-1).  Early-
stage (T1-2, N0) NSCLC where lesions are localized and have not metastasized to regional 
lymph nodes, account for approximately 14% of the total lung cancer4. Effective treatment 
options for these lesions are either surgery, radiation therapy, or both. In this thesis, we 
focus on contemporary radiation therapy techniques.  
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Table 1-1: The TNM staging of NSCLC. Table adapted from Edge et al. 2,5 
Stage Tumor (T) Nodal (N) Metastasis (M) 5-year survival 
Occult Carcinoma TX            N0 M0  
0 Tis N0 M0  
IA T1a,b N0 M0 49% 
IB T2a N0 M0 45% 
IIA T2b N0 M0 30% 
 T1a,b N1 M0  
 T2a N1 M0  
IIB T2b N1 M0 31% 
 T3 N0 M0  
IIIA T1a,b T2a,b N2 M0 14% 
 T3 N1, N2 M0  
 T4 N0, N1 M0  
IIIB T4 N2 M0 5% 
 Any T N3 M0  
IV Any T Any N M1a,b 1% 
T denotes tumour size: 
x: Primary tumour cannot be assessed, tumour proven by presence of malignant cells but not visualized by 
imaging or bronchoscopy 
is: Carcinoma in situ 
1: Surrounded by lung or visceral lung without bronchoscopic evidence of invasion more proximal than lobar 
bronchus. 
   1a: Tumor 2 cm or less in greatest direction 
   1b: Tumor more than 2 cm but less than 3 cm in greatest direction 
2: Tumor has any of: involves main bronchus, 2 cm or more from carina; or invades visceral pleura; associated 
with atelectasis, or obstructive pneumonitis that extends to the hilar region but does not involve entire lung 
   2a: Tumor more than 3 cm but less than 5 cm in greatest direction 
   2b: Tumor more than 5 cm but less than 7 cm in greatest direction 
3:  Tumor more than 7 cm or one that directly invades any of: parietal wall, chest wall, diaphragm, phrenic 
nerve, mediastinal pleura, parietal pericardium; or tumour in the main bronchus less than 2 cm distal to the 
carina but not involving the carina; or associated atelectasis or obstructive pneumonitis of the entire lung, or 
separate tumor nodule(s) in the same lobe 
4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent 
laryngeal nerve, esophagus, vertebral body, carina, separate tumour nodules in a different ipsilateral lobe  
N denotes extent of regional lymph nodes spread 
0: No regional lymph node metastasis 
1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, 
including involvement by direct extension 
2: Metastasis in ipsilateral mediastinal and/or sub-carinal lymph nodes 
3: Metastasis in: contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, and 
supraclavicular nodes 
M denotes distant metastases 
0: No distant metastasis 
1: Distant metastases  
   1a: Separate tumour nodule(s) in a contralateral lobe, tumour with pleural nodules or malignant pleural 
effusion 
   1b: Distant metastasis (in extrathoracic organs) 
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1.2 Treatment Strategies for Early-Stage NSCLC 
1.2.1 Surgical Resection 
Surgical resection through lobectomy or sublobar resection, remains the standard of care 
in treatment of early-stage NSCLC patients. Lobectomy provides superior outcomes over 
sublobar resection with improved local control and extended overall survival (OS)6. 
Estimated 3-year OS for lobectomy is 79% and 80% for local and nodal recurrence free 
survival7, respectively. Although surgical resection has shown promising outcomes, it is 
often precluded due to significant co-morbidities, poor cardiac function, or decreased 
pulmonary reserve exhibited by the patient.   
1.2.2 Radiation therapy  
1.2.2.1 Conventional Radiation Therapy  
Options for early-stage NSCLC patients deemed inoperable or who refuse to undergo 
surgery are radiation therapy, or observation without cancer specific treatment. In external 
beam radiation therapy, the tumour is targeted using high energy x-rays. However, some 
dose is deposited to normal tissue along the x-ray beam paths to the tumour, as 
demonstrated for a sample patient in Figure 1-1. 
 
Figure 1-1. Colour wash of the dose distribution for an early-stage NSCLC patient. The 
prescription dose was 54 Gy (absorbed energy per unit mass, J/kg). The purple colour 
depicts the low dose deposited along the paths of the beams. 
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In deciding the prescription dose and dose distribution, the goal of radiation therapy is to 
provide the optimal tradeoff between targeting the tumour to increase tumour control 
probability (TCP), while reducing normal tissue complication probability (NTCP)8. 
Conventional three-dimensional conformal radiation therapy (3D-CRT) is delivered with 
a prescribed tumour dose of 60 Gy or more delivered over the course of six weeks, in 30 
daily fractions. The fractionation scheme of 2 Gy per fraction resulted in low NTCP, but 
unfortunately, outcomes of such conventional fractionations also yielded low TCP and 
overall survival, leading inoperable patients to forego any treatment options9,10. Dose 
escalation to early-stage NSCLC lesions has been shown to provide improved TCP11,12, but 
the increase in fractionation dose is associated with increased dose to normal lung, and 
potential worsening of NTCP.  
Dosimetric lung parameters used to predict radiation induced lung toxicities are the percent 
volume of lung receiving 20 Gy or more (V20Gy), the absolute volume of lung receiving 
50% of the prescription dose (V50%), and the mean lung dose (MLD)13–15. Treatment 
planning requires maintaining these dosimetric parameters as low as possible to help avoid 
potential radiation-induced lung toxicities. 
1.2.2.2 Stereotactic Ablative Body Radiotherapy (SABR) 
Over the past decade, stereotactic ablative body radiotherapy (SABR), a hypo-fractionated 
treatment technique imitating the surgical knife in ablating the tumor with a high dose of 
radiation delivered within a two-week period, has been implemented in the clinic16. 
Outcome studies for SABR have revealed impressive 3-year local control rates upwards of 
90%17–21. More recently, a study concluded SABR as a viable treatment option in operable 
early-stage NSCLC patient, with 3-year OS, and local or nodal recurrence free survival of 
95% and 86%, respectively, surpassing surgical outcomes of 79% and 80%, respectively 7.  
SABR treatment prescriptions vary based on organs at risk (OAR) in proximity to the 
target; lesions located adjacent to the chest wall are prescribed 55 Gy in five fractions, 
lesions located within 2 cm of the mediastinum are prescribed 60 Gy in eight fractions, and 
centrally located lesions are prescribed 54 Gy in three fractions, spanned over one or two 
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weeks. Conventional treatment for NSCLC includes a prescription dose of 60-66 Gy in 30 
daily fractions (or 6 weeks).  
1.2.2.3 Intensity Modulated Radiation therapy (IMRT) 
Treatment with intensity modulated radiation therapy (IMRT) in SABR leads to 
improvement in target dose conformity and reduction in toxicities to normal tissue22. 
Treatment is optimized by reducing the objective function based on set objectives for the 
target and normal tissue sparing.  Intensity gradients of dose are created by modulating the 
fluence of incident beams using a computer controlled multi-leaf collimator (MLC) to 
produce beam segments within each treatment beam. Efficiency in IMRT can be improved 
by incorporating automated treatment planning to set the beam geometry, create regions of 
interest to aid treatment planning, and to determine optimization objectives (Appendix A). 
There are different modalities to deliver IMRT that can be classified into: fixed beam 
IMRT (FB-IMRT)22,23, volumetric modulated arc therapy (VMAT)24,25, and helical 
tomotherapy (HT)26–28.  FB-IMRT implies the gantry is held stationary (per beam) while 
all segments required to modulate the beam are delivered. The FB-IMRT group can be 
further subdivided into step-and-shoot and sliding window techniques. In step-and-shoot 
delivery, the beam intensity pattern is the weighted summation of all its segments. During 
each segment, the MLC leaves remain stationary. In sliding window delivery, the MLC 
leaves transition during irradiation. VMAT treatments are designed using a broad treatment 
beam as the gantry rotates, simultaneously varying gantry speed, dose rate, and MLC leaf 
positions25. Modulation is dynamically achieved as the gantry rotates in an arc. Equally 
spaced positions along the arc are initially coarsely sampled (Figure 1-2A) followed by 
added sampling points equally spaced between previous points until desired spacing in 
sampling points is achieved (Figure 1-2)25. Another rotational IMRT modality, HT 
delivery, is a slice-by-slice treatment delivery using a fan beam, a binary MLC, and 
synchronizing couch motion through the bore, to gantry rotation during treatment. In the 
clinic, there is a lack of consensus on which IMRT technique is optimal for radiotherapy 
planning in SABR22–24,26. Chapter 2 of this thesis compares these various treatment options 
and techniques.  
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Figure 1-2. Continuous treatment beam and MLC motion in VMAT is modeled as static 
source positions initially coarsely spaced (a). During treatment planning optimization, 
sampling points are added midway between previous points (b, c).  The next sample set are 
added starting at the beginning of the gantry range (d). Additional samples are continuously 
added until the desired sampling frequency of gantry rotation is reached. Adapted from 
Otto25 
1.2.2.4 Dose Calculation Algorithms 
With increasing complexity of treatment planning and delivery, as in IMRT, the dose 
calculation algorithm selected during treatment planning is an important step to ensure 
quality of treatment plan. There are multiple dose calculation algorithms available, where 
Monte Carlo technique is considered the gold standard. Monte Carlo technique is a 
randomized statistical method to determine the probability of certain events occurring. In 
radiation therapy planning, for a large number of histories, the path of a particle is 
simulated by using knowledge of the probability of photon and electron interactions29,30. 
However, Monte Carlo based dose algorithms require long computational times.  Other 
dose calculation algorithms modelled include collapsed cone convolution (CCC), and 
Acuros XB.  
In convolution-based dose calculation algorithm, the modelled primary energy fluence is 
projected through the medium. The total energy released per unit mass (TERMA) is 
calculated at each voxel based on the mass attenuation coefficient of the medium and the 
primary fluence. The dose distribution is calculated by convolving TERMA with the dose 
point spread function, or kernels, at each voxel. Dose point spread functions are modelled 
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using Monte Carlo for a homogeneous phantom. Dose heterogeneity corrections are 
required to account for different densities. Dose calculation time is reduced from voxel 
based in convolution, to a set of arrays, or cones, in CCC to be convolved with TERMA31,32. 
CCC is applied clinically in all IMRT treatment delivery techniques described above.  
Acuros XB dose algorithm is based on a solution to the linear Boltzmann transport equation 
and directly handles the effects of tissue heterogenity33,34. The linear Boltzmann transport 
equation describes primary and secondary particle interactions as they travel through a 
medium. Acuros XB dose algorithm treatment planning results in similar dose distribution 
from Monte Carlo based algorithms for small fields with tissue heterogeneity, as in early-
stage NSCLC35-37. Both, CCC and Acuros XB dose algorithm, are applied in Chapter 2 of 
this thesis.  
 
1.3 Respiratory-Induced Target Motion  
In the treatment of thoracic cancer, interfractional changes include patient’s weight loss, 
tumour growth or shrinkage, and variations in respiratory motion pattern, and 
intrafractional motion includes cardiac, muscular and respiratory breathing motion. 
Respiratory motion induces variability in target position for both interfraction and 
intrafraction conditions.  
Respiratory breathing is comprised of involuntary and voluntary physiological 
mechanisms. In quiet breathing, the alveolar pressure, or the intrapulmonary pressure, is 
controlled by the diaphragm and intercostal muscles, Figure 1-3. During inhalation, the 
diaphragm, a dome-shaped muscle, contracts and descends, while the external intercostal 
muscles contract, and move the rib cage upwards and outwards. This allows a decrease of 
alveolar pressure relative to the atmospheric pressure, and air flows into the thoracic cavity. 
During expiration, the diaphragm muscle relaxes and ascends, and the intercostal muscles 
move downwards and inwards, simultaneously. The alveolar pressure increases relative to 
barometric pressure and air will flow out of the thoracic cavity.  
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Figure 1-3. Diagram displaying the process of quiet breathing. Adapted from Silverthorn 
et al.38  
The individual lungs are enclosed by the visceral pleura, and an outer membrane, the 
parietal pleura, surrounds the thoracic cavity maintaining separation from the mediastinum. 
The space in-between the visceral and parietal pleura creates the intrapleural space and 
helps keep the lungs inflated through the intrapleural pressure. Trans-pulmonary pressure 
is the difference between the alveolar pressure and the intrapleural space, typically about -
3 mmHg38. Pneumothorax, or collapsing of the lung, occurs if trans-pulmonary pressure 
drops to zero, causing fluid or air to fill the intrapleural space.  
The elasticity required to aid in exhalation and the lung tissue viscoelasticity causes an 
increase in the volume at the same pressure during inhalation, leading to lung hysteresis. 
This can lead to variabilities in the respiratory motion.  
The diaphragm is the most important muscle in quiet breathing accounting for 60% to 75% 
of lung volume changes. The contraction and relaxation of the diaphragm can lead to an 
increase in motion magnitude of proximal tumours, primarily in the superior-inferior (SI) 
direction. The intercostal muscles connect adjacent ribs and help enlarge the chest cavity 
in the anterior-posterior (AP), and lateral direction to allow more airflow38. In thoracic 
cancers, the lesion will move in conjunction with respiratory breathing motion. A study by 
Yu et al39 has reported a median tumour motion of 4.2 mm in the SI direction for early-
stage NSCLC. For lesions located in the lower lobes, a median tumour motion of 9.2 mm 
in the SI direction was observed39. Respiratory motion is unpredictable and variable 
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between patients and within the same patient over the course of treatment40–45. Therefore, 
different techniques have been developed to monitor breathing patterns during irradiation.  
1.3.1 Motion-Induced Dosimetric Uncertainties  
In the presence of motion, the static dose distribution to the target will be blurred, 
potentially causing under-dosage to the tumour and over-dosage to surrounding normal 
tissue. In a single IMRT fraction, the impact of intrafraction motion can result in errors up 
to 18% to 20% compared to the intended static target dose46–48. IMRT-defined radiation 
fields are not exclusively restricted by the primary collimators, but are defined by moving 
MLC leaves. The motion of the target is independent of the motion of the MLC leaves 
allowing for the potential of the target to unintentionally move in and out of these gradients. 
The lack of synchronicity between the MLC leaves and tumour motion causes an “interplay 
effect” and is not accounted for in radiation treatment planning systems. As radiation fields 
become more modulated, the potential for errors due to the interplay effect increases. Over 
the course of treatment, studies have shown that the interplay effect may average out for 
conventional fractionations, causing an estimated 2% error47,49.  However, lung SABR 
treatments are often limited to three to eight fractions, resulting in less opportunity for the 
interplay effect to average out. On the other hand, individual SABR treatments are longer, 
due to the increased dose per fraction, reducing the interplay effect on tumours that move 
by up to 1-cm50–54.  
Respiratory motion management is required for patients exhibiting large tumour motion 
amplitudes, highly modulated fields, and fast beam delivery54. According to the AAPM 
task group 76 on respiratory motion effects in radiation therapy, respiratory management 
techniques are advised for tumour motion greater than 5 mm to help reduce uncertainty in 
dose delivery and normal tissue toxicity55. Respiratory motion can expose surrounding 
healthy tissue to radiation and increase the risk of radiation-induced pulmonary toxicities56–
58. Two common toxicities associated with lung cancer radiotherapy are radiation 
pneumonitis, an early adverse effect, and irreversible fibrosis, a late effect13,59,60, further 
investigated in Chapter 3. 
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1.3.2 Motion Artifacts in CT Image Acquisition  
The precision of dose delivery relies on an accurate representation of a patient’s internal 
anatomy depicted by computed tomography (CT) imaging. A stationary subject is assumed 
during CT simulation, and respiratory motion hinders image quality by causing imaging 
artifacts in thoracic CT61–64.  During acquisition of an image slice, variability in respiratory 
phase causes slice displacement artifacts in the reconstructed CT volume. Tumour 
movement in-between the image slice acquisitions, inflicts geometric uncertainties in the 
reconstructed CT volume61, as shown by Figure 1-4.  
 
Figure 1-4. Respiratory motion induced imaging artifacts in CT.  A) Target motion as CT 
slices are acquired, B) Distorted reconstructed volume representation. Adapted from Balter 
et al.61 
Severity of imaging distortions are related to the sampling time per slice, slice thickness, 
gantry speed, respiratory motion period and amplitude, and size of the lesion. The resulting 
target volume exhibits geometric uncertainties i.e. shrinking or lengthening of the target, 
and discontinuities in the edge geometry (Figure 1-5). Respiratory motion induced artifacts 
from CT simulation are manifested as tumour and normal tissue delineation errors. These 
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distortions can adversely affect treatment plans, dose calculation accuracy, and in turn, 
treatment delivery.  
 
Figure 1-5. Reconstructed CT volume images with respiratory motion induced artifacts; 
A. True geometry for the static spherical object; B-E. Different artifacts obtained by 
standard axial CT scanning. Adapted from Rietzel et al63. 
Respiratory motion is more problematic for images acquired on a treatment machine for 
patient setup guidance before treatment, referred to as “on-board imaging”. The slow 
rotation speed in on-board CT imaging causes substantial respiratory induced artifacts, 
such as blurring, doubling, streaking, breakup, and distortions65–69 (Figure 1-6).  
 
Figure 1-6. Respiratory induced artifacts in on-board CT imaging. The image on the left 
is static square-shaped phantom, and the magnitude of motion applied to the phantom in 
the SI direction (or up and down direction) increases from left to right. Adapted from Song 
et al68. 
 
A. B. C. D. E. 
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1.4 Respiratory Motion Management Techniques 
Respiratory motion should be considered during both CT simulation and treatment 
delivery. The impact of respiratory motion in early-stage NSCLC can be limited through 
breath-hold methods, tumour immobilization, respiratory tumour tracking, and respiratory 
gating. Reduction in target motion results in smaller treatment field sizes, and potentially 
reduced normal tissue toxicity.  A brief overview of each method will be provided in the 
following subsections while respiratory gating will be explained in greater detail in section 
1.5.  
1.4.1 Motion-Encompassing Methods (4D-CT) 
Respiratory motion introduces imaging artifacts and hinders accurate localization of the 
tumour and internal structures acquired during 3D-CT simulation. Large margins for the 
tumour can be incorporated to ensure full target coverage for the observed range of motion, 
but cause greater risk of radiation induced toxicities to normal tissues. Imaging techniques 
that allow for better visualization of the envelope of target motion, and permit more 
accurate margins are required.  
Four-dimensional CT (4D-CT) is the most common approach that integrates organ motion 
into the acquisition of the CT dataset to facilitate treatment planning63,70–73. Here, 
volumetric image data is acquired at different respiratory phases by oversampling each 
slice position in synchrony with a respiratory breathing signal (Figure 1-7). Helical and 
cine acquisition mode are two techniques utilized to acquire 4D-CT dataset74. Slice 
positions in helical 4D-CT are oversampled by reducing the pitch, or reducing the ratio of 
the scanning table translation per gantry rotation. In cine mode, sequential CT data is 
acquired over a full breathing cycle at fixed scanning table positions.  
During 4D-CT acquisition, the respiratory motion of an external surrogate labelled with 
infrared reflective markers is tracked using an infrared camera. The external surrogate is 
placed between the xyphoid process and umbilicus, and records the AP motion of the 
abdomen surface. Respiratory phase is determined from the respiratory signal and the 
image data acquired simultaneously is tagged according to the corresponding respiratory 
phase (Figure 1-7B). Retrospectively, all acquired image data are sorted into different 
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phase bins (Figure 1-7A). If a respiratory trace is divided into ten bins, the 0% phase 
represents the end inhalation, 10% - 40% phase represent mid exhalation, 50% phase 
represents the end exhalation, and 60% - 90% phase represents mid-inhalation. A 3D-CT 
volume reconstructed from image data acquired from a single phase, represents a 3D 
volumetric image at one respiratory phase bin. A 4D-CT dataset is the collection of the 3D-
CT volumes reconstructed from all phases.  
  
Figure 1-7. 4D-CT phase-sorting process. In this simplified example, the acquired CT 
images are sorted into only four distinct bins (A) based on respiratory phase of the 
respiratory signal (B). Adapted from Vedam et al71. 
In early-stage NSCLC, 4D-CT imaging can facilitate target delineation to provide a 
representation of target excursions caused by full breathing motion. The gross target 
volume (GTV), can be contoured in each of the phases of the 4D-CT, where the union of 
all the phases represents the internal target volume (ITV), as shown in Figure 1-8.   
B. A. 
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Figure 1-8. 4D-CT image displays the gross target volume (GTV) in the end-inhalation 
(A), end-exhalation (B), the internal composite target volume (ITV) in green with the 
planning target volume (PTV) in yellow (C). Adapted from Glide-Hurst et al75. 
However, delineating the GTV and all OARs in all of the 4D-CT phases substantially 
reduces workflow efficiency. Instead, post-processing tools can derive 3D-CT datasets to 
provide a representation of the target. A time-averaged intensity CT image is generated 
from the average voxel value across the breathing cycle image data acquired to represent a 
blurred volume. Maximum intensity projection (MIP) 4D-CT is derived by fusing the 3D-
CT volumes of the different respiratory phases based on the maximum intensity of each 
voxel76–78.  In MIP images, the high density tumour appears brighter than low density 
lung63. MIP 4D-CT is useful for peripheral tumours but delineation of tumours in proximity 
to the chest wall, mediastinum, or diaphragm becomes more difficult. 
For SABR, 4D-CT dataset acquisition for treatment planning aids in determining the 
mean79, and range of tumour motion80. Improved delineation of the tumour and critical 
structures mitigates potential target misses, especially for tumours exhibiting large 
magnitude of motion81. 
The disadvantage of using motion-encompassing methods includes irradiating larger target 
volumes and, as a consequence, larger normal lung volumes. In tumours exhibiting motion 
greater than 5 mm, other methods to minimizing tumour motion during treatment delivery 
can yield significant normal tissue sparing55.  
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1.4.2 Breath-hold Methods  
A method to minimize target volumes during treatment is through control of respiratory 
breathing either voluntarily or by an occlusion valve 55,82. An occlusion valve is used in 
active breathing control (ABC), where air flow to the patient is temporarily blocked at end-
inhalation, immobilizing the lung and stalling target motion83,84. The treatment beam 
irradiation is enabled once the target has been immobilized according to the desired tidal 
volume. Another common breath-hold technique uses deep inspiration breath-hold (DIBH) 
where the patient voluntarily controls his or her breathing while interactively observing 
their respiratory trace82,85–88. Prior to treatment, the patient is coached through quiet 
breathing followed by two breathing periods of slow deep inspiration and expiration prior 
to the breath hold, as in Figure 1-985. This provides reproducible motion control at end-
inhalation. In both techniques, the breath is held for 10 – 20 seconds for every iteration. 
Respiratory motion is tracked during treatment using spirometry, surface markers, or an 
external surrogate. Regardless of the technique used for breath-holding during treatment 
(ABC or DIBH), the same management technique should be also used during CT 
simulation. 
Motion management through the use of breath-hold at deep-inspiration provides tumour 
immobilization and the added benefit of a reduced lung density that enhances tumour 
contrast and visualization85. 
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Figure 1-9. Deep inspiration breath-hold (DIBH) consists of slow quiet breathing session 
followed by a reproducible deep breath hold. Adapted from Hanley et al85. 
DIBH relies on active participation of the patients but inoperable NSCLC patients treated 
with SABR often exhibit poor pulmonary function and are often fragile, making breath-
hold a very challenging task. Another limitation during breath-hold is that some patients 
exhibit continuous diaphragm oscillatory motion, leading to fluctuations in tumour 
position55. 
1.4.3 Tumour Immobilization Methods 
The magnitude of respiratory motion during treatment and CT simulation can be minimized 
mechanically by forced shallow breathing. Abdominal compression is the most common 
approach where a body frame with pressure plate is applied to the patient’s abdomen to 
limit diaphragm motion89-91. The maximum possible pressure a patient can comfortably 
manage is pressed against the abdomen. The position and pressure applied during CT 
simulation, is recorded to provide reproducible setup during each treatment fraction.  
While attempting to minimize respiratory motion, abdominal compression is not well 
tolerated by patients92. Studies have shown a statistically significant increase in 
interfractional variation of tumour position for SABR lung patients treated with abdominal 
compression methods90,92,93.  
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1.4.4 Respiratory Tumour Tracking Methods 
In the above techniques, large margins are required to encompass the target as it moves 
during full respiratory motion, or suppressing tumour motion through breath-hold and 
abdominal compression causes discomfort to the patients that may be intolerable. In 
respiratory tumour tracking, the patient breathes freely and target margins are reduced by 
tracking the tumour motion within the radiation beam94. Safe incorporation of respiratory 
tracking requires monitoring of the tumour trajectory, and compensation for the tumour 
motion geometrically and dosimetrically.  
The motion trajectory of the target can be acquired through imaging, such as fluoroscopy, 
for lesions located centrally in the lung where normal structures will not obstruct visibility; 
however, lesions located adjacent to normal tissue (diaphragm, mediastinum, and chest 
wall) will lack visibility. Fiducial markers are high atomic number metals, typically gold 
pellets, and can provide high contrast when implanted within the lesion of interest using a 
percutaneous or bronchoscopic implanting technique. Three or more fiducial markers are 
required to allow for measurements of rotation and translation between the markers55. The 
position of fiducial markers within the tumour, is determined using imaging or from an 
emitted radiofrequency (RF) signal. However, placement of fiducial markers is an invasive 
procedure, and can be susceptible to migration during treatment. External surrogates on the 
chest can be used alternatively to account for breathing motion if the correlation with 
tumour trajectory motion can be verified.  
The radiation beam mechanically follows the tumour using MLC tracking95,96 or a robotic 
linear accelerator with six degrees of freedom97–99. However, delays in linear accelerator 
reposition once motion coordinates are determined can occur; in the case of MLC tracking, 
time delays of 200 ms or more occur100. There are additional time delays for determining 
the coordinates of the tumour in the images. Position predictive algorithms based on 
previously acquired motion trajectory are used to prospectively adapt the radiation beam.  
These algorithms assume periodicity of motion from planning to treatment delivery101.  As 
mentioned in section 1.3.1, respiratory motion may exhibit both inter- and intra- fractional 
variability42,45,102. 
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Radiation treatment planning requires computation of dose distributions in all the 
respiratory phases of the 4D-CT dataset because of geometric displacements and lung 
density changes. The relationship between respiratory phase and the tumour motion 
trajectory, adapts the treatment dosimetrically103.  
A summary of the different motion management techniques is provided in Table 1-2.
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Table 1-2. Summary of the different methods of respiratory management and variations in intra- and inter-fraction motion. 
Abbreviations: BH: breath-hold, ABC: active breathing control, SD: standard deviation, LR: left-right, AP: anterior-posterior, SI: 
superior-inferior, DIBH: deep inspiration breath-hold, *includes setup error, 3D—3-dimensional error, mDIBH moderately deep 
inspiration breath-hold. Adapted from Keall et al55. 
Motion 
Management 
Technique 
Advantages  Disadvantages Study Mitigation 
Method 
Intra-fraction 
variation (cm) 
Inter-fraction 
variation (cm) 
Breath-hold - Limited 
tumour 
motion 
- Reduced lung 
density 
- Does not 
require 
specialized 
software and 
hardware 
- Efficient due 
to continuous 
treatment 
beam during 
breath hold 
- May require 
patient active 
participation  
- Patient exhibit 
continuous 
diaphragm 
motion 
 
Cheung et 
al104 
BH at 
inspiration with 
ABC 
- 
SD: 0.18 LR, 
0.23 AP, 0.35 
SI 
 Dawson et 
al105 
BH at exhalation 
with ABC 
SD: 0.25 SD: 0.44 
 Remouch-
amps et 
al106 
mDIBH with 
ABC 
Mean: 0.14  
SD: 0.17 
Mean: 0.19 
 SD: 0.22 
 
Hanley et 
al85 
DIBH 
Mean: 0.1  
SD: 0.09 
Mean: 0.25 
SD: 0.16 
Tumour 
Immobiliza-
tion 
- Limit tumour 
motion 
- Not well tolerated 
by patients  
Negoro et 
al107 
Abdominal 
compression  
Mean 3D: 0.7 
Range: 0.2–
1.1 
Mean 3D: 
0.49* Range: 
0.4–0.8* 
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 - Significant 
interfraction 
variation 
Wulf et al89 
Abdominal 
compression  
- 
SD: 0.33 LR, 
0.34 AP, 0.44 
SI 
 Bissonnette 
et al90 
Abdominal 
compression 
Mean 3D: 
0.24 
Mean 3D: 0.3 
 
Mampuya 
et al93 
Abdominal 
compression 
- 
SD: 0.21 LR, 
0.19 AP,  
0.31 SI 
Respiratory 
Tracking 
- Patient is free 
breathing 
- Treatment 
time is not 
limited 
- Adapts to the 
full 3D 
motion 
- Requires periodic 
respiratory 
breathing  
- Mechanical delay 
uncertainties  
Hoogeman 
et al108 
Robotic linear 
accelerator 
SD: 0.19 LR, 
0.25 AP,  
0.19 SI 
- 
Respiratory 
gating  
- Limit tumour 
motion 
- Patient is free 
breathing 
- Increased 
treatment time  
- Internal target 
and external 
surrogate 
correlation 
uncertainty 
Ford et 
al109 
Gating at 
exhalation with 
RPM 
Mean: 0.26  
SD: 0.17 
Mean: 0.0  
SD: 0.39 
 
Wagman et 
al110 
Gating at 
exhalation with 
RPM 
Mean: 0.20 - 
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1.5 Respiratory Gating Methods 
Respiratory gating also allows the patient to breath freely, and the treatment beam is 
triggered only within a predetermined portion of the breathing cycle111–116. In respiratory 
gating, the portion of the breathing waveform where the treatment beam is activated, is 
coined the “gating window”. The gating window is predetermined according to the stable 
portion of the breathing cycle, most often during the end-exhalation period. The respiratory 
motion within the gating window is considered as the residual motion117. The respiratory 
gating efficiency, or duty cycle, is defined as a percentage of the “beam on” time to total 
treatment time112. The gating window is determined based on a tradeoff between limiting 
residual motion, and optimizing the duty cycle to reduce overall treatment time. A subset 
of the 4D-CT dataset corresponding to the respiratory phases within the intended gating 
window are averaged to form the subset average 4D-CT dataset that is used for treatment 
planning.  The subset average 4D-CT incorporates the residual motion within the gating 
window. The ITV, in this case, is generated based on the blur of the target volume in the 
subset 4D-CT. Planning and set-up uncertainties are included in the planning target volume 
(PTV) by the addition of a margin to the ITV, in early-stage NSCLC 5 mm margin is 
used117. The result is a significant reduction in the target margins compared to conventional 
free breathing ungated radiotherapy and as a result, reduced normal tissue irradiation111.   
Internal respiratory gating, similarly to respiratory tracking, is facilitated through the use 
of fiducial markers118. Originally developed by Mitsubishi Electronics Co. (Tokyo, Japan), 
internal gating defines the gating window through fluoroscopic detection of fiducial 
markers during treatment. Position of the fiducial markers is identified during treatment in 
three dimensions using four sets of diagnostic x-ray imaging systems. Within the gating 
window, the x-ray kV acquisition pulses are interlaced with the treatment MV pulses to 
avoid scatter from the MV reaching the fluoroscopic detectors. As mentioned previously, 
implantation of the fiducial markers is an invasive procedure generally not well tolerated 
by inoperable SABR patients.  
External respiratory gating relies on surrogate signals of a respiratory motion, and is a non-
invasive alternative method for respiratory gating applicable to almost all patients55. The 
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external surrogate is an infrared reflective plastic box (Figure 1-10A) placed between the 
xyphoid process and the umbilicus, to maximize the AP motion. During 4D-CT acquisition, 
a mark is tattooed on the patient’s skin to ensure reproducible placement of the external 
surrogate box during treatment. Infrared markers on the surrogate box have fixed non-
symmetric positions to facilitate observation of potential misalignment during geometric 
calibration. The displacement of the external surrogate box is detected by the position 
sensors with the in-room infrared camera (Figure 1-10B) generating a respiratory trace.  
 
Figure 1-10. Respiratory gating external surrogate box with infrared markers (A) and 
infrared Polaris Spectra NDI camera that tracks the markers (B). 
Prior to each treatment session, the starting phase of the respiratory trace is matched to the 
corresponding phase in the reference trace, recorded during 4D-CT acquisition (Figure 
1-11) and used in treatment planning. Irregularities between 4D-CT acquisition and 
treatment session breathing traces can be reduced through respiratory breathing training. If 
the recorded waveform period does not match the reference waveform, the treatment beam 
is triggered “off” and will not be allowed to begin.  
In Figure 1-11, the gating window is dictated by the upper and lower gating thresholds. If 
the thresholds are set to the same range, system will consider the gate as fully open and 
beam holding will not occur.  
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Figure 1-11. Respiratory chart demonstrating the gating window (yellow shaded area) 
defined by the upper and lower gating thresholds (blue and orange lines, respectively). The 
reference trace from the 4D-CT acquisition is demonstrated by the green waveform, and 
the treatment waveform is displayed by the black waveform. Adapted from VitalBeam 
imaging manual119. 
1.5.1 Amplitude Gating 
Amplitude gating is based upon the displacement of the external surrogate box as a 
representative metric of the tumour at a certain position (Figure 1-12)116. The total 
displacement in the respiratory signal is the position difference between end-inhalation and 
end-exhalation. The respiratory waveform shown in Figure 1-12 displays the amplitude, or 
motion above the baseline, versus time.  The gating window, shown by the highlighted 
yellow area in Figure 1-12, is defined as a window of displacement (solid line) allowed 
from end-exhalation.  
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Figure 1-12. Amplitude based respiratory gating waveform. The solid black curve 
represents the waveform trace as a function of time, whereas the dashed black lines 
represent the recurring respiratory phase (0 to 2π radians) as a function of time. The upper 
and lower thresholds are displayed by the blue and orange lines, respectively. The gating 
window is shown in the shaded yellow area.  
1.5.2 Phase Gating  
A sinusoidal pattern is used to approximate the real-patient waveform and analyze the 
respiratory waveform. Phase values of a full breathing cycle (0 to 2π radians) are converted 
into percent and divided into 10 equal bins ranging between 0% to 100%119. In the “needle 
diagram” (Figure 1-13A) the end-inhalation is represented by 0% and end-exhalation by 
50%. Inhalation occurs when the needle is in the left half of the dial (50%-100%), whereas 
exhalation occurs in the right half of the dial (0%-50%). In phase gating, the gating window 
is represented by two angular positions (dashed line) of the respiratory waveform (Figure 
1-13B)116.  
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Figure 1-13. Phase based respiratory gating waveform: A) Needle diagram representing 
cyclic phase where the orange tick mark represents the entry to the gating window, and the 
blue tick mark represents the exit of the gating window; B) Displacement waveform as a 
function of time is shown in the solid black line, whereas the dashed black lines represent 
the respiratory phase as a function of time. The entrance and exit of the gating window are 
displayed by the orange and blue lines, respectively. The gating window is shown in the 
shaded yellow area. 
1.5.3 Learning Respiratory Motion  
For both amplitude gating and phase gating, the respiratory waveforms are analyzed for 
reproducibility. Raw data points from the external surrogate box are converted into a 
smooth wave using polynomial fitting119. The end-inhalation and end-exhalation are 
attained through a peak and trough detection to produce an estimate of the breathing 
respiratory period. Each peak is assigned at 0%, with succeeding peak assigned at 100%. 
A fixed value for end-exhale is not assigned but it is estimated to be around 50%. The 
respiratory phase of end-exhalation depends on the pattern of the breathing cycle, in 
respiratory traces exhibiting longer inhalation than exhalation, end-exhalation will occur 
at phases <50%, whereas, respiratory traces exhibiting shorter inhalation than exhalation, 
end-exhalation will occur at phases >50%. 
Patient breathing characteristics are measured during the learning period that lasts for four 
complete breathing cycles. Within the learning period, respiratory motion is required to be 
periodic in order to provide a reproducible breathing trace. Fast breathing peaks in the 
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learning period, defined as less than 1.5 seconds between consecutive inhalation or 
exhalation peaks, or 0.5 seconds between inhalation and exhalation peak, are ignored and 
not included in the motion characteristics analysis. The average end-exhale position is 
measured over the learning period and assigned as the baseline value. The baseline value 
is set to zero in the respiration chart and is only updated if re-learning of the breathing trace 
is required. The respiratory trace acquired during 4D-CT is used as a reference and re-
learned if necessary, prior to every treatment session. 
The periodicity of respiratory breathing trace is measured by calculating a phase-
displacement scattergram (Figure 1-14). Predictive filters are employed to correct for 
irregular, non-periodic breathing by setting a threshold for the beam “on”120. The predictive 
filter aids in restricting inaccurate treatment delivery by triggering the beam “off” when 
the motion does not match the 4D-CT reference values within a predefined tolerance. In 
respiratory gating, the treatment beam is paused if respiratory position falls outside of the 
gating window, or if the motion periodicity falls outside of the predictive filter margins. 
 
Figure 1-14. Characterizing periodicity in respiratory breathing trace. Examples for a 
regular and irregular breathing cycles are shown. A sample gating window is displayed for 
amplitude (blue shaded) and phase (red shaded) gating with a 40% duty cycle.  
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1.5.4 Respiratory Gating Limitations  
The respiratory gating window is optimized based on a tradeoff between duty cycle and 
residual target motion. As duty cycle is minimized, treatment session times are increased. 
Increased treatment time may cause intrafractional setup errors due to potential movement 
from patient discomfort. Patient throughput on the treatment machine is also reduced by 
increased treatment times. Studies have indicated potential reduced tumour control for 
treatments that require longer than 20 mins122,122. This becomes increasingly important 
with the combination of high dose per fraction SABR prescriptions, with respiratory gating.  
Respiratory phase analysis relies on a sinusoidal approximation, leading to substantial 
inconsistencies for patients that exhibit irregular respiratory motion (Figure 1-14). Phase 
calculations are based on preceding breathing cycles so that inconsistencies between 
breathing cycles will produce incorrectly defined respiratory phases. By comparison, 
amplitude gating has demonstrated less variability when respiratory motion lacks 
periodicity123–125.  
The large uncertainty in external respiratory gating lies in the accuracy of an external 
surrogate marker to predict the internal motion of the tumour. The magnitude of 
displacement between the external surrogate and tumour motion does not need to be the 
equal but must be correlated. However, correlation is contingent on the external signal 
phase predicting the internal tumour respiratory phase. The inability to observe tumour 
motion directly leads to uncertainties in the displacement and phase relationship between 
the surrogate and the tumour126.  
The internal and external correlation is disrupted or lost completely by transient and 
continuous changes in respiratory motion breathing or instability in oscillatory mechanical 
systems55,127. Lack of correlation can cause the radiation beam to trigger incorrectly in parts 
of the breathing cycle (Figure 1-15). The external surrogate and internal target correlation 
is further investigated in Chapter 4 of this thesis. 
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Figure 1-15. Comparison of the internal and external motion without a phase shift (a), and 
with a phase shift (b). The red lines indicate beam exposure times that are out of synchrony 
with the target motion. Adapted from Keall et al55 
Respiratory gated treatments are susceptible to inter-fraction variability in tumour and 
external surrogate relationship, requiring relearning of periodicity before each fraction. The 
risk of baseline variations increases with treatment time leading to the tumour movement 
outside the gating window128. Intrafractional variation can cause discrepancies in dose 
delivery with some targets being on the verge of under-dosage129,130. 
 
1.6 High Dose Rate Gated SABR 
1.6.1 TrueBeam Linear Accelerator  
The Varian TrueBeamTM (Varian Medical Systems, Palo Alto, USA) linear accelerator 
(LINAC) is a recent technical development that allows for the integration of respiratory 
gating with VMAT and is the subject of Chapters 3-5. Respiratory-gated VMAT provides 
the ability to safely combine the normal tissue sparing capabilities of respiratory gating to 
superior treatment efficiency achieved through VMAT131. In respiratory gated VMAT, the 
interplay effect contributes insignificantly to dose delivery errors due to minimal residual 
motion, although increased motion irregularity in patients treated with gated VMAT has 
shown to negatively affect the intended dose distribution50,132.  
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Treatment delivery efficiency is improved by removing the flattening filter to enhance dose 
rate. The flattening filter is located prior to the monitor chambers and succeeding the target 
and primary collimators. The distribution of photons after the target is strongly forward 
peaked, and the conical shaped flattening filter is used to obtain a uniform dose distribution 
at a referenced depth. However, the role of the flattening filter is negligible for SABR 
treatments due to the associated small field sizes (Figure 1-16). The advantage of flattening 
filter free (FFF) beams is an increase in photon fluence allowing for higher treatment dose 
rates (monitor units (MU) per minute). For example, a 10 MV FFF x-ray beam has a peak 
dose rate of 2400 MU/minute, and a 6MV FFF beam has a peak dose rate of 1400 MU/min.  
A conventionally flattened beam, on the other hand, has a peak dose rate of only 600 
MU/minute133. The application of FFF beams in SABR treatments has significantly 
improved efficiency134–136 while radiobiological properties are maintained137. Increased 
efficiency in treatment times reduces potential intrafraction errors from patient movement, 
as has been observed for treatment session times lasting more than 30 minutes138.  
  
 
Figure 1-16. Axis dose profile at different depths in water, comparing flattened beams (A), 
and FFF beams (B). The dose rates have been renormalized at a central depth of 2 cm. 
 
Another feature of TrueBeam linac is the “Research Mode” interface that allows a 
knowledgeable user to program motion trajectories of major accelerator components. 
Research Mode provides access to the user to go beyond clinically approved modalities 
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and investigate novel treatment and imaging techniques in a non-clinical setting139–143. The 
user formulates specific axes of motion for each of the imaging and treatment delivery 
trajectories, such as gantry, collimator, on-board kV imaging source and detector, etc, as a 
function of cumulative dose, written in extensible markup language (XML).  
1.6.2 Pre-Treatment Verification  
As radiotherapy planning and delivery is becoming increasingly complex, dose delivery 
verification (i.e. quality assurance) are even more necessary.  For respiratory gated 
radiotherapy, verification of the intended gating window and the relationship between the 
external surrogate motion and internal tumour motion is required during treatment delivery. 
Image-guided radiation therapy (IGRT) has therefore been implemented prior and during 
treatment to facilitate patient set-up, detect patient deformation from CT-simulation to 
treatment delivery, and for dose verification.  
Prior to treatment delivery, on-board imaging (OBI) or the electronic portal imaging device 
(EPID) can be used to facilitate patient set-up and ensure there are not any significant 
deformations in patient anatomy between the plan and the delivery session (Figure 1-17).  
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Figure 1-17. Varian TrueBeam mounted on-board imaging (red squares) and electronic 
portal imaging detector (orange square). 
The EPID uses the MV beam to acquire a single image of the patient for setup verification. 
Patient bony anatomy landmarks on the image can be used to guide patient alignment. High 
energy photons reduce the overall noise in MV images144. However, poor image contrast 
from the MV energy x-rays hinder soft tissue and, often, bony anatomy visualization.  
On-board kV imaging, achieves contrast superior to images acquired with an MV source145. 
The TrueBeam LINAC allows acquisition of a pair of orthogonal respiratory gated kV 
radiographs. During respiratory gated patient setup, these planar images are compared to 
digital reconstructed radiographs (DRR) generated from the planning CT dataset145,146.  
The TrueBeam LINAC allows for kV fluoroscopy. The ability to also acquire a respiratory 
trace simultaneously with the external marker block brings forth real-time monitoring and 
correlation of visible lung structures. The position of the tumour can be determined as a 
function of time. If the visibility of the tumour is poor, another moving anatomic surrogate, 
such as the diaphragm, can be used to define the relationship of internal motion with the 
kV source  kV detector   
MV detector   
MV source  
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external surrogate motion.  The gating window should be adjusted if a consistent time delay 
of 0.5 sec or greater exists between internal and external surrogate motion55. To limit 
radiation dose during continuous imaging, the imaging voltage and current can be lowered, 
at the cost of image quality. 
Continuous kV imaging acquired at multiple gantry angles allows for generation of a 
volumetric cone-beam CT (CBCT)138. Volumetric CBCT permits soft tissue matching with 
the treatment planning CT. There are two different types of filter applied to modify the kV 
energy spectrum, in order to improve image quality. A 0.89 mm titanium filter is applied 
to remove low-energy x-rays in the beam. Whereas, the bowtie filter is an aluminum shaped 
filter applied to compensate for greater attenuation by the patient at center field, and reduce 
patient skin dose.  In full-fan CBCT, using a full-bowtie filter, the FOV is limited by the 
detector size. In scans where patient size surpasses the detector size, such as thoracic scans, 
half-fan CBCT scanning technique is used. In half-fan CBCT, using the half-bowtie filter, 
the FOV width is increased by offsetting the position of the detector and scanning only half 
of the patient for part of the rotation and offsetting the position of the detector in the 
opposite direction for the remainder of rotation. The shifted projections are retrospectively 
stitched together.  
1.6.3 Intrafraction Treatment Verification 
Pre-treatment verification aids in diminishing inter-fractional uncertainties. However, 
intra-fractional uncertainties are still persistent during SABR lung treatments128 and can 
inhibit treatment delivery accuracy if not accounted for. 
Acquiring MV portal imaging during treatment can allow for a dosimetric and real-time 
verification of radiation dose delivery. The EPID can acquire beam’s-eye-view (BEV) 
projections throughout treatment. Either a “single shot” image can be acquired or a 
synchronized MV, or cine loop, can be used to acquire continuous readout of images 
between beam pulses147. Both provide a utility to verify the target is within the gating 
region. For dosimetric verification using unsynchronized MV, the EPID can be operated 
in integrated mode and continuously reads out and assimilates acquisitions, resulting in a 
single image representing the total dose delivered per beam. These images can be used to 
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reconstruct the 3D dose distribution for comparison to the planned dose distribution; 
deviations in the accumulated dose could be accounted for in subsequent fractions148. MV 
imaging using FFF beams during treatment provides shaper images compared to standard 
flattened beams, due to a reduction in primary head scatter149.  
A technique to combine kV and MV imaging for intra-treatment verification in VMAT and 
fixed beam IMRT is discussed by Ren et al139. For clinical respiratory-gated delivery 
verification, kV imaging can been triggered prior to or at the exit from the gating 
window150–152.  However, triggered kV imaging is limited in examining residual motion 
inside the gating window. Geometrical verification and residual motion analysis can be 
investigated through kV fluoroscopy during treatment153. Fluoroscopic imaging acquired 
during respiratory gated SABR treatment provides additional intrafraction information at 
the cost of additional imaging dose. Also, the ability to trigger fluoroscopic imaging only 
within the gating window is not possible in current clinical mode of operation. Therefore, 
longer treatment times associated with respiratory gated SABR, make this application 
impractical due to the significant increase in imaging dose to the patient and the strain on 
the x-ray tube. In chapters 3 and 4 of this thesis, respiratory gated kV imaging is 
investigated using Research Mode of operation.  
The image quality of in-treatment fluoroscopy is significantly reduced due to patient scatter 
of the treatment beam to the kV detector154. The percent of the scatter dose from the 
isocenter to the detector ranges between 0.0154% to 0.0174% for 10 cm by 10 cm field 
size with a 10 MV beam (Appendix B)155. Different groups have investigated removing the 
MV contribution to the kV detector through readout of unexposed kV frames156, and 
interlacing kV projections between MV pulses157,158.  
 
1.7 Research Questions and Hypothesis 
The aim of this research is to optimize and improve radiation treatment planning and 
delivery using state of art technologies for early-stage NSCLC patients treated with SABR. 
SABR fractionation schemes consist of high doses (54 Gy - 60 Gy) delivered in only a few 
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fractions (3–8), requiring very high precision in sparing normal tissue and dose target 
conformity to the target. However, respiratory motion is the major roadblock in treatment 
accuracy.  High dose SABR treatment delivery lessens potential averaging of respiratory 
motion uncertainties, as observed in conventional dose fractionations, and therefore 
escalates consideration of the moving target.  
Respiratory gating can mitigate the effects of respiratory motion, while the combination of 
respiratory gating with VMAT using high dose rate delivery of FFF beams can increase 
treatment efficiency. However, additional uncertainties are introduced in respiratory gated 
VMAT by the additional degrees of freedom, such as the gantry rotation and variable dose 
rate. Respiratory gating window will lead to multiple stops of the gantry motion, causing 
ramping up-and-down of the dose rate when entering and exiting the gating window. These 
potential uncertainties introduced in dose delivery must be studied. Advanced on-board 
imaging protocols in TrueBeam Research mode can be generated to provide intrafraction 
verification of respiratory gated VMAT. The following questions were articulated to 
address these concerns:  
 Which IMRT delivery technique optimizes dose distribution and delivery for early-
stage NSCLC patients?  
 Will respiratory-gated VMAT reduce the potential for radiation induced normal lung 
toxicity?  
 Can we safely use intra-treatment kV imaging for delivery verification of respiratory 
gating? 
The answer to these questions can be summed up under the hypothesis of this thesis: 
Simultaneous real-time kV imaging during radiation treatment delivery will improve 
the precision of respiratory gated VMAT for early-stage NSCLC such that the 
expected benefits can ultimately be realized clinically. 
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1.8 Research Objectives 
The goal of this thesis is to validate and improve respiratory gated treatment planning and 
delivery for early-stage NSCLC patients with SABR. More specifically, the focus of this 
thesis is to investigate treatment planning using high dose rate IMRT and respiratory gated 
VMAT, and to verify treatment delivery with real-time on-board gated kV imaging 
synchronized to the treatment beam. The breakdown of the research objectives to attain 
this goal are formulated as: 
 To compare various IMRT treatment techniques by determining which provides the 
optimal trade-off between treatment efficiency and dose conformity in early-stage 
NSCLC treated with SABR. 
 To assess the reduction of radiation induced lung toxicities, pneumonitis and fibrosis, 
by the combination of respiratory gated VMAT in early-stage NSCLC patients 
exhibiting significant tumour motion.  
 To determine if on-board kV imaging can be used as a tool to ensure that the motion 
of the external surrogate used for respiratory gating correlates well with internal 
target motion using patient specific waveforms during respiratory-gated VMAT 
treatment delivery.  
 To investigate imaging parameters in intrafraction CBCT by using gated kV 
fluoroscopy acquired during respiratory-gated and ungated VMAT. 
 
1.9 Thesis Roadmap 
1.9.1 Chapter 2 - Dosimetric planning comparison of IMRT 
techniques for early stage non-small cell lung cancer with 
SABR  
Retrospectively, radiation treatment plans for ten patients with early-stage NSCLC were 
computed with eight various IMRT modalities: 1) Three FB-IMRT methods; 2) Two 
VMAT methods; and 3) Three Tomotherapy methods. The goal of this work was to 
determine which modality provided the optimal trade-off between dose conformity and 
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treatment efficiency. Dosimetric parameters including dose conformity (minimum PTV 
dose, conformity indices of the PTV etc), dose volume histogram metrics (maximum dose 
to healthy structures, mean lung dose, contralateral V5Gy, etc), and treatment efficiency 
(MLC degradation, treatment delivery time, etc) were compared amongst each of the 
treatment planning techniques. This chapter is adapted from a research paper entitled 
“Comprehensive dosimetric planning comparison for early stage non-small cell lung 
cancer with SABR: fixed-beam IMRT versus VMAT versus tomotherapy” by Xhaferllari 
I, El-Sherif O, and Gaede S. in press at the Journal of Applied Clinical Medical Physics 
 
1.9.2 Chapter 3 - The potential for respiratory-gated VMAT to 
reduce normal lung toxicity in SABR patients 
In this chapter, respiratory gated VMAT is compared theoretically to ungated VMAT for 
20 early-stage NSCLC patients exhibiting significant breathing-induced tumour motion. 
Dosimetric parameters (V20Gy and mean lung dose) corresponding to early induced lung 
toxicities, such as pneumonitis, and (V50%) corresponding to late induced lung toxicities, 
such as fibrosis, were calculated for all retrospective treatment plans. This chapter is 
adapted from research paper entitled “Dosimetric planning study of respiratory-gated 
volumetric modulated arc therapy for early-stage lung cancer with stereotactic body 
radiation therapy” published in Practical Radiation Oncology vol. 5 (3): pp. 156-61 (2015) 
by Xhaferllari I, Chen JZ, MacFarlane M, Yu E, Gaede S.  
 
1.9.3 Chapter 4 - The use of on-board kV imaging during respiratory 
gated VMAT delivery to evaluate the correlation between 
tumour motion and external surrogate motion in patient-
specific waveforms 
Correlation of the internal target motion and the external surrogate marker motion was 
investigated using different real-patient breathing waveforms in free breathing ungated, 
amplitude gated and phase gated conditions. In this chapter, on-board gated fluoroscopy 
during VMAT was investigated as a tool to correlate the external marker motion with 
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internal target motion, and to calculate pre-determined simulated phase shifts. This work 
was performed using the TrueBeam Research mode and a programmable respiratory 
motion phantom. This chapter is based on a research paper entitled “The use of on-board 
kV imaging during respiratory gated VMAT delivery to evaluate the correlation between 
tumour motion and external surrogate motion in patient-specific waveforms” by 
Xhaferllari I, El-Sherif O, Stevens T, Gaede S to be submitted to the Medical Physics 
journal.   
 
1.9.4 Chapter 5 – Investigation of image quality of intrafraction cone 
beam CT for 3D verification of respiratory-gated VMAT 
delivery 
Despite MV degradation of image quality, intra-fractional kV CBCT during SABR VMAT 
treatment delivery was investigated as a volumetric dosimetric verification method. 
Imaging parameters to optimize image quality and target delineation were explored. 
Respiratory motion artifacts were studied by using a programmable respiratory motion 
phantom embedded with multiple sized spheres under free breathing ungated, amplitude 
gated, and phase gated conditions. The contents of this chapter are in preparation for a 
submission entitled “Investigation of image quality of intrafraction cone beam CT for 3D 
verification of respiratory-gated VMAT delivery” by Xhaferllari I, Dekker K, Hajdok G, 
Gaede S to Physics in Medicine and Biology journal. 
 
1.9.5 Chapter 6 - Conclusions and Future Work  
In this final chapter, an overview of the important findings and conclusions of the thesis 
are summarized. Main limitations from Chapters 2-5 are discussed. The thesis concludes 
with potential topics of interest that can further build upon this work.  
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Chapter 2  
2 Dosimetric planning comparison of IMRT techniques for 
early stage non-small cell lung cancer with SABR  
This chapter is adapted from a research paper entitled “Comprehensive dosimetric planning 
comparison for early stage non-small cell lung cancer with SABR: fixed-beam IMRT 
versus VMAT versus tomotherapy” accepted in the Journal of Applied Clinical Medical 
Physics by Xhaferllari I, El-Sherif O, and Gaede S. 
2.1 Introduction  
Cancer is the leading cause of death worldwide, with non-small cell lung cancer (NSCLC) 
being the most common cause of cancer related mortality1. In the treatment of early-stage 
NSCLC, surgical resection is considered the standard of care2. However, some patients are 
deemed medically inoperable due to age, decreased pulmonary reserve, cardiac function, 
or significant co-morbidities3. Medically inoperable patients, as well as patients unwilling 
to undergo surgery, have the option to be treated using stereotactic ablative radiotherapy 
(SABR). SABR is a hypofractionated technique where a very high ablative dose per 
treatment is delivered in few fractions, normally three to eight. Therefore, tumor 
conformality and sparing of normal tissue is increasingly crucial with SABR in comparison 
to conventional fractionation. SABR treatments are computed using multiple beam angles 
to achieve sharp dose gradients needed to spare healthy tissue. Outcome studies have 
shown SABR has an overall survival of 41.2% compared to 66.1% for patients who 
undergo lobectomy at five years, meanwhile, local control at three years has improved with 
SABR, 87.8%, compared to lobectomy resection, 85%2.  
Although non-coplanar three-dimensional conformal therapy (3D-CRT) remains a popular 
technique for delivering SABR, intensity modulated radiation therapy (IMRT) has become 
increasingly popular due to the ability to improve dose conformality and reduce toxicities 
to normal tissue4. There are various techniques available to compute IMRT: fixed beam 
(FB)4,5, volumetric modulated arc therapy (VMAT)6, and helical tomotherapy (HT)7.  FB 
involves holding the gantry fixed in each beam direction as each segment of the beam, 
formed using a multi-leaf collimator (MLC), is delivered. FB can be accomplished by step-
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and-shoot delivery (SS) and sliding window (SW). VMAT techniques deliver radiation 
using gantry rotation up to 360ᴼ around the patient while simultaneously varying gantry 
speed, leaf motion, and dose rate8. Both FB and VMAT can be optimized using direct 
machine parameter optimization (DMPO) capable with the Pinnacle3 treatment planning 
system (Philips Medical Systems, Fitchburg, USA) and Acuros XB (AXB) v11.3 dose 
calculation algorithm capable with the Eclipse treatment planning system (Varian Medical 
Systems, Palo Alto, USA). HT delivery is accomplished by synchronizing couch motion 
through the bore to the gantry rotation; intensity modulation is attained by a thin fan beam 
of various sizes and binary multi-leaf collimator 9, and most recently with dynamic jaws10.   
Lung SABR treatment plans consist of small fields with substantial heterogeneity from the 
high density tumour and the low density lung. Dose calculation algorithms available in 
commercial products vary in accuracy of dose computation11,12. The dose calculation 
algorithm available with Pinnacle3 and TomoTherapy treatment planning systems is 
collapsed cone convolution13, and in Eclipse treatment planning system, AXB is employed 
14.  
 The goal of this retrospective planning study was to provide an extensive comparison of 
the various FB, VMAT, and HT techniques for delivering IMRT based treatment for early-
stage NSCLC patients with SABR. This study will conclude which technique and vendor 
provides the highest dosimetric benefit by comparing indices for the region of interest and 
organs at risk.  
 
2.2 Material and Methods 
2.2.1 Patient selection and contouring 
A total of ten patients with medically inoperable early-stage NSCLC were enrolled in this 
retrospective planning study. These patients were chosen based on criteria of motion 
greater than 0.5 cm, and internal target volume (ITV) in the range of 4.4 - 53.1 cm3, as 
typically observed in NSCLC SABR treatment cases. Patient specific characteristics, 
including staging, lesion location, and target volumes are shown in Table 2.1.  
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Table 2-1. General patient demographics 
Patient Stage Tumor location 
ITV size 
(cm3) 
PTV size 
(cm3) 
1 T1bN0M0 RLL* Central 17.2 47.3 
2 T1aN0M0 RLL Peripheral 4.8 22.5 
3 T2aN0M0 RLL Central 22.6 58.8 
4 T2aN0M0 RLL Peripheral 35.2 78.0 
5 T2aN0M0 RLL Central 27.7 69.5 
6 T2aN0M0 RLL Peripheral 53.1 106.0 
7 T1aN0M0 RML§ Peripheral 16.2 42.8 
8 T2aN0M0 RML Central 48.8 103.8 
9 T2bN0M0 LLL‡ Central 40.9 92.2 
10 T1aN0M0 LULll Peripheral 4.4 17.9 
Abbreviations: *RLL-Right Lower Lobe; §RML-Right Middle Lobe; ‡LLL-Left 
Lower Lobe; llLUL- Left Upper Lobe  
Four-dimensional computed tomography (4D-CT) scans, reconstructed into 10 phases, 
were acquired for each patient using Varian’s Real-time Position Management (RPM) 
system (Varian Medical Systems, Palo Alto, CA) in the Philips Brilliance Big Bore CT 
scanner (Philips Medical Systems, Cleveland, OH). The gross target volume, (GTV), was 
contoured on each of the ten respiratory phases and motion encompassing internal target 
volume, (ITV), was created by summing the ten individual GTVs. Consecutively, the 
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planning target volume (PTV) was created by adding a 5 mm expansion to the ITV in the 
untagged average 4D-CT. Target volumes and contours of the critical structures were 
imported onto the untagged average 4D-CT and employed for treatment planning across 
different techniques.  
2.2.2 Treatment Planning 
For each patient, eight treatment plans were optimized: three FB, two VMAT, and three 
HT plans; for 80 treatment plans total. A dose of 54 Gy in three fractions was prescribed 
for each patient. To ensure target coverage and provide normalization, 95% of the PTV 
must be covered by the prescription isodose (RTOG 0618)15.  
FB plans were computed by separate board certified dosimetrists who specialize in Eclipse, 
and Pinnacle treatment planning. Prior to FB planning, the dosimetrists were instructed to 
use nine-eleven coplanar beams in each of their plans to have the highest quality plan 
attainable. For each patient, two SS plans, with a maximum allowed segments of 33 and 
100 to represent low modulation (SS-LM) and high modulation (SS-HM), respectively, 
were retrospectively planned in Pinnacle3 v9.1 treatment planning system, and the dose 
was calculated using collapsed cone convolution. The SW plans were generated by a 
different board certified dosimetrist than the SS plans using Eclipse treatment planning 
system; therefore, SW was composed of nine to eleven coplanar beams and did not have 
the same beam arrangement as SS. All the FB plans were recomputed using 10X flattening 
filter free (FFF) beams to optimize the efficiency of expected treatment delivery, and SW 
was recomputed using AXB dose algorithm version 11.3. Once recomputed, each of the 
plans was validated to ensure they are clinically acceptable, and if needed, the plans were 
re-optimized. 
SA treatment plans were generated by employing clinically used Pinnacle host script via 
Pinnacle3 planning system with collapsed cone convolution, and RA treatment plans were 
computed with a clinically approved protocol in Eclipse planning system with AXB dose 
calculation algorithm. Two partial arcs were used depending on the location of the lesion 
in the lung to avoid overdosage to the contralateral lung. According to the clinical script, 
the SA plans consisted of two 225⁰ beam arcs with the dimensions of 180.1⁰- 45⁰ clockwise 
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and 45⁰ - 180⁰ counterclockwise if the lesion was located in the right lung, or 315⁰-179.9⁰ 
clockwise and 180⁰-315⁰ counterclockwise if the lesion was located in the left lung. 
Whereas, the RA plans were computed using two 210⁰ beam arcs with the dimensions of 
180.1⁰-30⁰ clockwise and 30⁰-180⁰ counterclockwise if the lesion was in the right lung, 
and 330⁰-179.9⁰ clockwise and 180⁰- 330⁰ counterclockwise if the lesion was situated in 
the left lung. Both partial arcs were generated using 10X FFF beam energy and a maximum 
2400 MU/min dose rate.   
 All FB and VMAT techniques were prepared utilizing FFF beams to maximize efficiency 
in these hypofractionated deliveries. FFF beams allow for safe treatment delivery with dose 
rates up 2400 MU/min, significantly reducing treatment time16,17. Clinical assessment of 
utilizing FFF beams to treat early-stage NSCLC patients with SABR have demonstrated 
early local control rates upwards of 89%17.  
The three HT plans with varying beam fan width of 1 cm, 2.5 cm, and 5 cm (HT-1cm, HT-
2.5cm, and HT-5cm respectively) were generated by a board certified dosimetrist using 
HiART TomoPlan 3.1.1 (Accuracy Inc, Sunnyvale, CA).  For the patients in this study, a 
0.172 pitch and 1.3 modulation factor were used. All HT plans were designed using a 6X 
beam with 600 MU/min dose rate and optimized with inverse planning based on least 
squares optimization method. The dose was calculated by employing collapsed cone 
convolution algorithm18,19.   
Pinnacle, Eclipse and HT treatment planning systems have different optimization methods, 
as well as varying cost functions. The planning constraints cannot be set the same between 
the different planning systems to achieve highest dose computation results within each 
treatment planning system. However, all plans computed in this study were clinically 
acceptable and satisfied SABR protocol20,21.  
2.2.3 Plan Comparison 
The dose distribution from planning in all the different techniques and one set of contours 
were transferred to MiM v.5.6.5 (MiM Software Inc., Cleveland, OH) for analysis 
purposes. The independent software allows for consistent and unbiased plan evaluation 
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based on dose volumetric histogram (DVH) parameters by using the same sampling 
algorithm. Parameters that characterize dose conformality, DVH statistics, and treatment 
delivery efficiency were obtained and compared. Further analysis to identify main 
difference amongst fixed beam, VMAT and HT was performed by grouping the most 
clinically appropriate plans SS-LM and SS-HM plans, RA and SA VMAT plans, and HT-
2.5cm and HT-5cm plans. SW and HT-1cm were not included in the combined group 
analysis due to their inherent lack of efficiency18,22. 
2.2.3.1 Dose conformality  
To evaluate dose fall-off from the PTV to normal tissue, the maximum dose at least two 
centimeters from the PTV, D2cm, was calculated. For the PTV, the maximum and mean 
dose have been computed, and the conformality index was calculated for the 95% (CI95%), 
80% (CI80%), and 50% (CI50%) isodose levels according to the RTOG model defined by: 
𝐶𝐼𝑅𝐼 =  
𝑉𝑅𝐼
𝑇𝑉
 
Where VRI represents the volume covered by the reference isodose and TV is the volume 
of the PTV23.   
2.2.3.2 DVH statistics 
The maximum point dose (Dmax) to nearby critical organs at risk (OAR), such as the 
esophagus, spinal cord, heart, trachea, and proximal bronchus, was compared amongst all 
patients. Lung toxicity parameters analyzed include the absolute volume of normal lung 
covered by 50% of the prescription or more (V50%), predictive of fibrosis
24, the mean dose 
to the normal lung (MLD), the normal lung receiving 5, 10, 20, 27 Gy or more (V5Gy, V10Gy, 
V20Gy, V27Gy, respectively), and contralateral lung receiving at least 5, or 10 Gy (V5GyC, 
V10GyC, respectively). 
2.2.3.3 Treatment delivery efficiency 
The intensity gradients in IMRT planning were acquired using multiple MLC based control 
points. Increased modulation induces increased MLC travel, potentially causing a 
devaluation of the MLC track, requiring more frequent replacement. The total MLC travel 
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was compared between all fixed beam and VMAT plans. The total monitor units required 
for each treatment technique was analyzed to evaluate treatment efficiency. The treatment 
delivery time was simulated for each beam of the fixed beam and VMAT plans based on 
the dose rate for each segment. Plan automation, available with TrueBeam linear 
accelerators, was assumed to calculate time for gantry rotation in the FB treatment plans. 
Meanwhile, the treatment delivery time in HT treatment plans was estimated based on the 
pitch and monitor units, available in the DICOM header of the radiation plan dose files.  
2.2.4 Statistical Analysis 
All dosimetric parameters compared in this study were summarized by their respective 
means and standard deviation. Statistical analysis was performed in IBM SPSS v.20 (IBM 
SPSS Statistics for Windows, Armonk, NY) using Shapiro-Wilk normality tests followed 
by one-way analysis of variance. The data significantly deviates from a normal distribution 
if Shapiro-Wilk test was less than 0.05, and the null hypothesis was rejected. If the 
distribution was considered not normal, a non-parametric test, Kruskal-Wallis one-way 
analysis of variance, was utilized to find significance; followed by a Wilcoxon-Mann-
Whitney test to find between-subject significance. Whereas, the data was considered 
normally distributed if the Shapiro-Wilk test was greater than 0.05 and the null hypothesis 
was accepted. For normally distributed parameters, a one-way analysis of variance 
(ANOVA) was computed to find significance followed by a Tukey’s post hoc test to check 
for between-subject significances.  
 
2.3 Results 
Dose distribution for the eight various IMRT techniques compared in this study are 
displayed in Figure 2-1 for one patient, and the corresponding DVH of the PTV and normal 
lung tissue, the lung tissue minus the ITV, are provided in Figure 2-2. In the axial slice for 
all HT plans (Figure 2-1), the contralateral lung is covered by the 5 Gy or higher isodose 
volume. As the width of the fan beam in HT increases to the 5 cm plan, an increase in the 
low dose spillage is noticed in the superior-inferior direction shown in the coronal slice.   
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Figure 2-1. Dose distributions of the axial and coronal slice for each of the eight different 
planning techniques for patient 4, from top left to bottom right: SS-LM FB, SS-HM FB, 
SW FB, SA, RA, HT-1cm, HT-2.5cm, and HT-5cm. 
HT planning achieved dose homogeneity in the PTV surpassing other techniques, as can 
be observed in the cumulative DVH (Figure 2-2); however, for SABR treatment, dose 
uniformity and lack of hot spots within the target is not an essential priority for ablative 
radiotherapy. Although hypoxic regions are irradiated with all IMRT techniques, the 
increased heterogeneity within the PTV is regarded as clinically desirable, and provides 
the ability to deliver inherently higher doses to potential hypoxic regions25–27. 
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Figure 2-2. Cumulative DVH for patient 4 for the PTV (solid lines) and the normal lung 
tissue (dashed lines) obtained from the eight techniques used. All plans are normalized 
such that 95% of the PTV receives 54 Gy or more. 
Table 2.2 summarizes the average and standard deviation (SD) of the ten patients for each 
of the parameters described in this study. Parameters for dose conformality, DVH related 
statistics, and treatment efficiency amongst different planning modalities are displayed 
along with between- and within-subject significance.  Although every plan met the SABR 
COMET criteria20, all HT techniques showed a significance decrease in the PTV Dmax and 
mean dose compared to all other modalities in this study. This is further supported by the 
dose homogeneity seen in the PTV in Figure 2-2. On the contrary, there was a significant 
increase in conformality index, CI80%, CI50%, observed for the HT-5cm plan compared to 
all other modalities, other than HT-2.5cm for CI50; RA&SA plans resulted in the most 
conformal dose to the PTV. A significant increase in contralateral V5Gy was observed for 
all HT plans (p=0.002) compared to SS and VMAT. A significant increase in mean lung 
dose was attained for the HT-5cm plan (p=0.002). In both scenarios, RA&SA achieved the 
lowest values. 
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Table 2-2. Mean values ± standard deviation of all parameters compared. A p-value < 0.05 determines significance. 
  
SS-
LM 
 
SS-HM    
 
SW RA SA HT-1 cm 
HT-2.5 
cm 
HT-5 cm 
p-
value 
PTV Dmax (Gy) 
73.8 ± 
4.1f,g,h 
65.8 ± 
23.2f,g,h 
71.7 ± 
3.3f,g,h 
71.2 ± 3.8 
f,g,h 
74.3 ± 
2.9f,g,h 
62.9 ± 
2.4a,b,c,d,e 
63 ± 
5.8a,b,c,d,e 
64.1 ± 7.4 a,b,c,d,e 
< 
0.001 
 
Mean dose 
(Gy) 
62.6 ± 1.9 
f,g,h 
62.5 ± 1.9 
f,g,h 
62.5 ± 
1.4f,g,h 
62 ± 1.5 f,g,h 
61.4 ± 
1.2f,g,h 
58.7 ± 
1.8a,b,c,d,e 
58.6 ± 
3.4a,b,c,d,e 
58.8 ± 4.1 a,b,c,d,e 
< 
0.001 
 D2cm (%) 58.6 ± 8 58.4 ± 6.8c 
62.4 ± 
5.5b,d 
53.2 ± 4.3 
c,e,h 
60.5 ± 6d 57.2 ± 6 58.7 ± 6.6 60.9 ± 6.7d < 0.05 
 CI95% 
1.28 ± 
0.08h 
1.28 ± 0.08h 1.3 ± 0.09 
1.23 ± 
0.09f,g,h 
1.23 ± 
0.06f,g,h 
1.37 ± 
0.13d,e 
1.35 ± 
0.14d,e 
1.43 ± 0.19a,b,d,e < 0.01 
 CI80% 
1.96 ± 
0.23h 
1.97 ± 0.24h 
1.88 ± 
0.18h 
1.78 ± 0.2h 
1.89 ± 
0.19h 
1.96 ± 0.21h 
2.07 ± 
0.31 
2.35 ± 
0.47a,b,c,d,e,f 
< 0.01 
 CI50% 
4.75 ± 
0.77h 
4.73 ± 0.77h 
4.75 ± 
0.72h 
4.31 ± 0.75h 
4.56 ± 
0.84h 
4.43 ± 0.57h 
4.92 ± 
0.83h 
6.03 ± 1.38* < 0.05 
Cord Dmax(Gy) 14.3 ± 4 13.3 ± 3.9 15.8 ± 7.1 11.2 ± 3.2 11.2 ± 1.4 13.9 ± 5.2 13.7 ± 5.5 13.8 ± 5.2 > 0.05 
Bronchus Dmax(Gy) 13.2 ± 9.3 13.4 ± 8.7 
15.5 ± 
10.8 
16.2 ± 9.2 17 ± 11.1 17.2 ± 11.9 
18.7 ± 
13.9 
19.6 ± 14 > 0.05 
Esophagu
s 
Dmax(Gy) 14.1 ± 6.3 14.1 ± 6.2 16.2 ± 8.5 14.9 ± 5.5 16.2 ± 6.4 15.6 ± 5.4 14.1 ± 3.9 14.4 ± 5.7 > 0.05 
Heart Dmax(Gy) 14.5 ± 6.4 15 ± 6.7 17.9 ± 7.6 17.1 ± 7.2 18 ± 6.4 19.2 ± 10.9 
18.4 ± 
11.3 
17.6 ± 10.2 > 0.05 
Trachea Dmax(Gy) 2.4 ± 5.2h 2 ± 4.3h 1.5 ± 2.7 1.1 ± 2.1h 1.5 ± 2.6 1.4 ± 2.4 1.7 ± 2.4 2.7 ± 3a,b,d > 0.05 
Total lung MLD (Gy) 4.8 ± 1.3h 4.8 ± 1.3 h 4.9 ± 1.4 h 4.7 ± 1.2 h 4.6 ± 1 h 5.1 ± 1.3 h 5.8 ± 1.6 7.1 ± 1.7a,b,c,d,e,f < 0.01 
 V50% (cm3) 191 ± 78 189 ± 80 185 ± 77 172 ± 66 173 ± 67 179 ± 75 200 ± 83 250 ± 108 > 0.05 
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 V50% (%) 4.1 ± 1.6 4 ± 1.6 4 ± 1.5 3.7 ± 1.4 3.7 ± 1.3 3.8 ± 1.6 4.3 ± 1.7 5.3 ± 2 > 0.05 
 V20Gy (%) 6.3 ± 2.3 6.2 ± 2.2 6.2 ± 2.4 5.9 ± 2.2 6 ± 2.1 5.9 ± 2.3 6.7 ± 2.6 8.3 ± 2.9 > 0.05 
 V10Gy (%) 
12.9 ± 4.6 
h 12.8 ± 4.4
 h 14.3 ± 5 13.9 ± 4.4 
12.3 ± 2.7 
h 
14.1 ± 4.8 16.7 ± 6 20.7 ± 7a,b,e < 0.01 
 V5 Gy (%) 
23.5 ± 6.9 
h 
23.7 ± 6.9 h 
24.7 ± 7.7 
h 
22.9 ± 6.8 h 22 ± 6.2g,h 29 ± 8.2 h 
33.4 ± 
9.1e 
40.8 ± 11.8 
a,b,c,d,e,f 
< 
0.001 
Cont. lung V10Gy (%) 0.9 ± 1.7 0.8 ± 1.4 2.8 ± 4.1 0.4 ± 1 0.4 ± 0.7 1.4 ± 2 1.5 ± 2.1 1.9 ± 2.5 > 0.05 
 V5 Gy (%) 
7.9 ± 
6.6f,g,h 
8.4 ± 6.1f,g,h 10.8 ± 8 6.6 ± 7.6f,g,h 7.4 ± 7f,g,h 
18.9 ± 
10.9a,b,d,e 
19 ± 
11.2a,b,d,e 
21 ± 15.2a,b,d,e < 0.01 
Efficiency MLC 
Motion (cm) 
837 + 509 
b 
3170 + 
1475a,c,d,e 
1279 + 563 b 1184 + 341 b 
960 + 
310b 
N/A N/A N/A 
<0.00
1 
Monitor 
Units 
3823 ± 
792b,c,d,f,g 
4946 ± 
1226a,c,e,f 
8288 ± 
3412a,b,d,e,f 
4782 ± 
655a,c,e,f 
4023 ± 
678b,c,d,f 
11208 ± 
1510a,b,c,d,e,h 
7047 ± 
4407a 
5457 ± 3451f 
< 
0.001 
 
Delivery 
time (min) 
2.5 ± 0.3* 3 ± 0.5* 
4.4 ± 
1.4a,b,d,e,f,g 
2 ± 
0.3a,b,c,f,g,h 
1.9 ± 
0.2a,b,c,f,g,h 
13.2 ± 
1.8a,b,c,d,e,h 
8.3 ± 
5.2a,b,c,d,e 
6.4 ± 4.1a,b,d,e,f 
< 
0.001 
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To further emphasize estimated treatment delivery time amongst all techniques, a 
significant increase was observed in all HT, and SS plans compared to SA; however, a 
statistically significant difference is not found between RA&SA (p=.393) (Figure 2-3). 
 
Figure 2-3. The mean estimated treatment delivery time for each treatment planning 
technique over all patients. 
In the overall MLC travel comparison, SS-HM required significantly more MLC motion 
than all other modalities compared, as shown in Figure 2-4. SA resulted in the lowest MLC 
travel time, and therefore, least amount of potential degradation on the MLC track, 
compared to all other techniques, albeit, significance was not detected.   
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Figure 2-4. Box plot of the total MLC traveled in each plan in millimeters for all treatment 
modalities compared. For each plot, the median is displayed by the central line, the upper 
and lower border of the rectangle represent the 75th and 25th percentile or interquartile 
range, and the whiskers represent the extreme data points not considered outliers. Outliers 
were illustrated by ‘o’ and significance was shown by ‘*.' 
In the two VMAT techniques, RA displayed significantly superior D2cm,
 dose fall-off 
parameter, to SA (p= 0.011), whereas total monitor units significantly increased (p=0.043). 
However, VMAT showed improved overall treatment quality and efficiency compared to 
all other modalities with SA achieving optimum efficiency.   
Further analysis to identify main differences amongst fixed beam, VMAT and HT was 
completed by grouping the SS-LM and SS-HM plans, RA and SA VMAT plans, and HT-
2.5cm and HT-5cm plans (Table 2.3). SW and HM-1cm treatment plans were not included 
in this analysis based on poor performance in efficiency parameters, while dose distribution 
was not improved, as observed in Table 2.2.  A significant reduction in maximum dose to 
the spinal cord was observed in the VMAT plans (p=0.017) compared to the SS. Although 
not statistically significant for the remainder of the parameters, a reduction was found 
between SS and VMAT (other than esophagus, bronchus and heart). When comparing SS 
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to HT, target conformality (CI95%) significantly improved in the SS plans (p=0.015), at the 
cost of the target mean and maximum dose which was significantly reduced in the HT plans 
(p<0.001). Similarly, target mean and maximum dose (p<0.001) showed a significantly 
reduction in the HT plans compared to the VMAT plans while all three target conformality 
parameters significantly improved with VMAT (p<0.05 for all). In the DVH parameters, 
maximum dose to the trachea and normal lung, V10Gy and V5Gy, contralateral lung V5Gy, 
and mean lung dose significantly reduced using both the SS and VMAT treatment planning 
compared to HT. These differences show that patients treated with SS or VMAT may be 
less susceptible to radiation-induced lung toxicities compared to HT treated patients. 
Estimated treatment delivery time was significantly reduced with VMAT plans compared 
to all other techniques (p<0.001). 
Table 2-3. Significance for each parameter studied between grouped SS, VMAT, and HT 
(significance identified when p<0.05). 
   p-value  
  
SS & 
VMAT 
SS & HT 
VMAT & 
HT 
PTV Dmax (Gy) 0.957 <0.001 <0.001 
 Mean dose (Gy) 0.213 <0.001 <0.001 
 D2cm (%) 0.978 0.168 0.152 
 CI95% 0.058 0.015 <0.001 
 CI80% 0.117 0.055 <0.001 
 CI50% 0.176 0.083 0.003 
Cord Dmax(Gy) 0.017 0.507 0.323 
Bronchus Dmax(Gy) 0.611 0.218 0.742 
Esophagus Dmax(Gy) 0.686 0.993 0.755 
Heart Dmax(Gy) 0.152 0.552 0.552 
Trachea Dmax(Gy) 0.626 0.004 0.020 
Total lung MLD (Gy) 0.561 0.005 0.001 
 V50% (cm
3) 0.779 0.369 0.113 
 V50% (%) 0.756 0.341 0.093 
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 V20Gy (%) 0.918 0.247 0.119 
 V10Gy (%) 0.990 0.002 0.002 
 V5 Gy (%) 0.898 <0.001 <0.001 
Cont. lung V10Gy (%) 0.778 0.091 0.044 
 V5 Gy (%) 0.204 <0.001 <0.001 
Efficiency MLC Motion 0.123 N/A N/A 
 Monitor Units 0.607 0.516 0.787 
 Delivery time (min) <0.001 <0.001 <0.001 
 
2.4 Discussion  
In this study, all 80 IMRT plans generated conformal dose distributions and provided 
clinically acceptable plans according to the guidelines of RTOG 0618 and our in-house 
protocol based on SABR-COMET. Various IMRT planning techniques for treating SABR 
were compared to conclude which IMRT modality is propitious by proving the most 
favorable dose conformality, DVH parameters and treatment efficiency. In this study, 
VMAT planning, RA and SA, provided for the optimal trade-off in treatment efficiency 
and dose coverage. The inherent rotational nature of VMAT and tomotherapy treatment 
planning optimization allows for greater degrees of freedom compared to fixed beam and, 
therefore, should lead to higher quality radiation therapy treatment plans. Furthermore, the 
application of a broad beam in VMAT compared to a thin fan beam in tomotherapy, led to 
significantly improved treatment delivery efficiency. In treatment planning studies, Pareto 
efficiency should be achieved using multi-criteria optimization to ensure accurate planning 
comparison28. However, this technique was not available during the course of this study. 
To overcome the lack of multi-criteria optimization, each treatment plan was computed by 
a certified dosimetrist or by the application of a clinically acceptable protocol.  
Several other studies have investigated the role of different IMRT treatment techniques in 
the treatment of early stage NSCLC with SABR to reduce lung toxicities29,30. Kannarunimit 
et al.29 compared three SABR treatment techniques robotic surgery, RA and HT plan for 
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treatment of central lung with SABR. They concluded that HT and VMAT provided more 
efficient treatment delivery and higher target dose homogeneity while robotic surgery and 
VMAT provided a lower risk of radiation-induced lung pneumonitis, with VMAT yielding 
the lowest risk in cases of large PTV coverage. During hypofractionated radiation 
treatment, sharp dose gradients outside the PTV are desirable, hot spots in the center of the 
PTV are invoked to aid a dose fall off outside the PTV25–27. Alluding to dose homogeneity 
parameters not being included in the study, where traditionally HT planning excels. The 
findings on the reduction of radiation-induced pneumonitis during VMAT plans by 
Kannarunimit et al. were further supported by our study where RA and SA demonstrated 
the lowest risk of radiation pneumonitis by having the lowest MLD and V20Gy values. A 
significant reduction in MLD was found when grouping both VMAT techniques and 
comparing to HT (p<0.001); however, no significant difference was found between the two 
VMAT techniques31. For further analysis of radiation-induced lung toxicity, our study 
investigated the reduction in the risk of fibrosis amongst the different treatment planning 
techniques (V50%); VMAT achieved reduced V50% values. However, the differences in V50% 
were not found to be statistically significant.  
Weyh et al.30 compared RA, HT and fixed beam for SABR treatment to lesions in the 
peripheral lung to conclude RA and fixed beam plans were equivalent but the reduction in 
treatment time with RA makes them more preferable. This study has supported their work 
and furthermore, our results demonstrate a decrease in all normal lung DVH parameters in 
RA and SA, albeit not significant. Weyh et al. executed their study in eight patients for a 
total of 24 treatment plans, whereas this study expands on validating different treatment 
methods within FB, VMAT and HT compromising of 80 treatment plans. Treatment plans, 
in both Weyh et al. 30 and Kannarunimit et al. 29, were generated using traditional beams 
with flattening filter (FF) and analytical anisotropic algorithm (AAA) dose calculation 
algorithm.  Whereas in this study, FFF beams were utilized in all linear accelerator based 
plans. Studies have shown that FFF treatment planning provides equivalent dose 
distribution to FF beams while significantly reducing treatment delivery time and 
increasing dose distribution conformity16. AXB dose calculation algorithm, computed in 
this study for Eclipse treatment planning in RA and SW plans, has been shown to generate 
treatment plans comparable to x-ray voxel Monte Carlo (XVMC) developed by 
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BrainLab14.  Moreover, AXB allows for faster computational time to XVMC, while 
maintaining higher accuracy when dealing with tissue heterogeneity in the lung compared 
to AAA. 
An important parameter when considering IMRT treatment, degradation of the MLC 
carriage due to MLC motion required during treatment delivery. The jaw opening in the 
field sizes in all treatment plans ranged between 4-cm to 9-cm to surround the PTV but 
limit MLC motion. Even though a significance was only found when comparing each of 
the techniques to SS-HM, within the VMAT techniques, there was a reduction in MLC 
motion for the SA in nine of ten patients compared to RA. SA based treatment planning 
could result in a longer lifespan of the MLC carriage.  
The limited number of patients used in this study may have led to insufficient statistical 
power to show significance between some of the parameters analyzed. The statistical power 
of 0.76 was measured using ANOVA repeated measures in G-power v.3.1.9.232. 
 Although other various treatment modality comparison studies have been conducted for 
the treatment of NSCLC with SABR, to the best of our knowledge, there are not any other 
studies comprehensively covering a wide range of different IMRT techniques from various 
commercial vendors. In this study, the most up to date treatment planning using FFF beams 
to reduce significantly treatment times was used for both fixed beam and VMAT planning.  
2.5 Conclusion  
In the treatment of early-stage NSCLC patients with SABR, this study has demonstrated 
VMAT treatment planning techniques to have the optimal trade-off between dose 
conformality and sparing normal tissue, and treatment efficiency. Although all plans were 
clinically acceptable, VMAT outperformed HT in all parameters measured, and statistical 
superiority was observed in 12 parameters when comparing grouped VMAT and HT 
techniques. In the comparison between SS and VMAT techniques, an increase in dose to 
the heart, esophagus and bronchus, was observed, although insignificant. VMAT was 
dosimetrically advantageous in all other parameters while providing significantly shorter 
treatment times than any other modality studied.  
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RA and SA VMAT techniques performed comparably; RA displayed significantly sharper 
dose fall off while SA optimization was statistically more efficient. 
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Chapter 3  
3 The potential for respiratory-gated VMAT to reduce 
normal lung toxicity in SBRT patients  
This chapter is adapted from research paper entitled “Dosimetric planning study of 
respiratory-gated volumetric modulated arc therapy for early-stage lung cancer with 
stereotactic body radiation therapy” published in Practical Radiation Oncology vol. 5 (3): 
pp. 156-61 (2015) by Xhaferllari I, Chen JZ, MacFarlane M, Yu E, Gaede S.  
3.1 Introduction          
Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer death. 
Twenty percent of NSCLC diagnosed are in early-stage and it continues to rise due to better 
diagnostic techniques1. Common treatments for early-stage NSCLC are surgery and 
radiation therapy. Patients undergo radiation therapy if they are inoperable or refuse 
surgery. To provide inoperable patients comparable treatment, early-stage lung tumors are 
treated with strereotactic ablative body radiotherapy (SABR), a technique of high precision 
radiation therapy where high doses (54 - 60 Gy) are delivered in fewer fractions (three to 
eight)2. Studies have demonstrated SABR to have comparable local control and regional 
reoccurrence to surgery3. Local control in 3 years surpasses 90% and the 3-year survival is 
84.7% for early-stage NSCLC patients treated with SABR4. 
However, in lung cancer radiotherapy, respiratory motion may have large impact on the 
dose to both the tumour and the normal lung. Studies have shown the magnitude of motion 
is variable and unpredictable between patients and within a patient over treatment days5–9. 
Respiratory motion, in conjunction with the complexity of intensity-modulated radiation 
therapy (IMRT) delivery, can lead to the interplay effect, caused by the asynchronous 
movement of the tumor and the multi-leaf collimator (MLC)10,11. Beam-intensity gradients 
are defined by MLC and the target may move in and out of these gradients. This movement 
is not accounted for in the treatment planning systems.  
In lung radiotherapy, a method of accounting for respiratory motion is to create a full 
motion encompassing margin called the internal tumor volume (ITV) with the aid of four-
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dimensional computed tomography (4D-CT)12. When motion is considered “significant”, 
breathing motion management technique such as respiratory gating, abdominal 
compression, voluntary/involuntary breath hold technique, or tumor tracking can be used13. 
In recent years, volumetric modulated arc therapy (VMAT) has been implemented in many 
centers for the treatment of SABR for early-stage NSCLC and has shown to provide better 
normal tissue sparing to critical organs while maintaining proper dose coverage to the 
target14. The Varian TrueBeamTM System (Varian Medical Systems, Palo Alto, CA) has an 
integrated respiratory gating and motion management system using an external surrogate, 
allowing for the delivery of respiratory gated VMAT. To increase treatment efficiency, 
respiratory-gated VMAT can be delivered with flattening filter free mode (FFF) for both 6 
MV and 10 MV beams, allowing for dose rates four times greater than previously available. 
Another feature of the TrueBeamTM System is advanced image guidance, allowing for 
gated kV imaging before or during treatment. Typically, prior to respiratory gated VMAT 
treatment, a free breathing cone-beam CT is acquired for anatomical verification of patient 
setup, followed by orthogonal gated kV imaging to verify the gating window by 
comparison with the digital reconstructed radiographs produced during planning.  
This paper investigates the potential dosimetric advantage of combining respiratory gating 
and VMAT using FFF beams for treating early-stage NSCLC with SABR. 
3.2 Materials and Methods 
3.2.1 Patient Selection  
In this study, 4D-CT scans from twenty early-stage NSCLC patients with respiratory tumor 
motion greater than 5 mm peak-to-peak were randomly selected from recent patient data. 
Table 3-1 displays the patient demographics and the calculated centroid tumor motion. 
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Table 3-1. Patient tumor location, motion, size, and the gating window used in the study. 
Patient  
Tumor 
location 
3D Motion (cm) Free 
Breathing 
ITV size 
(cm3) 
Gated 
ITV size 
(cm3) 
Gating 
window 
Sup/Inf Ant/Post Lat 
1 RLL* 3.0 1.3 0.8 22.1 13.2 40% - 60% 
2 RLL 3.0 1.3 0.0 17.2 5.6 40% - 70% 
3 RLL 2.8 0.8 0.3 22.6 10.7 30% - 60% 
4 RLL 2.6 0.7 0.6 4.8 1.6 40% - 70% 
5 RLL 1.9 0.5 0.3 35.2 17.2 40% - 70% 
6 LLL† 1.7 0.2 0.1 40.9 27.3 30% - 60% 
7 RLL 1.6 0.9 0.1 27.7 16.8 40% - 70% 
8 RLL 1.6 0.4 0.1 26.7 18.3 30% - 60% 
9 LLL 1.4 0.3 0.2 143.1 113.0 30% - 60% 
10 RLL 1.3 0.2 0.2 53.1 37.5 40% - 70% 
11 RML§ 1.2 0.1 0.2 16.2 9.9 40% - 70% 
12 RUL‡ 1.0 0.9 0.2 16.6 10.3 30% - 60% 
13 RLL 1.0 0.2 0.2 17.3 11.6 30% - 60% 
14 RLL 0.9 0.6 0.1 97.8 68.7 30% - 70% 
15 RML 0.9 0.3 0.1 48.8 31.0 30% - 60% 
16 LLL 0.6 0.2 0.2 10.2 6.1 40% - 70% 
17 LULll 0.6 0.1 0.2 4.4 3.1 40% - 70% 
18 LLL 0.5 0.2 0.1 3.9 2.7 30% - 60% 
19 RUL 0.4 0.5 0.2 27.9 16.3 30% - 70% 
20 LLL 0.3 0.2 0.7 3.4 2.1 40% - 70% 
Abbreviations: *RLL-Right Lower Lobe; †LLL-Left Lower Lobe; §RML-Right Middle 
Lobe; ‡RUL-Right Upper Lobe; llLUL- Left Upper Lobe 
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3.2.2 Treatment planning  
Each patient was retrospectively planned with gated and non-gated VMAT using SmartArc 
technique on Pinnacle treatment planning system version 9.0 (Philips Radiation Oncology, 
Fitchburg, MA) and the dose was calculated using collapsed cone convolution. SmartArc 
is a VMAT optimization system developed by Philips Radiation Oncology Systems in 
collaboration with RaySearch Laboratories AB (Stockholm, Sweden)15. The non-gated 
VMAT plans were generated using the average intensity projection CT images 
encompassed by the entire 4D-CT dataset. The ITV in the non-gated VMAT scenario was 
defined as the envelope of the GTV delineated in all 10 phases of the respiratory cycle. The 
gated VMAT plans were generated using a subset average of the intensity projection CT 
images encompassed by only those phases which lie within the intended gating window. 
The gating window was chosen based on the analysis of the 4D-CT images to provide the 
optimal trade-off between an increase in treatment time and a decrease in motion, keeping 
residual motion in the gating window within 3 mm. The gating window for each patient is 
listed in Table 3-1. The ITV, in the gated case, was defined as the envelope of the GTVs 
delineated in the phases defined by the subset average CT. For both gated and non-gated 
scenarios, a five millimeter margin was added to account for set-up uncertainties, defining 
the planning target volume (PTV).  
Each VMAT plan consisted of two 225 degree arcs, one clockwise and one 
counterclockwise, with beam energy of 10X FFF and a maximum dose rate of 2400 
MU/min. The dose prescription was based on the tumor location; for tumors near or 
adjacent to the chest wall, a dose of 55 Gy in 5 fractions was prescribed, whereas for all 
other cases, a dose of 54 Gy in 3 fractions was prescribed. The prescription was set 
according to RTOG 0618, 100% of the dose to 95% volume of the PTV. All dosimetric 
parameters satisfied the requirements of our in-house SABR protocol16–18. In order to avoid 
dosimetry bias between the gated and non-gated plans, a Pinnacle planning script was 
generated and used to optimize all 40 plans. The planning script generated the beams 
required according to the location of the target, set IMRT optimization parameters, and 
then optimized using Pinnacle’s direct machine parameter optimization (DMPO) for 25 
iterations (Appendix A). After the plan was completed, minor adjustments were sometimes 
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necessary to satisfy limits of dose to normal structure and target. Any adjustments 
performed on one of the patient’s plan were repeated for their other respective plan. 
3.2.3 Statistical Analysis 
The main normal lung parameters considered in this study were V20Gy, the percent volume 
of the normal lung minus the ITV receiving at least 20 Gy and V50%, the absolute volume 
of lung minus the ITV receiving at least 50% of the prescription dose. In studies, V20Gy has 
shown to be a predictive of pneumonitis19 while V50% is an important parameter used to 
control the amount of intermediate dose spillage, and hence, the total volume of potential 
irreversible fibrosis16–18. Other common lung parameters considered were: contralateral 
V5Gy, the percent volume of contralateral lung receiving at least 5 Gy, MLD, mean normal 
lung dose and D2cm, the maximum dose that is 2 cm away from the PTV. D2cm is a useful 
parameter representing the extent of dose falloff outside the PTV, which is crucial for lung 
SABR18. The total number of monitor units (MU) necessary to deliver each plan was also 
compared. Other parameters compared were the maximum dose to nearby critical organs 
such as the cord, esophagus, heart, bronchus, and trachea, and the ITV and PTV size.  
To test for significance, initially Shapiro-Wilk tests were done to check for normality. If 
the significance value is less than 0.05, then the null hypothesis is rejected and the 
parameter values were not normally distributed; whereas if it is above 0.05, the null 
hypothesis was accepted and the parameter was normally distributed. Based on the 
Shapiro-Wilk test, the volumes of the ITV and PTV, and the maximum dose to the trachea 
were not normally distributed. Consequently, tests of significance for these parameters 
were performed using the Wilcoxon–Mann–Whitney non-parametric test. Paired t-test was 
performed for all other parameters.   
 
3.3 Results  
For each plan, target coverage and organ sparing was achieved according to the 
requirements of our in-house SABR protocol by using a Pinnacle planning script with some 
adjustments. However, there were significant differences in the dose distributions due to 
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the differences in PTV sizes between the gated and non-gated VMAT plans. The dose 
distribution for both gated and non-gated VMAT plans for one patient are shown in Figure 
3-1 in the transverse and coronal planes through the isocenter. The volume covered by the 
100% of the prescription, 54 Gy, and 50% of the prescription, 27 Gy, is noticeably greater 
in the non-gated case than the gated case.  
 
Figure 3-1. Dose distribution for a non-gated VMAT plan (left) and gated VMAT plan 
(right) in the transverse and coronal planes. The isodose line of 54 Gy, and 27 Gy are shown 
in white and black respectively, while the planning target volume is the black contour.   
Figure 3-2 compares V20Gy amongst the 20 patients. The use of gating significantly reduced 
V20Gy from (6.05 + 2.06)% to (5.21 + 1.75)% (p=0.00004). 
Figure 3-3 compares V50% amongst the 20 patients. The use of gating significantly reduced 
V50% from (158.17+61.12) cm
3 to (125.71+49.46) cm3 (p=0.00002). 
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Figure 3-2. Comparison of the percent of the lung volume receiving at least 20 Gy (V20Gy) 
for both the non-gated and gated VMAT plans for all 20 patients. 
 
Figure 3-3. Comparison of the volume of lung receiving 50% of the prescription dose 
between gated and non-gated VMAT plans for all 20 patients. 
Table 3-2 compares each parameter considered in this study with their respective mean 
values and corresponding p-value. A decrease is seen in all the parameters between non-
gated and gated VMAT plans. A significant p-value was found for the difference of each 
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parameter between gated and non-gated VMAT plans except for the maximum dose to 
critical structures.  
Table 3-2. Mean values and statistics for each of the parameters studied. 
Metric 
Non - 
gated 
Gated p-value 
Tests of Normality 
Shapiro-Wilk 
    Gated Non - gated 
ITV* 32.00 cm3 21.13 cm3 <0.001 0.000 0.000 
PTV† 71.61 cm3 50.54 cm3 <0.001 0.000 0.001 
D2cm‡ 61.38% 59.27% 0.007 0.625 0.197 
V20Gy§ 6.05% 5.21% <0.001 0.178 0.292 
V50%ll 158.17 cm3 125.71 cm3 <0.001 0.054 0.553 
V5Gy¶ 14.10% 11.59% <0.001 0.139 0.159 
Cord dose 11.35 Gy 11.19 Gy 0.895 0.006 0.904 
Esophagus 
dose 
14.87 Gy 14.27 Gy 0.278 0.297 0.491 
Bronchus dose 15.59 Gy  15.44 Gy 0.814 0.115 0.039 
Trachea dose 3.83 Gy 3.44 Gy 0.059 0.000 0.000 
Heart dose  18.2 Gy 17.38 Gy 0.121 0.325 0.642 
MLD# 455.24 Gy 408.02 Gy <0.001 0.176 0.667 
MU** 3707.7 3434.9 0.003 0.981 0.942 
Abbreviations: *ITV - Internal Target Volume; †PTV - Planning Target Volume; ‡D2cm - Percent 
ratio of the dose 2 cm away from the PTV to the prescription; §V20Gy - Percent volume of healthy 
lung receiving 20 Gy or more; llV50% - Absolute volume of healthy lung receiving 50% of the 
prescription; ¶V5Gy - Percent volume of contralateral lung receiving 5 Gy or more; Critical organ 
dose – maximum dose to that organ; #MLD - Mean Lung Dose; **MU - Monitor Units  
 77 
 
3.4 Discussion  
Several studies have investigated the benefits of VMAT in providing accurate target dose 
while sparing normal tissue in lung radiotherapy 20,21. However, one of the largest sources 
of dosimetric error in NSCLC treatment, including VMAT, is respiratory motion. 
Respiratory gating is one method of managing respiratory motion. Respiratory gated 
VMAT is now possible with TrueBeamTM and previous studies have shown that gated 
VMAT delivery with TruebeamTM can be performed accurately22,23.  
This study is demonstrating the potential clinical benefits of respiratory-gated VMAT with 
FFF beams in reducing lung toxicities associated with SABR for early stage lung cancer. 
Reducing margins of the target volume by using respiratory gating can aid in sparing of 
normal tissue while maintaining clinically feasible treatment times. A predictor for early 
toxicity seen in the lung, pneumonitis, is the percent volume of the lung receiving 20 Gy 
(V20Gy); the lower the V20Gy, the lower the risk. We have shown the use of respiratory-gated 
VMAT can significantly reduce V20Gy and V50% compared to non-gated VMAT, commonly 
used in clinics worldwide. It should be taken into account that the ITV in the non-gated 
case contains normal lung volume not accounted for in the calculation of V50% and, 
therefore, the values received represent an underestimation of the true values in the non-
gated case. Also, the volume of lung during full breathing cycle is greater than the volume 
of lungs in the end-exhale. 
In Table 3-2, the max dose of other normal tissues such as cord, esophagus, heart, bronchus, 
and trachea decreased in respiratory gated VMAT compared to non-gated VMAT, albeit 
not significantly. A greater maximum dose reduction in critical organs was seen in cases 
where the tumor was proximal to these critical organs.  In all other cases, the reduction in 
margin did not result in a significant difference. Otherwise, all the parameters studied have 
shown to be significantly decreased when gated VMAT planning is performed. In general, 
the doses to critical organs are expected to decrease with respiratory gating because of the 
reduction of the PTV volumes with gating. The dose falloff parameter, D2cm, significantly 
decreased with gated VMAT, meaning less normal tissue being exposed to higher doses.  
Dose spillage or the percent of contralateral lung receiving at least 5 Gy, V5Gy, significantly 
decreased with gated VMAT. 
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A disadvantage to respiratory gating is increase in the treatment time. However, FFF-based 
treatment reduces gated treatment times with higher dose rates. Treatment time was 
estimated based on the planning dosimetric values, monitor units, dose rate and gating 
window. On average, each non-gated VMAT treatment requires 1.5 minutes whereas gated 
VMAT treatment requires 4.7 minutes. However, based on the electronic treatment records 
for 30 fractions of patients treated clinically with 10X-FFF SABR VMAT, treatment time 
for respiratory gated VMAT was increased by a factor of 2.3 compared to non gated VMAT 
delivery. A study by Malinowski et al showed changes in the spatial relationship between 
tumour and surrogate marker occurred mostly in 30-minute treatment fractions; however, 
as we showed above, typical respiratory gated SABR VMAT treatments with FFF beams 
have significantly lower treatments times, a tenth of the values reported in the study24.  
Figure 3-2 and Figure 3-3 shows cases of patients, 16, 17, 18, and 20, where gated VMAT 
may not be necessary since there is only a slight difference in reduction of normal lung 
dose; the p-values for V20 Gy and V50% difference for these four patients are 0.286 and 0.040 
respectively. This lack of reduction in normal lung dose may be due to the target in each 
of these plans not being located centrally in the lung. Also, the paucity of motion may 
contribute, in each of these cases, maximum target motion in any direction is less than 6 
mm; there is only one other patient with motion of similar magnitude as seen in Table 1. 
The slight increase in sparing of lungs may not outweigh the increase in treatment time 
during gated treatment, inferring that gating is not necessary for all patients. 
A weakness of this study was that treatment planning for non-gated cases was performed 
on the average intensity projection from the full 4D-CT dataset, and not using 4D dose 
accumulation. However, a study by Li et al showed that there was no significant difference 
in both the target and normal tissue dose distribution using 3D or 4D dose calculation25. 
Also, since the definition of normal lung in this study was lung-ITV, we are actually 
underestimating the dose to the normal lung, as mentioned earlier, thereby increasing the 
necessity for motion management strategies such as respiratory gating. 
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3.5 Conclusion 
This dosimetric planning study has shown that respiratory gated VMAT using flattening 
filter free technology has the potential to reduce dose to normal lung compared to free 
breathing VMAT, without greatly compromising treatment delivery time. There was a 
significant decrease in normal lung V20Gy and V50%, both of which are important parameters 
to consider when minimizing the risk of radiation-induced lung toxicity. 
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Chapter 4  
4 The use of on-board kV imaging during respiratory gated 
VMAT delivery to evaluate the correlation between 
tumour motion and external surrogate motion in patient-
specific waveforms  
This chapter is based on a research paper entitled “The use of on-board kV imaging during 
respiratory gated VMAT delivery to evaluate the correlation between tumour motion and 
external surrogate motion in patient-specific waveforms” by Xhaferllari I, Stevens T, El-
Sherif O, Gaede S to be submitted to the Medical Physics journal.   
4.1 Introduction 
Respiratory motion leads to significant uncertainties in the treatment of thoracic and 
abdominal tumors with radiation therapy1. Respiratory gating is one method used to limit 
intra-fractional breathing motion, resulting in reduced target margins and radiation-induced 
lung toxicities2–4. The gating window can be determined based on either the amplitude or 
phase of the periodic external surrogate motion waveform.  The gating threshold in 
amplitude based gating is defined on motion displacement relative to the baseline, the mean 
motion at end-exhale calculated during the learning of the respiratory motion5. Whereas, 
gating thresholds in phase gating are defined as two angular positions of the respiratory 
waveform5. Of these two techniques, amplitude gating has demonstrated to be more 
reliable when tracking irregular respiratory motion over time6–8. Phase gating assumes 
constant periodicity in respiratory breathing motion, and can lead to substantial targeting 
errors for irregular non-periodic waveforms9. Variabilities in respiratory waveform 
characteristic, such as slope and period, lead to discrepancies in the motion displacement 
sorted to the same phase during phase-based respiratory gating. 
In respiratory gating, predictive filters are employed to control for irregular, non-periodic 
breathing by setting a threshold of periodicity for triggering the beam on10. The breathing 
waveform recorded during 4D-CT acquisition is used as a reference for radiation treatment. 
The threshold applied to the predictive filter aids in restricting inaccurate treatment 
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delivery by triggering the beam off when the motion does not match the 4D-CT reference 
within the specified threshold.  
The main uncertainty in respiratory gated treatment lies in the assumption that an external 
surrogate can accurately predict the internal motion of the target. Respiratory gated 
treatments are susceptible to baseline changes during treatment and overall variability in 
intrafraction tumor motion9.  Intrafraction motion variability may invoke a phase shift 
between the external trace and the internal target motion. In gated delivery of lung cancer, 
this can lead to discrepancies in dose delivery, with some target volumes being on the verge 
of under-dosage11,12. Previous studies have investigated the correlation between the motion 
of external markers and internal targets during 4D-CT acquisition13–15, before treatment16–
18, and with the use of ultrasound19 or fiducial markers18,20,21.  
Respiratory gated volumetric modulated arc therapy (VMAT) is a method used to treat 
early-stage non-small cell lung cancer (NSCLC) with stereotactic ablative body 
radiotherapy (SABR). However, the impact of multiple gantry “starts and stops” as well as 
multiple dose rate “ramp-ups and ramp-downs” during high dose rate respiratory-gated 
VMAT on the internal/external correlation and, subsequently, the dose to the target is 
unclear. The increase in treatment delivery complexity may cause latencies in machine 
response and recording external motion. The goal of this study is to examine the utility of 
using on-board kV imaging to: 1) determine the correlation of external surrogate motion 
and internal target motion during ungated, amplitude gated, and phase gated VMAT 
delivery using flattening filter free (FFF) beams ; and 2) identify known phase shifts 
between the internal and external trace. 
4.2 Methods 
4.2.1 Study subjects  
From our institutional database, five previously treated early-stage NSCLC real patient 
breathing (RPB) traces were selected, along with a sinusoidal trace, to represent variable 
breathing patterns and a range of motion irregularity.  For early-stage NSCLC patients, the 
breathing trace was acquired from the Real-Time Position Management (RPM) suite 
(Varian Medical Systems, Palo Alto, CA) during CT simulation. The RPM motion trace 
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file specifies a flag indicating acquisition of 4D-CT imaging. The portion of the respiratory 
motion waveform represented by the 4D-CT acquisition flag was extracted. The gross 
target volume, (GTV), was contoured on all ten 4D-CT phases using MIM software version 
6.3 (Mim Software Inc., Cleveland, OH). The centroid coordinates of the GTV contour 
were identified in each of the 4D-CT phase using MIM software, and the total motion of 
the GTV in the superior-inferior direction was calculated based on variability between 
phases. The respiratory breathing trace extracted from the RPM system was scaled to the 
total calculated motion of the GTV to represent the real-patient full respiratory cycle.  
The variability in target displacement at consecutive end-exhalation phases was calculated 
in each RPB waveform to determine motion irregularity. High standard deviation in the 
end-exhale position represented irregular breathing while low standard deviation 
represented periodic, regular breathing. In addition to the five real-patient breathing traces, 
a sinusoidal waveform with 1.5 cm peak-to-peak motion, and four second period was 
included in the study (patient 6). Variability in motion pattern was defined as periodic for 
regular RPB and sinusoidal trace, exhibiting a baseline drift if the position of the baseline 
was slowly veering, and defined as baseline shift for patients exhibiting sudden changes in 
displacement of the baseline position. Table 4-1 demonstrates characteristics of the patients 
analyzed.  
Table 4-1. Selected subjects motion characteristics 
Patient 
Centroid tumor 
motion (cm) 
Standard Deviation (cm) Motion 
Irregularities End-Inhale End-exhale 
1 1.23 0.092 0.017 Periodic 
2 1.02 0.254 0.060 Baseline drift  
3 0.93 0.219 0.127 Baseline shift 
4 0.73 0.168 0.170 Baseline shift 
5 0.60 0.300 0.179 Baseline drift  
6 1.50   Periodic 
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4.2.2 Treatment planning and delivery  
RPB traces were acquired corresponding to previously treated patients from our in-house 
respiratory gated SABR protocol. All treatment plans corresponding to these patients were 
optimized using SmartArc VMAT technique in Pinnacle Treatment Planning system v9.6 
(Philips Medical Systems, Fitchburg, MA) and consisted of two 225⁰ arcs.   
The Varian TrueBeam linac version 2.0 with the integrated respiratory gating system, 
operating in Research Mode (Varian Medical Systems, Palo Alto, CA), was used for 
treatment delivery due to its ability to design customized beam and imaging trajectories. 
Here, the axes of the treatment delivery, such as the gantry, collimator, couch, and MLC, 
and imaging points are user controlled and programmed as a function of cumulative control 
points. Research Mode trajectories were written in an extensible markup language (XML) 
and allowed for modification of the partial 225° arcs from the original VMAT treatment 
plans. Namely, simultaneous kV imaging was added to the VMAT arc. These plans were 
then delivered to the Quasar programmable respiratory motion phantom (Modus Medical 
Devices, London, ON). The Quasar programmable respiratory motion phantom contained 
a cedar insert with an embedded 3 cm delrin sphere, to simulate healthy lung with a tissue-
like tumour. The internal trace was extracted from the superior-inferior motion of the insert. 
Meanwhile, the external trace was obtained from the respiratory gating box, placed on a 
platform stage with vertical motion (Figure 4-1). The phantom operates using a circular 
shaped cam for sinusoidal motion, and another cam for typical respiratory cycle to drive 
both the platform stage and insert. The Quasar motion phantom was programmed according 
to the real-patient one-dimensional breathing trace derived above. 22 
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Figure 4-1. Quasar programmable respiratory motion phantom, depicting the moving 
cedar insert with an embedded delrin sphere (internal motion) and the platform stage for 
the respiratory gating box (external motion). 
Treatment delivery was performed under free breathing ungated, amplitude gated, and 
phase gated conditions. Free breathing ungated conditions encompassed 100% duty cycle 
via phase gating while respiratory gated conditions encompassed 40% duty cycle at end 
exhalation. The free breathing ungated delivery condition was used to test reproducibility 
of motion with variability in the phantom. Amplitude gating has shown to perform well 
with the lack of consistent periodicity in breathing6–8, whereas phase gating has been shown 
to produce errors under irregular motion conditions that can lead to inconsistent triggering 
of the beam on and off 8.  
The predictive filter defines a threshold within which the respiratory breathing trace should 
correspond to the reference breathing trace. Before treatment delivery, the predictive filter 
registers amplitude versus respiratory phase data points to define periodicity in the 
breathing trace. The threshold of the predictive filter, or quality of gating, applied during 
treatment allows the beam to trigger off if the breathing traces falls outside of these limits. 
We further investigated the impact of the predictive filter threshold on phase-based gating 
acquired with kV imaging. All respiratory phase gated deliveries were repeated with a 
predictive filter of 0, 2, 5, and 10% threshold, or as set in the XML treatment file with the 
gating quality of 0, 0.02, 0.05, and 0.1.  
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4.2.3 Image acquisition 
On-board gated kV projections were acquired simultaneously during MV beam-on while 
inside the gating window. A dynamic gain fluoroscopy protocol, with an imaging 
frequency of 7 frames/second, was designed to maintain low kV dosage while attaining 
sufficient imaging data to establish an internal breathing trace. A head and neck clinical 
pre-treatment cone-beam CT protocol was used to define imaging parameters. The 
fluoroscopic imaging parameters were 100 kVp, 20 mA, with a 20 ms duration of the kV 
pulse. A full bow-tie filter was applied.  
4.2.4 Analysis of the internal and external trace 
The phantom was set-up under static breathing conditions such that the 3-cm delrin sphere 
was located at isocenter. The delrin sphere, embedded in cedar, exhibits one-dimensional 
motion in the superior-inferior direction or y-orientation in the kV projection. The location 
of the delrin sphere was determined by acquiring multiple line profiles from 1-cm left to 
1-cm right of the center of the sphere (Figure 4-2). In all the line profiles, the noise and 
average intensity in the cedar were determined. The delrin sphere was identified as 
consecutive values in the line profile that deviate from the cedar. Profiles affected by the 
noise of MV degradation or obstructed from the treatment couch were removed if deviating 
by two standard deviations of the centroid mean position. The remaining profiles were 
averaged to determine the centroid in the kV projection. The internal trace was defined as 
the variability of the centroid position between consecutive projections. Afterward, the 
motion trace was manually inspected for projections, or centroid points, deviating from the 
programmed motion. These points were removed from further analysis if manual analysis 
revealed differing centroid values. The header of the imaging files enclosed the amplitude 
of the external surrogate box for each kV projection. The external trace was defined as the 
variability in amplitude of the external surrogate box from consecutive kV projections.  
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Figure 4-2. Quasar respiratory motion phantom depicting the moving cedar with the 
embedded delrin sphere. Centroid of the delrin sphere was calculated based on line profiles 
between the dashed lines. 
Linear regression was used to compare the accuracy of the external surrogate trace in 
predicting the internal trace. Based on this model, correlation of determination, R2, was 
determined for all deliveries. The point-to-point root-mean-square-error (RMSE) was 
calculated over the waveform of the internal and external motion. The difference in 
correlation between free breathing ungated, phase gated, and amplitude gated conditions 
for each of the six breathing traces under varying predictive filters were investigated.  
The data acquired from the on-board kV imaging was also used to examine the variations 
in the residual motion in amplitude and phase based respiratory gated during VMAT 
delivery. The length of gating window for the breathing cycle was calculated based on the 
time stamp associated with each projection. Displacements in the position at the start and 
end of the gating window was analyzed to investigate discrepancies in amplitude associated 
with the same phase. The amplitude value of the time stamp associated with the entering 
or exiting the gating window in amplitude and phase gating was measured. 
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4.2.5 Phase shift  
A phase shift of the external surrogate can occur during treatment due to either patient 
specific physiology or system latency in machine response to recording the external data 
points and triggering respiratory gating. Unfortunately, the Quasar respiratory motion 
phantom is unable to decouple the external platform motion from the insert motion. 
Therefore, the ability of during treatment kV imaging to identify a phase shift between the 
internal and external trace, was investigated by using a second phantom, the Quasar 
programmable motion platform (Modus Medical Devices, London, ON), with independent 
motion. The external motion trace and, hence, the respiratory gating trigger, were obtained 
via the second phantom while the internal trace was obtained via on-board kV imaging of 
the Quasar programmable respiratory motion phantom. A sinusoidal motion pattern with a 
2-cm peak-to-peak motion and 4 second period, was programmed for both phantoms with 
eight known shifts spaced 0.4 seconds apart. The correlation of determination coefficient 
in the linear regression statistical test was performed for each experimental set of 
respiratory traces. The observed phase shift was calculated by shifting the external trace, 
in time, until correlation was maximized. 
 
4.3 Results 
4.3.1 Correlation analysis 
The calculated internal and external trace along with the programmed breathing pattern for 
the ungated, amplitude gated, and phase gated treatment delivery, is displayed in Figure 
4-3 for the first 45 seconds of treatment of patient 1. This respiratory trace entailed 
repetitive RPB motion with low deviations in the end-exhale position. A correlation of R2 
= 0.996, 0.948, 0.973 was achieved for free-breathing ungated, amplitude gated, and phase 
gated, respectively.  
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Figure 4-3. Computer controlled respiratory breathing trace (solid line), and the internal 
target (circle symbol) and external surrogate trace (asterisk symbol) are shown for free-
breathing ungated, end-exhale amplitude gated, and phase gated in the first 45 seconds of 
treatment delivery. Over the course of the treatment delivery, a correlation of R2 = 0.996, 
0.948, 0.973 was achieved for free-breathing ungated, amplitude, and phase gating, 
respectively. 
The correlation observed in free breathing ungated treatment delivery, validates the Quasar 
motion phantom accuracy in reproducing the computer controlled real patient breathing 
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trace, and the automation technique in delineating the internal trace despite MV 
degradation, and obstruction from the acrylic of the phantom and treatment couch at some 
angles. Regardless of motion irregularities programmed, the correlation in the free 
breathing ungated scenario for all patients ranged between R2 = 0.950-0.997 with a mean 
of 0.986, as shown in Figure 4-4A. Similarly, for amplitude gated and phase gated 
scenarios, correlation ranged between R2 = 0.919-0.987 or a mean of 0.942, and R2 = 0.959-
0.981 or a mean of 0.974, respectively.  
Different predictive filter thresholds were applied during respiratory phase gated delivery. 
The correlation coefficient for treatment deliveries with a predictive filter threshold of 0%, 
2%, 5%, and 10% ranged between R2 = 0.959 to 0.981, 0.938 to 0.976, 0.890 to 0.975, and 
0.890 to 0.975, respectively (Figure 4-4B). The correlation was high for all scenarios 
including the sinusoidal case (patient 6) where no variability amongst treatment delivery 
techniques was observed. In RPB with high end-exhalation position variability, the MV 
and kV beams were not able to trigger due to the periodicity of motion remaining outside 
of the threshold. For these breathing traces, only a zero threshold could be used to allow 
the MV and kV beam to trigger. This can be observed by the lack of points in Figure 4-4B 
for patients 4 and 5.   
 92 
 
    
 
Figure 4-4. The coefficient of determination, R2. (A) Free breathing ungated (circle 
symbol), amplitude-gated (asterisk symbol), and phase-gated (square symbol). (B) Phase-
gating with different predictive filter thresholds applied of 0% threshold (circle symbol), 
2% threshold (asterisk symbol), 5% threshold (square symbol), and 10% threshold.  
The variety of RPB patterns traces is displayed in Figure 4-5 along with the corresponding 
linear regression analysis in the free breathing ungated, amplitude gated and phase gated 
scenario. Patient 1 (Figure 4-5A) represented a repetitive RPB waveform, patient 2 (Figure 
4-5B) represented a baseline drift scenario, and patient 3 (Figure 4-5C) represented an RPB 
trace exhibiting baseline shift. The phase-based gated deliveries exhibited a greater range 
of motion, approaching the motion magnitude of the free-breathing in Figure 4-5C.  
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Figure 4-5. Different programmed motion traces and the corresponding linear regression 
analysis for free breathing ungated (circle), amplitude gated (asterisk), and phase gated 
(square). A) Patient 1 exhibited a repetitive breathing with a low standard deviation in the 
end-exhalation, b) patient 2 exhibited amplitude variation, and c) patient 3 exhibited a 
baseline shift and varying periodicity.  
The calculated RMSE for the different treatment delivery techniques and the inclusions of 
various predictive filters are shown in Figure 4-6.  Submillimeter accuracy was found in 
all deliveries. The free breathing ungated delivery, with the greatest motion magnitude, 
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resulted in the largest error at a range of 0.023 cm to 0.065 cm, whereas the error in the 
residual motion in amplitude gating and phase gating resulted in a range of 0.015 cm to 
0.024 cm and 0.015 cm to 0.033 cm, respectively (Figure 4-6A).  With various predictive 
filters the RMSE ranged between 0.015 cm to 0.033 cm, 0.014 cm to 0.026 cm, 0.014 cm 
to 0.026 cm, and 0.014 cm to 0.025 cm, for predictive thresholds of 0%, 2%, 5%, and 10%, 
respectively (Figure 4-6B). 
 
Figure 4-6. Root mean square error, RMSE, comparing the error between the internal and 
external trace during free breathing ungated (circle symbol), amplitude-gated (asterisk 
symbol), and phase-gated (square symbol) deliveries. (A); phase-gating with different 
predictive filter thresholds of 0% threshold (circle symbol), 2% threshold (asterisk 
symbol), 5% threshold (square symbol), and 10% threshold (B).   
4.3.2 Residual motion analysis 
The length of the gating window during amplitude and phase gated deliveries is shown in 
Figure 4-7. The overall deviations with phase gating were lower than with amplitude gating 
at 0.276 seconds and 0.757 seconds, respectively.   
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Figure 4-7. Variation in the length of the duty cycle during amplitude (diamond) gated, 
and phase gated (circle) deliveries. The symbol represents the average while the whiskers 
represent the standard deviation.  
Irregular, non-periodic motion has been shown to lead to significant variabilities in phase 
gating6. On board kV imaging was utilized to compare the amplitude displacement 
variability at the entrance and exit of the gating window during amplitude- and phase-based 
respiratory gated VMAT, as shown in Figure 4-8. On the contrary to the length of the gating 
window, the position variations in the entry and exit of the gating window were less in 
amplitude gating than phase gating, shown in Figure 4-8 by small whiskers in the mean 
position of amplitude gating. The mean position variations in exiting and entering the 
gating window were 0.024 cm and 0.131 cm in amplitude and phase gating, respectively.   
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Figure 4-8. The amplitude of motion at entry, left, and exit, right, the gating window in 
phase-gating. Diamond and circle symbol represents the mean amplitude when entering 
and exiting the gating window, while the whiskers represent the standard deviation.  
4.3.3 Determining a phase shift  
Known baseline phase shifts between the external surrogate trace and internal target trace 
were introduced to investigate the ability of kV imaging to detect such phase shifts. A 
second independently programmed phantom was used to trigger the kV and MV beam 
while the original phantom’s trace was shifted at 0.4-second intervals. The correlation 
coefficient between the internal and external trace for each shift was 0.229 ± 0.14. The 
external waveform was shifted until the correlation coefficient was maximized, resulting 
in a mean ± standard deviation correlation of 0.974 ± 0.03  (Table 4-2).  
 
 
 97 
 
Table 4-2. Programmed shifts between the internal target motion and the external surrogate 
marker were measured using the correlation coefficient.  Their respective correlation 
values are shown.   
Shift (seconds) 
Correlation of Determination 
(R2) 
Programmed Measured Before shift After shift 
0.4 0.364 0.026 0.915 
0.8 0.636 0.027 0.981 
1.2 1.182 0.166 0.993 
1.6 1.455 0.434 0.989 
-0.4 -0.455 0.007 0.994 
-0.8 -0.909 0.127 0.997 
-1.2 -1.200 0.269 0.995 
-1.6 -1.727 0.773 0.929 
 
The results indicated that the kV projections were able to accurately detect any phase shifts 
in phase respiratory gating, shown in Figure 4-9, where the programmed and measured 
shift are displayed. The correlation between the known shifts and the measured was 
determined to be 0.997. Ideally, the slope of the line between the measured and 
programmed data points should be one, and the y-intercept should be zero. However, the 
values achieved are within the resolution of the imaging, of 0.091 seconds per frame or 11 
frames per second.  
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Figure 4-9. The programmed shift between the two independent phantoms, and the 
measured shift when maximizing the correlation.  
 
4.4 Discussion  
To the best of our knowledge, this is the first study that investigated kV imaging as a tool 
to evaluate internal target and external surrogate verification during gated VMAT treatment 
without the use of fiducial markers. This was accomplished by varying respiratory gating 
parameters such as the mode (free breathing ungated, amplitude and phase-gated), and the 
predictive filter threshold used in phase gated delivery. 
Sinusoidal motion trace, 1.5 cm peak-to-peak and 4 second period, was tested, along with 
five RPB waveforms exhibiting repetitive motion, baseline drifts, and baseline shifts with 
differing end-exhale deviations. Decreasing correlation between the internal and external 
trace could be due to a time delay on the acquisition kV imaging inside the gating window 
and/or latencies in recording the external trace. Chugh et al. concluded time delays of over 
100 ms can be expected in breathing waveform with period variations23. In all treatment 
R² = 0.9972
y = 0.9909x - 0.0819
-2
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
1.2
1.6
2
-2 -1.6 -1.2 -0.8 -0.4 0 0.4 0.8 1.2 1.6 2
M
ea
su
re
d
 P
h
as
e
 S
h
if
t 
[s
]
Programmed Phase Shift [s]
 99 
 
delivery scenarios, a high correlation was observed despite increasing deviation in the end-
exhale and non-periodicity. 
Despite a higher correlation between the external surrogate and internal target observed in 
phase gating compared to amplitude gating, in Figure 4-3, gated kV images appear to be 
acquired outside the end-exhalation during phase-based respiratory gating. Phase gating 
relies on sinusoidal approximation based on previous breathing periods. Learning period 
of four waveform periods is required to learn the characteristics of the respiratory trace, as 
discussed in section 1.5.3 of this thesis. In TrueBeam Research Mode, treatment delivery 
was initiated without learning the characteristics of the breathing trace. Consecutively, the 
beam triggered outside of the end-exhalation gating in the beginning of the trace, as 
observed in phase gating of Figure 4-3.  
Clinically, the reference breathing trace recorded during 4D-CT acquisition is used to 
provide a histogram of displacement versus phase. This allows for calculations of the 
respiratory waveform periodicity. Malone et al. 2014  recommend the use of a 5%-40% 
predictive filter for reproducible treatment delivery10. In treatment delivery, a predictive 
filter threshold reduces the potential of triggering the MV beam when the patient is outside 
the limitations included in the 4D-CT acquisition, i.e. the patient coughs, takes a deeper 
breath, or exhibits a lack of periodicity. However, the addition of the predictive filter to 
treatment delivery increases treatment delivery complexity, along with high dose rate 
respiratory gated VMAT, which in turn can cause latencies in machine response. A strong 
correlation was observed in all deliveries where a predictive filter was included. In the 
selected group of waveforms analyzed, patients 4 and 5 had the greatest deviations in end-
exhale position which inhibited the use of a predictive filter during respiratory gating. 
Patient 2 was the only study subject that required removal of one to four projections out of 
the total 278 - 368 projections acquired after manual verification. The poorer results of the 
internal trace can explain the lower correlation values seen in this patient.  
Phase gating is susceptible to dosimetric uncertainties due to potentially long treatment 
times and due to potential drift occurring with the external surrogate which leads to phase 
shifts in the internal and external trace9,11. In SABR treatments that use high dose rates, 
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capable with flattening filter free beams, the treatment time can be reduced to 3-4 minutes4 
making these patients less vulnerable to baseline drifts. Shifting the external trace along 
the internal trace to maximize the correlation coefficient provided the ability to accurately 
observe phase shifts. Although only tested for sinusoidal motion, this method can still 
provide an approximation of more complex real patient breathing waveforms. Uncertainty 
in the phase shift experiment lies in the usage of two independently programmed phantoms, 
allowing the study to become prone to additional mechanical errors.  
Previous studies have investigated the internal and external correlation via acquisition of 
the planning CT dataset13,14, via pre-treatment image verification techniques16–18, during 
treatment using fiducial markers and the Mitsubishi Real-Time Radiation Therapy 
system16,20,24 or via fluoroscopy in the CyberKnife system19.  Most of these studies require 
additional imaging dose, but it is important to limit kV exposure time to limit skin dose25. 
This study investigated computer customized kV images acquired at specific imaging 
points, and the imaging parameters maintained similar to pre-treatment CBCT protocol 
while capturing fewer projections.  
During treatment, kV imaging can also provide verification of the gating window. The 
length of the gating window exhibits more variance in amplitude gating than phase gating 
because amplitude gating is based on a threshold for displacement, whereas phase gating 
relies on two angular phases in every breathing cycle. Variation in the baseline amplitude 
and length of the end-exhale will cause deviations in the length of each gating window in 
amplitude gating. Whereas the variations listed above, as well as periodicity of the 
respiratory signal, will influence the position of each breathing cycle in phase gating as 
shown in Figure 4-6 and Figure 4-7. Recently, studies have demonstrated the capability of 
during treatment verification using the on-board MV or kV imaging26–30.  
This study was limited to phantom experiments as it was completed using Research mode 
of Varian TrueBeam linear accelerators and does not investigate the correlation in patients 
during treatment. Patient-specific hysteresis may alter the relationship between the internal 
and external targets not accounted for during respiratory gated VMAT delivery31. 
However, the method investigated here can provide a tool to triage irregular RPM 
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waveforms to make clinical decisions on the use of respiratory gated motion management 
if there is a lack of correlation. Clinical use of kV-imaging during gated VMAT delivery 
could detect discrepancies in correlation and potentially be accounted for in subsequent 
treatment fractions. 
 
4.5 Conclusions 
In this study, on-board kV imaging has been validated as a tool that can verify the external 
surrogate motion and internal target motion correlation during respiratory gated VMAT. 
The technique examined RPB exhibiting regular and irregular motion with different 
breathing waveform patterns, considered various gating scenarios, and was able to 
accurately detect any phase shifts. Verification of respiratory-gated VMAT delivery is 
essential, especially for adaptive radiation therapy, which relies on accurate intrafraction 
knowledge of tumour position for accurate dose calculation.  
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Chapter 5  
5 Investigation of image quality of intrafraction cone beam 
CT for 3D verification of respiratory-gated VMAT delivery 
The contents of this chapter are in preparation for submission to Physics in Medicine and 
Biology entitled “Investigation of image quality of intrafraction cone beam CT for 3D 
verification of respiratory-gated VMAT delivery” by Xhaferllari I, Dekker K, Hajdok G, 
Gaede S. 
5.1 Introduction  
Respiratory motion causes a major challenge in the treatment of thoracic and abdominal 
cancers with radiation therapy1,2. At the same time, the clinical implementation of 
stereotactic ablative body radiotherapy (SABR) in early-stage non-small cell lung cancer 
(NSCLC) has led to higher doses per fraction, requiring tight margins3–5. Respiratory 
gating is a technique to manage respiratory motion by limiting the radiation beam to 
specific portions of the breathing cycle6,7. As a result, high doses are delivered to the target, 
while limiting dose to normal tissue. One of the main limitations of respiratory gating is 
that it relies on the accuracy of an external surrogate to predict the internal motion of the 
target, despite intrafraction variations in respiratory motion8,9. Therefore, treatment dose 
verification methods are required to ensure the planned dose distribution are accurately 
delivered during respiratory gated radiotherapy.  
The application of image-guided radiation therapy (IGRT) improves tumour targeting10. 
On-board kV imaging and electronic portal imaging device (EPID) are widely used as a 
pre-treatment image-based verification method11. Cone-beam CT (CBCT) can be 
reconstructed for volumetric verification when kV or MV planar images are acquired in an 
arc. Pre-treatment CBCT portrays patient anatomy before treatment and aids in reducing 
patient misalignments. However, CBCT acquired prior to treatment does not guarantee 
accurate dose delivery to the target during treatment delivery, especially for moving 
targets.  
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Continuous imaging through EPID in cine mode has been used for during treatment 
verification.  However, EPID is limited in the investigation of anatomy alignments by the 
field-of-view (FOV) of the treatment beam, especially for SABR treatment delivery with 
small field sizes. Recently, intrafraction verification techniques using on-board kV 
projections have been investigated for treatment verification of SABR, including 
volumetric modulated arc therapy (VMAT)12–15. The benefit of during VMAT imaging is 
the ability to reconstruct a volumetric CBCT. However, added imaging dose from the on-
board kV unit should be maintained as low as possible16.  For during treatment verification, 
the added imaging dose is reliant on the treatment session time and the imaging acquisition 
mode. Treatment session times are greater during respiratory gated SABR compared to 
ungated conventional radiation therapy, due to higher doses per fraction in SABR, and the 
restriction of radiation beam delivery to portions of the breathing cycle. The ability to 
compute gated-kV imaging concurrent with treatment can help reduce patient exposure and 
limit imaging dose for respiratory gated patients. Another limitation of intrafraction kV 
imaging is the potential degradation of the kV projections due to MV scatter hitting the kV 
detector17–19.  
The hypothesis of this study is that gated on-board kV CBCT can be used as a 3D method 
to validate the delivery of respiratory-gated VMAT using a programmable respiratory 
motion phantom. This was tested by evaluating imaging quality and target visualization 
capabilities of during treatment gated on-board kV CBCT while minimizing kV beam-on 
time. 
 
5.2 Methods  
5.2.1 Quasar Motion phantom  
The Quasar programmable respiratory motion phantom (Modus Medical, London, ON) 
was used in all on-board kV CBCT reconstructions. It is a dynamic phantom with the 
ability to insert different moving components, useful for investigating the impact of motion 
on imaging and radiation delivery (Figure 5-1A). For the purpose of this study, a cedar 
cylindrical insert, representing lung equivalent electron density with embedded polystyrene 
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spheres, representing tumour equivalent electron densities, was added (Figure 5-1B, C). 
The polystyrenes spheres ranged in sizes of 3-cm, 2-cm, 1-cm, and 0.5-cm, best 
exemplifying detectability properties of different sized lesions typically seen in early-stage 
NSCLC treated with SABR. The cedar and polystyrene unit moves in the superior-inferior 
(SI) direction by the magnitude specified in the programmed motion trace. 
 
Figure 5-1. Quasar programmable respiratory motion phantom (A). Moving insert 
composed of cedar, representing normal lung tissue, and embedded polystyrene spheres, 
representing tumour tissues (B). (C) Schematic of the moving insert with various sizes and 
locations of polystyrene spheres. 
5.2.2 Imaging Acquisitions  
Varian TrueBeam linear accelerator v.2.0 (Varian Medical System, Palo Alto, CA) in 
Research Mode was used to obtain on-board kV imaging simultaneous to the MV treatment 
beam. Research Mode allows for user defined imaging and treatment delivery protocols, 
and has the capability of synchronizing image acqusition to treatment delivery. On-board 
kV imaging was acquired concurrently to treatment beam delivery of a clinical SABR lung 
plan delivered in a 225° partial arc. Ungated and triggered gated kV acquistion projections 
were collected with a stationary and moving phantom, respectively. A full bow-tie filter 
and a titanium filter were added to compensate for greater attenuation of the x-ray beam at 
the center of the FOV by the phantom, and reduce low energy x-rays of the beam, 
respectively. 
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5.2.2.1 Imaging Parameters  
5.2.2.1.1  Treatment Deliveries under static conditions 
In the first set of measurements, static conditions were kept to investigate various imaging 
parameters on image quality and target detectability, in the absence of respiratory motion.  
This included reconstructing a pre-treatment on-board kV CBCT of the phantom in the 
absence of MV scatter, based on a current clinical protocol, acquired using a full 360° arc 
at 11 frames per second. A reference on-board kV CBCT, in the presence of MV scatter, 
was reconstructed using similar parameters to the pre-treatment on-board kV CBCT, but 
acquired at 7 frames per second.  The acquisition parameters for the reference on-board kV 
CBCT were 100 kVp, 20 mA, 20 ms, 7 frames per second, during SABR VMAT with arc 
range of 225°, and a kV source to detector distance (SDD) of 150 cm. MV scatter was 
added using the SABR-VMAT clinical plan of a previously treated patient. We varied the 
energy, tube current, and SDD. All static deliveries and respective test numbers, referred 
throughout this paper, are summarized in Table 5-1.  
Table 5-1. Imaging parameters of static acquisitions. The reference acquisition has been 
bolded. 
Test # Energy 
(kVp) 
Current 
(mA) 
Pulse length 
(ms) 
SDD 
(cm) 
Frame rate 
(fr/sec) 
Arc range 
(degrees) 
MV 
scatter 
1 100 20 20 150 11 360 No 
2 100 20 20 150 7 225 Yes 
3 80 20 20 150 7 225 Yes 
4 125 20 20 150 7 225 Yes 
5 100 10 20 150 7 225 Yes 
6 100 40 20 150 7 225 Yes 
7 100 20 20 140 7 225 Yes 
8 100 20 20 160 7 225 Yes 
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5.2.2.1.2 Treatment Deliveries under motion conditions  
In the second set of experiments, the motion phantom was enabled during treatment 
delivery as kV projections were captured. Three real-patient breathing (RPB) traces were 
tested to represent various breathing patterns, depicted by a simplified sinusoidal waveform 
in Figure 5-2. The three RPB waveforms were extracted from CT-simulation of previous 
patients treated with respiratory gating. Each RPB trace was normalized to the total motion 
measured in the 4D-CT dataset. A fast, repetitive RPB trace (Figure 5-2A) with a peak-to-
peak amplitude of 1.2 cm, was used to represent regular motion. RPB traces with irregular 
motion patterns were observed with a baseline drift20 (Figure 5-2B) and a trace with a 
baseline shift21 (Figure 5-2C). The baseline drift motion displayed a veering position of the 
baseline with a peak-to-peak amplitude of 1.0 cm. Whereas the baseline shift trace 
displayed sudden changes in the baseline amplitude of motion, with a peak-to-peak motion 
of 0.9 cm. A set of projections were acquired under free breathing ungated conditions, 
using a 100% duty cycle, and amplitude- and phase-based gating using a 40% duty cycle 
for each RPB. The reference imaging parameters, from acquisition (2) in Table 5-1, were 
used for all acquisitions. 
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Figure 5-2. Schematic of the different waveforms in a simplified sinusoidal waveform. A) 
Fast, repetitive breathing, B) Baseline drift (shown by the red line), C) Baseline shift 
(shown by the red step). 
5.2.2.2 CBCT reconstruction  
In clinical practice, CBCT images are generally reconstructed using the Feldkamp-Davis-
Kress (FDK) algorithm of filtered backprojections22. To simulate clinical application, all 
datasets in this study were reconstructed using the FDK algorithm with Hamming filter 
applied. Reconstructions were also computed using in-house CT projection code written in 
CUDA-C for GPU acceleration on a CPU with intel i7-2600 and GPU of NVIDIA GTX 
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780. The reconstructed matrix size was 512x512x384 pixels with isotropic voxel of 0.0517 
cm. Therefore, the FOV was 26.5 cm by 26.5 cm. The number of projections per scan 
varies with gantry speed, frame rate, treatment modality, and the periodicity of the 
respiratory breathing trace. The gantry speed was limited to 6° per second, and the highest 
dose rate of 2400 monitor units per minute was used for the treatment beam. The number 
of projections acquired in the pre-treatment on-board kV CBCT was 662. The during 
treatment on-board kV CBCTs were acquired under static conditions with approximately 
311 projections, due to shorter scanning angle and lower frame rate. The during treatment 
CBCTs acquired under respiratory motion conditions resulted in 311 projections for the 
ungated conditions, and 345 – 397 projections for gated conditions. Acquisitions with MV 
scatter resulted in fewer number of projections compared to the pre-treatment on-board kV 
CBCT, because a lower kV acquisition frame rate of 7 frames per second was used in 
acquisitions with MV scatter compared to 11 frames per second in pre-treatment on-board 
kV CBCT projections. CBCT acquired under gated conditions required greater projections 
than ungated conditions due to frequent ramp up and down of the dose rate limiting the 
gantry speed.   
In datasets acquired using imaging parameters expected to lead to a decrease in image 
quality (e.g. low mA, low kVp) with respect to the reference acquisition, and the reference 
acquisition, [(2), (3), (5), (8)], were reconstructed using an iterative reconstruction 
technique to potentially increase image quality. The iterative algorithm applied, OSC-
TV23, combines ordered subsets convex (OSC) algorithm24,25 and the total variation 
minimization (TV) regularization technique26. 
5.2.3 Evaluation methods  
5.2.3.1 Image Quality  
The CBCT datasets were exported into 3D-SlicerRT program for analysis27,28. 3D-Slicer is 
a multi-platform free, open source software for visualization and medical imaging 
computing. In the stationary phantom measurements, the polystyrene spheres and a 2-cm 
sphere region of interest (ROI) in the cedar, were delineated on the reference acquisition 
(2). These contours were imported onto the remaining static on-board kV CBCT datasets 
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(1) - (6) to remove contouring bias in the analysis process. The contours for on-board kV 
CBCT datasets (7) and (8) were delineated separately as these datasets had different image 
acquisition geometries. For the respiratory motion induced CBCT datasets, the polystyrene 
spheres and the cedar ROI, were delineated individually based on the blur of motion 
observed. 
Image quality was investigated for all CBCT datasets by calculating the contrast-to-noise 
ratio (CNR) between each of the polystyrene spheres and the ROI in the cedar29.  
𝐶𝑁𝑅 =  
𝜇𝑝 −  𝜇𝑐
𝜎𝑝
                                                                                                                            (1) 
where µp and µc are the mean linear attenuation coefficients of the polystyrene spheres, and 
the cedar ROI, respectively, and σp is the standard deviation of the linear attenuation 
coefficient of each polystyrene sphere.   
5.2.3.2 Target Delineation 
In the static acquisitions, target detectability was identified by calculating the full-width-
half-maximum (FWHM) for each of the polystyrene spheres. The central coronal slice, 
shown in the schematic of Figure 5-1C, displays the center through all four spheres. Based 
on the geometry of the cedar insert, profiles were calculated to obtain the FWHM.  
In the motion induced acquisition, the region of interest delineated in 3D-Slicer was 
compared to the static CBCT targets by calculating the volume percent difference (VPD) 
for each region of interest12.  
𝑉𝑃𝐷 =  
|𝑉𝑀 ∪ 𝑉𝑆  − 𝑉𝑀  ∩ 𝑉𝑆 |
𝑉𝑆
 
× 100%                                                                                                (2) 
where VM represents the volume blur of the polystyrene sphere in the moving phantom 
acquisition, and VS represents the respective polystyrene sphere in the stationary phantom 
delivery. All static and motion induced treatment deliveries were set-up at isocentre, 
inherently shifting the gated delivery targets to the end-exhalation extreme from the static 
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target. To limit registration error in the VPD calculation, the gated CBCT images were 
retrospectively shifted based on the number of pixels representing 40% of the total 
breathing motion.   
Statistical analysis was performed using a one-way analysis of variance (ANOVA) 
followed by a Tukey’s posthoc test in the statistics package of IBM SPSS v.20 (IBM SPSS 
Statistics for Windows, Armonk, NY). 
 
5.3 Results  
5.3.1 Effects of Acquisition Parameters on Image Quality 
The on-board kV CBCT acquisitions with a static phantom were used to investigate image 
quality in the different sized polystyrene spheres. In Figure 5-3, the coronal slice from the 
isocentre of the static CBCT reconstructions is shown using the same window and level. 
The reconstruction volume was cropped to display only the moving cedar with the 
polystyrene spheres. The pretreatment CBCT (labelled no MV) (1) displayed the best 
visualization of the spheres. However, each polystyrene sphere was visible in all 
reconstructions, except for the 0.5-cm sphere in the 80 kVp (3) CBCT volume. 
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Figure 5-3. Coronal slice at isocenter in all the static deliveries. The corresponding 
numbers represent the imaging parameters described in the methods section. For visual 
purposes, the slice is cropped to only represent the moving insert. The same window level 
is used in all eight CBCT images.   
The effect of MV scatter on on-board kV CBCT was investigated in polystyrene. Linear 
attenuation coefficients in the pre-treatment CBCT (1) and the reference acquisition (2) 
were compared by delineating the 2-cm polystyrene sphere. The difference in linear 
attenuation coefficient was investigated by subtracting the pre-treatment CBCT (1) from 
the reference acquisition (2), shown by the red histograms in Figure 5-4. In polystyrene, a 
decrease in the linear attenuation coefficient is observed, with a mean value of 0.027 cm-1, 
and spread or standard deviation of 0.01 cm-1. Previous studies have observed a significant 
effect of MV scatter on kV imaging18,30, however, the field size in these studies was 10 cm 
by 10 cm or greater, whereas this study used a smaller field size of 4.5 cm by 4.2 cm, as 
observed in early-stage NSCLC SABR treatment.  
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Figure 5-4. Difference in linear attenuation coefficient (µ) values in the polystyrene ROI 
between the reference CBCT acquisition in the presence of MV scatter (2), and the pre-
treatment CBCT acquisition in the absence of MV scatter (1). The difference in linear 
attenuation coefficient (µ) values is shown by the red histogram. 
The CNR between each polystyrene sphere and cedar ROI displayed the lowest values for 
acquisitions with 80 kVp (3), where CNR ranged between 1.8, for the 0.5-cm sphere, to 
2.2, for the 1-cm sphere, as shown in Figure 5-5. A significant reduction was found for 
volumes acquired with 80 kVp (3) (p = 0.002), and 10 mA (5) (p = 0.006), compared to the 
pre-treatment CBCT acquired without MV scatter (1). Similarly, a significant difference 
was observed when comparing CNR for 120 kVp (4) and 40 mA (6), to 80 kVp (3) and 10 
mA (5) (p < 0.015). Otherwise, no significant difference was observed amongst other 
CBCT volumes. For volumes acquired with the reference MV scatter acquisition (2), 
compared to the pre-treatment on-board kV CBCT (1), increased tube voltage acquisition 
(125 kVp) (4), and increased current acquistion(40 mA) (6), there was a greater 
discrepancy between CNR in the larger spheres, 3-cm and 2-cm, compared to the CNR in 
the smaller spheres 1-cm, 0.5-cm. The 0.5-cm sphere CNR ranged between 2.9 to 4.0, 
whereas the CNR in the 3-cm sphere ranged between 3.7 to 6.4.  
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Figure 5-5. Contrast-to-noise ratio (CNR) between each of the polystyrene spheres and a 
region of interest in the cedar in CBCT in a stationary phantom. 
Similarly, when comparing FWHM, the lower energy (80 kVp) (3) diminished the 
visibility of the 0.5-cm lesion (Figure 5-6). For the remaining CBCT datasets, the FWHM 
calculation for the 3-cm, 2-cm, 1-cm, and 0.5-cm spheres resulted in a range of 2.96 to 3.02 
cm, 1.98 to 2.07 cm, 0.92 to 1.11 cm, and 0.47 to 0.58 cm, respectively. No significant 
differences were found amongst different acquisition parameters. On-board kV CBCT 
acquired during SABR treatment delivery, resulted in detectability of different sized 
lesions for all acquisition parameters explored in this study.  
 117 
 
 
Figure 5-6. The full-width-half-maximum (FWHM) of all polystyrene spheres in the 
centroid slice of the CBCT dataset in a stationary phantom. 
5.3.2 Comparison of CBCT reconstruction techniques 
The FDK filtered backprojection algorithm is implemented clinically for pre-treatment 
CBCT reconstruction. All acquisitions were reconstructed using FDK filtered 
backprojection. Iterative reconstruction has recently been shown to improve imaging 
quality in lower dose acquisition modes, and in acquisitions with limited projections23. The 
reference acquisition (2), projections acquired with a low energy of 80 kVp (3), low current 
of 10 mA (5), and 160 SDD (8), were reconstructed using the OSC-TV iterative algorithm. 
The coronal slice of the reconstruction in the centroid position comparing FDK to OSC-
TV, is displayed in Figure 5-7.  
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Figure 5-7. Comparison of filtered backprojection (FDK algorithm) and iterative (OSC-
TV algorithm) reconstruction displayed in the coronal slice at isocenter. The same window 
level was used in both datasets. 
A significant increase (p<0.001) was observed in the CNR calculations with OSC-TV 
compared to FDK (Figure 5-8). The CNR increased by 2.6 times or more in the different 
polystyrene spheres for acquisitions with 80 kVp (3). The 0.5-cm sphere in the 80 kVp 
CBCT reconstruction (3) was visible and had a FWHM value of 0.53 cm. FWHM 
calculations on the iterative reconstructed CBCT datasets did not reveal significant 
differences (p>0.05) and all the ROIs were identified. The FWHM for the 3-cm, 2-cm, 1-
cm, and 0.5-cm polystyrene spheres ranged from 2.97-3.00 cm, 1.98 – 2.01 cm, 0.94-1.01 
cm, and 0.43 – 0.53 cm, respectively. Iterative reconstruction with OSC-TV demonstrates 
the potential to reduce imaging dose while maintaining detectability of various sized 
lesions.  
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Figure 5-8. Comparison of contrast-to-noise ratio (CNR) between filtered back projection 
(FDK algorithm) and iterative reconstruction (OSC-TV algorithm) for every polystyrene 
sphere. 
5.3.3 Target Motion Analysis 
Figure 5-9 demonstrates the coronal slice of the on-board kV CBCT for the static (reference 
imaging protocol), and the RPB trace exhibiting a baseline drift under free breathing 
ungated, amplitude and phase gated conditions. Blurring is observed among all polystyrene 
spheres in the free breathing ungated image, where the visualization for 0.5-cm and 1-cm 
spheres was difficult. 
 
Figure 5-9. Coronal slice at isocenter comparing static, free breathing ungated, amplitude 
gated and phase gated delivery for the RPB waveform with a baseline drift 
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Image quality was quantified by the CNR between the delineated polystyrene spheres and 
a ROI in the cedar (Table 5-2). A significantly lower CNR was observed for the free 
breathing ungated conditions encompassing the full blur of motion, compared to amplitude 
gating (p=0.001) and phase gating (p<0.001). However, amplitude gating and phase gating 
did not reveal significant differences (p>0.05).  
Detectability of different sized regions of interest was investigated by comparing the VPD 
between the motion induced acquisition and the static reference (2) on-board kV CBCT 
(Table 5-2). Similar to the CNR calculations, the VPD improved in respiratory gated 
deliveries compared to free breathing ungated conditions, albeit not significant (p>0.05). 
However, in the baseline drift RPB, the VPD decreased in the free breathing ungated 
conditions compared to gated conditions for the 0.5-cm sphere. The delineation of the 0.5-
cm polystyrene sphere was difficult in all CBCT datasets due to respiratory motion 
artifacts. A significant decrease was observed when comparing the CNR of the 0.5-cm 
sphere to the 2-cm sphere (p = 0.014) and the 3-cm sphere (p=0.028). This resulted in a 
significant increase of the VPD for the 0.5-cm sphere compared to the remaining 
polystyrene spheres (p<0.05).   
Table 5-2. Contrast-to-noise ratio (CNR), and volume percent difference (VPD) 
calculation for each polystyrene sphere amongst the different RPB traces and treatment 
delivery conditions. 
Polystyrene 
sphere  
Motion 
Management  
  
Fast, regular RPB 
trace 
Baseline drift 
RPB 
Baseline Shift 
RPB 
CNR VPD CNR VPD CNR VPD 
3-cm  Ungated 2.5 27.6 2.1 15.8 2.1 20.6 
  Amplitude  3.0 16.6 3.8 15.8 3.0 9.2 
  Phase 3.2 12.0 3.3 12.1 2.9 12.9 
2-cm Ungated 2.1 32.7 1.7 25.9 2.5 18.7 
  Amplitude  2.9 24.8 3.7 18.5 3.2 15.3 
  Phase 3.1 20.9 3.9 18.3 3.6 16.5 
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1-cm Ungated 1.8 52.3 1.5 43.4 1.9 43.0 
  Amplitude  2.3 34.8 2.1 38.5 2.7 22.0 
  Phase 2.7 17.6 3.2 32.8 2.7 35.8 
0.5-cm Ungated 1.8 142.0 1.1 41.7 1.9 66.1 
  Amplitude  1.9 85.6 2.7 78.8 2.5 48.9 
  Phase 3.0 57.8 1.5 57.8 1.9 65.5 
 
5.4 Discussion 
Current clinical practice relies on on-board kV CBCT acquired prior to treatment for proper 
patient set-up and verification. However, early-stage NSCLC patients are susceptible to 
intrafraction motion variations not accounted for in pre-treatment verification8,9. The 
objective of this study was to evaluate imaging quality and target visibility of intrafraction 
on-board kV CBCT, and to investigate the influence of respiratory motion on gated and 
free breathing CBCT in a respiratory motion phantom study. High visibility and imaging 
quality is required to allow for usability of on-board kV CBCT acquired during treatment. 
Despite results in literature regarding the negative effects of MV scatter from the treatment 
beam on during treatment kV-CBCT reconstruction18,30, we observed no significant 
differences in image quality and target visibility in CBCTs reconstructed in the presence 
of MV scatter compared to pre-treatment CBCT. Smaller field sizes in SABR treatment 
delivery minimize degradation in on-board kV CBCT from MV scatter, compared to 
studies where field sizes of 10 cm x 10 cm or greater were used.  
Respiratory motion artifacts were minimized through the use of gated on-board kV CBCT 
acquisition. This acquisition mode, restricts on-board kV acquisition to specific portions 
of motion in the phantom, limiting imaging dose. A significant decrease was observed in 
CNR between the free breathing ungated and respiratory gated on-board kV CBCT. For 
very small targets, respiratory motion, introduced motion artifacts in both gated and 
ungated CBCT, causing uncertainty in delineating the 0.5-cm spheres. A limitation in this 
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study was potential retrospective registration misalignment between the gated and static 
on-board kV CBCT calculations introducing uncertainties in the VPD calculations. These 
registration errors can be reduced by acquiring a subset average 4D-CT dataset to represent 
the gating window used during treatment delivery. The subset average 4D-CT can be 
applied to verify respiratory gated treatment delivery.  
Li et al. described a clinical application of gated on-board kV CBCT in patients by 
acquiring kV fluoroscopy during a treatment session, and retrospectively removing all 
projections acquired while the treatment beam is turned off15. This significantly increases 
imaging dose due to the increased length of a respiratory gated treatment session. Kincaid 
et al. investigated gated CBCT acquisition as a method to remove target blurring by 
limiting the MV exposure and shifting the treatment jaws to block the MV beam31. The 
CNR values reported were comparable to the measurements in this study. Our study 
evaluated image quality while maintaining low imaging dose exposure with 124 mAs in 
the free breathing ungated acquisition, and a range of 138 mAs to 159 mAs in the 
respiratory gated on-board kV CBCT, compared to 1478 mAs reported by Kincaid et al.31. 
The application of iterative reconstruction in on-board kV CBCT can further increase 
image quality and target detectability. In this study, various real patient breathing motion 
irregularities investigated did not lead to a significant difference amongst CNR and VPD, 
as expected during gated delivery. 
Imaging dose and potential wear-and-tear on the on-board kV unit was limited by acquiring 
kV projections as triggered gated acquisitions in TrueBeam Research Mode. This modality 
is currently not available in clinical mode but potential implementation could easily allow 
translation to gated on-board kV CBCT to early-stage NSCLC patients. In this patient 
group, gated CBCT will reduce motion artifacts, and limit imaging dose and MV 
degradation. Future work will investigate the role of intrafraction CBCT for usability in 
adaptive radiotherapy.  
5.5 Conclusions 
Intrafraction on-board kV CBCT acquired during gated VMAT SABR treatment can 
provide during treatment verification. In this study, CBCT potentially tarnished by MV 
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scatter during a partial arc delivery was observed to show insignificant differences 
compared to CBCT acquired without MV scatter using similar imaging parameters. In a 
motion induced thoracic phantom, intrafraction respiratory gated CBCT quality was 
significantly improved compared to free breathing ungated CBCT. This intrafraction 
treatment verification method can positively impact adaptive radiotherapy applications. 
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Chapter 6  
 “It always seems impossible until it is done” – Nelson Mandela 
6 Summary, Conclusion, and Future Work 
6.1 Summary  
The overall goal of this thesis was to optimize radiation therapy planning and delivery of 
respiratory gated IMRT and VMAT for early-stage NSCLC patients treated with SABR. 
This goal led to the formulation of the following research objectives:   
 To compare different IMRT treatment delivery techniques to deduce the most 
optimal trade-off between treatment efficiency, tumour dose conformality and 
healthy tissue sparing when treating early-stage NSCLC with SABR. 
 To evaluate the potential reduction of radiation induced lung toxicity through the 
use of respiratory gated VMAT, when treating patients that exhibit significant 
respiratory-induced tumour motion. 
 To determine if on-board kV imaging can be used as a tool to validate respiratory 
gated VMAT delivery by investigating the correlation of the external surrogate 
motion to the internal target motion, and by determining potential phase shifts.  
 To optimize imaging parameters of volumetric CBCT acquired by synchronizing 
kV imaging with respiratory-gated VMAT delivery to provide 3D verification of 
correct tumour targeting  
In the following subsections, an overview of Chapters 2-5 of the thesis will be provided, 
along with resulting conclusions from each study and impact on the above objectives.   
 
6.1.1 Dosimetric planning comparison of IMRT techniques for early 
stage non-small cell lung cancer treated by SABR  
In Chapter 2, various IMRT techniques were compared for the treatment of early-stage 
NSCLC with SABR. This was accomplished by retrospectively planning ten patients with 
three fixed beam techniques (step-and-shoot low and high modulation, and sliding 
 127 
 
window), two VMAT techniques (SmartArc and RapidArc), and Helical Tomotherapy 
with three different fan beam widths (1-cm, 2.5-cm, and 5-cm). The Eclipse v11.3 
treatment planning system employed the Acuros XB dose calculation algorithm and was 
used to compute sliding window fixed beam IMRT and RapidArc VMAT. High and low 
modulation step-and-shoot fixed beam plans and SmartArc VMAT were computed with 
Pinnacle v9.1 treatment planning system that uses collapsed cone convolution dose 
calculation algorithm. All HT treatment plans were planned in TomoPlan v.3.1.1, which 
employs a convolution/superposition dose calculation algorithm. Fixed-beam and VMAT 
plans were generated using 10MV FFF x-ray beams with a maximum dose rate of 2400 
MU/min, while HT plans were generated with 6MV beams with a maximum dose rate of 
600 MU/min. A comprehensive analysis was completed by comparing various parameters 
grouped into tumour dose conformality, dose volume histograms and indices, and treatment 
efficiency (i.e. minimization of MUs, MLC travel distance, treatment time delivery).  
VMAT treatment plans resulted in significantly lower contralateral lung V5Gy (p < 0.05) 
compared to the HT plans, and significantly lower mean lung dose (p<0.006) compared to 
HT-5cm treatment plans. Increased MLC leaf travel used to form intensity gradients in the 
beam can lead to potential degradation of the MLC carriage over time. SmartArc resulted 
in the least MLC leaf travel, while a significant difference was found between high 
modulation step-and-shoot and the remainder of the delivery techniques. Treatment 
efficiency was evaluated by calculating treatment delivery “beam on” time and a 
significant difference was found amongst HT and fixed-beam plans compared to VMAT 
modalities (p<0.001).  
Further comparison was completed by grouping the most efficient techniques from each 
modality, both step-and-shoot plans, VMAT plans, and HT 2.5-cm and 5-cm. VMAT 
outperformed HT, with statistical superiority observed in 11 parameters. In the comparison 
between step-and-shoot and VMAT techniques, an increase in dose to the heart, esophagus 
and bronchus was observed in the VMAT plans, although insignificant. VMAT showed 
significantly improved treatment efficiency and was dosimetrically advantageous for all 
other parameters. 
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In the comparison between the two VMAT techniques, SmartArc resulted in a significant 
reduction in the total monitor units (p = 0.05), whereas a significant decrease was observed 
in the dose fall-off parameter, D2cm, (p=0.05), in RapidArc treatment plans. Otherwise, 
RapidArc and SmartArc performed comparably. Although all techniques had clinically 
acceptable treatment plans, VMAT was dosimetrically advantageous in treating early-stage 
NSCLC with SABR as it provided the optimal trade-off between dose conformality and 
sparing of normal tissue, and treatment efficiency. Based on the results of this study, 
VMAT is recommended in treatment planning of early-stage NSCLC patients treated by 
SABR.  
6.1.2 Assessing the potential to reduce normal lung toxicity in 
SABR patients using respiratory-gated VMAT 
In Chapter 3, VMAT enhanced by respiratory gating was assessed for tumour motion of 5 
mm or more, identified as significant by the AAPM task group 761. Twenty patients were 
retrospectively planned using both the free breathing “untagged average” CT scan and the 
“subset average” 4D-CT data set, to represent non-gated and respiratory gated scenarios, 
respectively. The ITV in the non-gated plans was defined as the envelope of the GTVs 
delineated in all 10 phases of the respiratory cycle. In the gated plans, ITV encompassed 
only end-exhalation phases included in the subset average. Treatment planning was 
computed with 10MV-FFF x-ray beams using Pinnacle v.9.0 treatment planning software. 
Pinnacle scripts were developed to optimize all 40 plans in order to minimize dosimetric 
bias in treatment planning. Minor adjustments were sometimes necessary to fulfill dose 
limits to critical structures. The main parameters analyzed were V20Gy, predictive of 
radiation induced pneumonitis in healthy lung tissue2, and V50%, parameter used to control 
intermediate dose spillage and total volume of potential irreversible fibrosis3–5.  
There was a significant decrease in V20Gy, from (6.05 +/- 2.06)% to (5.25 +/- 1.75)% 
(p=0.00009) and V50% from (158.17 +/- 61.12) cm
3 to (125.71 +/- 49.46) cm3 (p=0.00002) 
in the gated plans. Also, there was a significant decrease in contralateral lung V5Gy, D2cm, 
MLD and total MU. However, non-centrally located lesions with motion less than 6 mm 
did not result in a significant difference in V20Gy (p=0.286) whilst a significant reduction 
was observed for V50% (p=0.04). Respiratory gated treatment delivery increased treatment 
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time by approximately a factor of 2.3 compared to non-gated VMAT delivery, and the 
application of respiratory gating should be limited only to patients with significant motion.  
The results of this study affirmed significant reduction of potential radiation induced lung 
toxicity, whilst previous studies resulted in safe delivery of respiratory gated VMAT in 
TrueBeam linacs6,7. This provides the foreground information to enable the clinical 
introduction of respiratory gated VMAT in the clinic for tumours with significant 
respiratory motion.  
6.1.3 On-board kV imaging during respiratory gated VMAT delivery 
to verify the correlation between internal tumour motion and 
external surrogate motion in patient-specific waveforms 
In Chapter 4, a method to investigate respiratory gated delivery uncertainties was 
evaluated. Respiratory gated delivery relies on the accuracy of the external surrogate 
marker to predict the correct internal target motion. Challenges arise when the internal 
motion is out of phase with the external surrogate motion, or when there are latencies in 
machine response or recording of the external motion. Several other studies have 
investigated the correlation in respiratory gating during 4D-CT acquisition8–10, before 
treatment11–13, and with the use of ultrasound14 or fiducial markers13,15,16.  Treatment 
delivery complexity is enhanced by combining respiratory gating with high dose rate 
VMAT, due to additional degrees of freedom, such as varying dose rates, and multiple 
pauses of the gantry motion. The goal was to evaluate on-board kV imaging as a tool to 
determine the internal and external correlation, and to detect phase shifts during respiratory 
gated VMAT delivery. The Quasar respiratory motion phantom, which contains a hollow 
body and drives a 3-cm delrin “tumour” sphere embedded in a cedar cylinder, was utilized 
to represent a tumour surrounded by normal lung tissue. This study was completed in 
TrueBeam Research Mode v.2.0 software to allow for computer customized kV 
fluoroscopy that was triggered only within the treatment beam gating window. VMAT 
treatment plans were delivered whilst the phantom motion was programmed using a simple 
sinusoidal conditions and five real-patient breathing conditions exhibiting variable 
respiratory motion, as characterized during 4D-CT acquisition. Treatment delivery was 
performed under free breathing non-gated, amplitude gated, and phase gated conditions. 
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For phase gating, the impact of various motion predictive algorithms was evaluated. The 
moving delrin target was automatically delineated in all kV projections and compared to 
the external platform (surrogate) motion integrated into the Quasar phantom. The external 
and internal correlation was evaluated by linear regression analysis; highest discrepancy 
(R2 = 0.919), however still a high correlation, was observed during amplitude-based gating 
for waveforms exhibiting amplitude variations. High correlation coefficients were 
observed in all deliveries, with a range of R2 = 0.950-0.997, 0.919-0.987, and 0.959-0.981 
in non-gated, amplitude and phase gated, respectively. Similarly, the correlation coefficient 
for treatment deliveries with a predictive filter threshold of 0%, 2%, 5%, and 10% ranged 
between R2 = 0.959 to 0.981, 0.938 to 0.976, 0.890 to 0.975, and 0.890 to 0.975, 
respectively. Submillimeter accuracy was found amongst the external and internal trace in 
all deliveries. During treatment on-board kV imaging provides for a tool to verify 
respiratory gated treatment.  
Two independently programmed phantoms were used to determine if on-board kV imaging 
technique can accurately identify known artificial phase shifts. The motion of the external 
surrogate, from the second phantom, was shifted at intervals of 0.4 seconds in a sinusoidal 
waveform with a four second period, to the internal motion of the Quasar motion phantom. 
Retrospectively, shifts were measured by maximising the correlation coefficient. The mean 
correlation increased from 0.229 ± 0.14 to 0.974 ± 0.03 after shifting the respiratory trace 
of the original phantom. The measured and known shifts did not reveal a significant 
difference (p=0.899, R2=0.997).  
This study was completed using TrueBeam Research Mode, and was limited to respiratory 
motion phantoms. However, real-patient breathing waveforms of various irregularity and 
various gated treatment delivery modes were programmed and assessed. In all scenarios, 
during treatment on-board kV imaging method was validated as a way to determine the 
correlation between the internal tumour motion and external marker motion during gated 
VMAT delivery. It can also be used to determine potential phase shifts between the motions 
of the tumour and the external surrogate marker. 
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Intrafraction on-board kV imaging will be useful in daily triaging of patients and allow for 
clinical decisions to be made on the use of respiratory gated motion management on a 
patient-specific basis. Also, clinical use of kV-imaging during gated VMAT delivery could 
be used for adaptive radiation therapy where any discrepancy detected in a daily beam 
delivery may be accounted for in subsequent treatment fractions. 
6.1.4 Investigation of image quality of intrafraction cone beam CT 
for 3D verification of respiratory-gated VMAT delivery  
Chapter 4 provided a two-dimensional verification of respiratory gated delivery, whereas 
in Chapter 5, intra- treatment CBCT was assessed as a three-dimensional treatment 
verification tool. The main goal of this study was to assess detection of different size 
targets, and image quality in intrafraction CBCT that is influenced by MV scatter. The 
range of the targets examined, 0.5-cm to 3-cm in diameter, coincide with typical lesion size 
in early-stage NSCLC patients. A “reference” CBCT of a stationary phantom was 
reconstructed using on-board kV-projections acquired simultaneously during MV 
treatment delivery of a 225° partial arc VMAT SABR treatment, using imaging parameters 
of 100 kVp, 20 mA, 20 ms and source to detector distance of 150 cm. Image quality and 
detectability were compared between this CBCT, and CBCT acquisition using a 360° arc 
acquired without MV scatter degradation. Then, imaging parameters were varied in order 
to evaluate image quality and detection of the targets while reducing imaging dose. For the 
static phantom, variable energy (80 kVp and 125 kVp), current (10 mA and 40 mA), and 
the source to detector distance (140 cm and 160 cm) were considered. Each acquisition was 
reconstructed using filtered back projection with a hamming filter. Imaging quality was 
defined as the improvement in the contrast-to-noise ratio (CNR), whereas detectability was 
defined by calculating the full-width-half-maximum (FWHM) of each of the spherical 
targets. 
A significant reduction in image quality was found in reconstructed CBCTs with 80 kVp 
and 10 mA compared to the CBCT acquired without MV scatter contribution, the high 
energy of 125 kVp acquisition, and high current 40 mA acquisition. However, no 
significant difference was observed in image quality between the CBCT acquired with the 
reference imaging parameters with and without MV scatter. All targets were identified with 
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the exception of the 0.5-cm sphere in the 80 kVp acquisition. The reference acquisition, 
along with three sets of acquisitions obtained using low energy (80 kVp), low current (10 
mA), and the greatest distance between the kV source and the detector (160 cm), were 
reconstructed using OSC-TV algorithm for iterative CT reconstruction. CNR significantly 
improved in all deliveries reconstructed with iterative reconstruction. No significant 
difference was observed in image detectability with all targets accurately identified.  
Real patient breathing traces with periodic motion, motion exhibiting a baseline drift, and 
motion with a baseline shift were programmed on the Quasar motion phantom with cedar 
insert embedded with polystyrene “tumour” spheres. For each motion scenario, projections 
were acquired using the reference imaging parameters during a free breathing non-gated, 
amplitude gated, and phase gated VMAT delivery during SABR. Respiratory motion 
induced artifacts in the detection of the different targets and image quality were examined. 
Detection of the target was identified as the volume percent difference (VPD) between 
respiratory motion targets, and static targets obtained with reference imaging parameters. 
A significantly lower CNR was measured in free breathing ungated conditions 
encompassing the full blur of motion, compared to amplitude gating (p=0.001) and phase 
gating (p<0.001), whereas, amplitude gating and phase gating did not reveal significant 
differences (p>0.05).  
This study has provided for verification of respiratory gated CBCT during treatment 
delivery. In most of the CBCT reconstructions, the smallest target at 0.5-cm remained 
visible, despite MV degradation on the acquired projections. Tarnished visibility was 
observed in free-breathing ungated on-board kV CBCT, but triggered respiratory gated on-
board kV CBCT reduced motion artifact. Intrafraction volumetric datasets can be applied 
to respiratory gated SABR patients with potential applicability in adaptive radiotherapy. 
Adapting treatment dose distribution based on intrafraction CBCT will allow for accurate 
presentation of the true anatomy.  
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6.2 Future work 
6.2.1 Simultaneous kV and MV imaging during treatment  
6.2.1.1 Three dimensional motion calculation during respiratory 
gated delivery  
In Chapter 4, internal and external correlation was investigated using only on-board kV 
imaging in two-dimensions. Interlaced MV imaging can provide for a three dimensional 
tracking of the respiratory trace during respiratory gated VMAT delivery. The EPID 
detector is located perpendicular to the kV detector and can acquire imaging at 90° 
simultaneous to on-board kV imaging. Customized kV imaging points can be triggered as 
a function of cumulative dose, while simultaneously, cine MV imaging can be acquired. 
Real patient breathing is predominantly in the superior-inferior (SI) direction, however in 
40% of the treatments, motion is dominant in the anterior-posterior (AP) direction or the 
right-left (RL) direction17. Simultaneous kV and MV imaging, will provide a three 
dimensional position of the target in space. Consecutive acquisitions can be used to extract 
the respiratory trace in the SI, AP, and RL of the internal target to compare to the external 
surrogate box location in respiratory gated treatment delivery.  
6.2.1.2 Simultaneous portal dosimetry and image verification  
The synchronous kV and MV imaging technique described above can be used for any 
treatment verification, and is not limited to respiratory gating based delivery. The on-board 
kV imaging allows for an anatomical verification to ensure patients are properly aligned, 
whereas, the interlaced MV imaging permits for a dosimetric verification of the true dose 
delivered to the target. In TrueBeam Research Mode, continuous MV can be acquired in 
dosimetry mode, while kV radiographic projections are programmed every 1° of gantry 
rotation. The integrated MV image is a beams-eye-view (BEV) overlap of the exit fluence. 
Portal images can be calibrated as defined by 1 calibrated unit (CU) is equal to 1 Gy for 
10x10 cm field size at 100 cm source-to-imager-distance18. The MV portal images can be 
compared to treatment dose distribution for variations in treatment dose delivery. Whereas, 
the simultaneous kV projections can be reconstructed, as described in Chapter 5, to allow 
for anatomical verification to the planning CT.  
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Ren et al19 discussed the combination of kV and MV imaging as a target verification tool 
by reconstructing volumetric imaging during treatment by the use of a priori information. 
The technique described increased the number of projections acquired, leading to improved 
image contrast while maintaining low imaging dose low in a non-clinical format. Whereas, 
the study being suggested here, includes the combination of kV and MV imaging for a 
dosimetric and anatomical intrafraction verification.  
 
6.2.2 MV scatter characterization during kV acquisition 
Chapters 4 and 5 exploit kV imaging as an intrafraction treatment verification method. 
However, the implementation of kV imaging, simultaneous with active MV treatment 
beams, cannot ignore the impact of the MV scatter and potential head leakage to the kV 
detector and, hence, the resulting image degradation. Wallace et al. investigated the kV 
signal to the kV detector as a ratio to the MV signal scattered to the kV detector in various 
frequencies of the kV source, and patient sizes20. We have performed preliminary work to 
quantify the scattered dose to the kV detector from the MV source. A 10X FFF beam with 
8 cm by 8 cm field size was used to deliver 3000 MU while the kV source to detector 
distance was 100 cm, located perpendicular to the MV beam. Transmission of the kV 
source was reduced by placing a lead block in the path of kV source and limiting the 
imaging parameters to 40 kVp, and 0.4 mA. Patient scatter of the treatment beam was 
simulated using the Quasar motion phantom (Modus Medical Devices, London, ON). 
Scattered dose was measured using ten optically stimulated luminescence dosimeters 
(OSLD), placed linearly along the on-board kV detector (Figure 6-1). 
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Figure 6-1. Scattered dose to the kV detector experimental setup. 
The exposed OSLD were read using microStar InLight Reader (Landauer Inc, Glenwood, 
IL). The dose measured to the OSLD ranged between 1.04 cGy at the top of the detector, 
to 3.55 cGy at the bottom of the kV detector, with the center of the detector receiving 2.75 
cGy, Figure 6-2.  
 
Figure 6-2. Scattered dose to the kV detector ranged between 1.04 at the top, to 3.55 cGy 
at the bottom of the detector. 
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 In Appendix B, a theoretical calculation of the estimated fraction of dose detected by a 
pixel in the kV detector was presented. According to the calculations, 3000 MU delivery 
will lead to 0.52 cGy to the kV detector at the centroid pixel, approximately 5 times less 
than measured in the OSLD experiment, 2.75 cGy. Despite the discrepancy between the 
calculated and measured values, both are low in comparison to the dose at isocentre, 3000 
MU. The scattering volume in the measurements was a phantom composed of different 
density material, such as acrylic, cedar, and delrin, whereas the calculations were based on 
mimicking beam calibration by using a water phantom with isocentre at 5-cm depth. Also, 
in the calculated value of Appendix B, charged particle equilibrium was assumed, and in 
the measured values, the OSLD were placed directly on the kV detector without a build-
up layer. Other potential sources for discrepancy in the measured values are head scatter, 
secondary scatter of photons, OSLD energy dependence, and backscatter from the 
treatment couch.  
Although this preliminary work provides an estimation, a more accurate Monte Carlo 
calculation that accounts for the different spectra of kV energies and MV energies is 
required. The MV scatter can be characterized based on the kV detector material and 
thickness, and the kV and MV beam pulse rate. This information may be used to 
retrospectively remove MV scatter from kV projections and improve image quality. 
Studies have investigated removing the MV scatter by the read-out of unexposed frames 
between kV exposures through external hardware21,22, interlacing kV projections in 
Research Mode without impact from the MV beam23, and by using a lead collimator on the 
kV source to estimate MV scatter24.  
6.2.3 Clinical implementation of intrafraction kV imaging 
A main clinical limitation in results of chapters 4 and 5 is the inability to trigger kV imaging 
solely in the gating window in clinical operation mode. Both studies were completed using 
TrueBeam Research mode only, which allows for user defined imaging trajectories but is 
not approved for clinical use.  
Current clinical implementation of intrafraction kV imaging can be achieved through single 
projection images triggered at the entry or exit of the gating window, or fluoroscopy 
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throughout the entire treatment session, regardless of MV beam-on or -off.  Triggered kV 
imaging at the entry or exit of the gating window will not supply a treatment verification 
simultaneous to the treatment MV beam, whereas, kV fluoroscopy will. However, the 
current kV fluoroscopy mode does not decipher between MV beam-on or -off with kV 
imaging continuously acquiring. Therefore, the imaging dose in kV fluoroscopy could be 
unacceptably high during respiratory gated delivery depending on the treatment time and 
the duty cycle. Also, projections acquired outside of the gating window are not useful for 
intrafraction verification but could be utilized to deduce accurate volumetric 
reconstructions absent of MV degradation.  
6.2.3.1 Adaptive radiotherapy application 
Future upgrades to include advanced imaging in clinical mode by allowing respiratory 
gated triggered kV will permit the implementation of methods examined in Chapters 4 and 
5 to be translated into intrafraction verifications for early-stage SABR patients. Early-stage 
NSCLC patients treated with VMAT will be enrolled in the study, and will undergo 
respiratory gated kV imaging. Based on the projections, the external marker motion will 
be retrospectively correlated to the internal target motion. This analysis will provide a 
respiratory gated treatment verification. The kV projections acquired, will be reconstruct 
into during treatment gated-CBCT. Gated-CBCT and the planned dose distribution can be 
overlapped to certify accurate dose delivery throughout a treatment course. CBCT acquired 
for all treatments will monitor day-to-day variations and provide a dataset to re-optimize 
treatment planning for subsequent treatments. This process can help eliminate the need to 
re-acquire 4D-CT simulation for treatment planning.  
6.2.3.2 Radiation induced lung toxicities in respiratory gated SABR 
patients  
Chapters 3 of this thesis discussed potential reduction in radiation induced lung toxicity 
using respiratory gated VMAT. While in Chapter 5, image quality and target detectability 
of intrafraction gated and ungated CBCT was investigated. During gated treatment, CBCTs 
can be used for retrospective dose calculation to provide accurate dose-volume parameters 
for clinical outcomes research. Occurrence of radiation induced pneumonitis and 
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irreversible fibrosis can be investigated in these patients by acquiring CT scans at 3 months, 
6 months, 12 months, and 24 months following radiation therapy. A future study in early-
stage NSCLC patients can involve correlating volumes of pneumonitis and irreversible 
fibrosis observed in follow-up scans and respective doses to these volumes in the 
intrafraction CBCT.   
6.2.3.3 Modelling on-board kV imaging in treatment planning 
system 
The pitfalls of intratreatment kV imaging is the additional dose to the patient and the wear 
and tear on the kV tube and detector. Currently, acceptance testing and commissioning is 
computed during the installation of the on-board kV imaging unit to determine localization, 
and imaging quality for different anatomical sites25. Quality assurance is performed at 
frequency dependent on the test to ensure the imaging unit operates safely and 
reproducibly25. In this future works study, the spectrum of kV energies will be modelled 
based on acquisition of protocols for various anatomical sites. The half value layer will be 
measured using Unfors RaySafe Xi Mam detector (Unfors RaySafe Inc. Cleveland, OH) 
while the computed tomography dose index (CTDI) will be measured using Unfors 
RaySafe Xi transparent detector. The treatment planning system can be adapted for low 
energy kernels to allow accurate dose calculation through the beam characteristics in the 
anatomical site of kV imaging protocols. Modelling the kV beam in the treatment planning 
system will allow for the imaging dose to be accounted for. This will, in turn, result in 
adaptation of the treatment plan accordingly. 
 
6.3 Conclusions 
The main findings of this thesis are summarized as follows 
 VMAT, RapidArc and SmartArc, are dosimetrically advantageous in treating early-
stage NSCLC with SABR compared to fixed-beam and helical tomotherapy while 
providing significantly shorter treatment times. 
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 Respiratory-gated VMAT using flattening filter free technology has the potential to 
reduce the dose to normal lung, and lower the potential for inducing pneumonitis, 
and irreversible fibrotic volume when respiratory motion is a concern. 
 On-board kV imaging was used to verify the external surrogate motion and internal 
target motion correlation during respiratory gated VMAT delivery. The technique 
was used in real-patient breathing traces exhibiting regular and irregular motion, 
and in a sinusoidal trace. All treatment deliveries resulted in a high correlation 
coefficient. Known artificial phase shifts were also accurately identified with on-
board kV imaging. 
 Intrafraction CBCT can provide high quality images and detectability despite the 
presence of MV scatter. Respiratory gated CBCT, acquired by customized kV 
imaging synchronously to respiratory-gated VMAT delivery, increases image 
quality by reducing the blur of motion compared to free breathing ungated CBCT. 
The results of this thesis will provide the application of respiratory gated on-board kV 
imaging simultaneous to treatment beam delivery as a method to validate respiratory gated 
VMAT delivery while potentially enhancing clinical benefits of respiratory gating in early-
stage NSCLC patients.  
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Appendices 
A. Appendix A – Automated IMRT planning  
Treatment plans in Chapter 1 and 2 optimized in Pinnacle treatment planning systems 
(Philips Radiation Oncology, Fitchburg, USA) were computed using planning scripts to 
remove bias and optimize efficiency. Planning scripts produced for early-stage NSCLC are 
based on previous scripts written for different sites, such as head and neck. This appendix 
is adapted from previous publication titled “Automated IMRT planning with regional 
optimization using planning scripts” published in the in the Journal of Applied Clinical 
Medical Physics vol 14(1):4052 (2013) by Xhaferllari I, Wong E, Bzdusek K, Lock M, and 
Chen J.  
A.1. Introduction 
Intensity-modulated radiation therapy (IMRT) has become a standard technique in 
radiation therapy to provide more conformal dose distribution to improve tumor control 
probability and/or to reduce radiation toxicities. Currently, more than half of every disease 
site uses IMRT1–4. For some simple cases, such as localized prostate cancer or whole breast 
irradiation, various class solutions or protocols can be developed to generate an IMRT plan 
efficiently5. However, for complicated cases such as some of head and neck cancers, it is 
still time-consuming to generate optimized IMRT plans. Besides requirements of accurate 
delineations of various target volumes and organs at risk (OAR), it is often required to 
generate additional IMRT optimization structures such as dose limiting ring structures, 
manually selecting beam directions and energies, IMRT objectives and associated weights. 
These parameters are generally adjusted manually during the optimization process with 
trial and error approach, including adding additional IMRT objectives to reduce various 
cold and hot spots in the dose distribution. 
There are on-going research activities to find more efficient ways for IMRT planning6–12. 
Multicriteria optimization technique13–20 has been introduced into IMRT planning in order 
to help solve issues faced with single objective planning where a weight for each objective 
needs to be set before the plan can be optimized. However, currently, it is still time-
consuming with multicriteria optimization to generate and navigate through a large number 
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of plans in Pareto surface. Recently, multicriteria optimization has been commercialized in 
RaySearch Laboratories planning system (RaySearch Laboratories, Stockholm, Sweden)21. 
Regional optimization22 is an effective way to improve IMRT plans by emphasizing 
specific region of interests to help create high-dose gradients between target volumes and 
critical structures during optimization using relatively high importance factors on small 
region of interests. In this study, we present an iterative method that can be incorporated in 
clinical process to improve IMRT plan quality and efficiency. Specifically, we have 
implemented regional optimization in a simple iterative algorithm in a commercial 
treatment planning system (Pinnacle, Philips Radiation Oncology, Fitchburg, MA). The 
regional optimization we implemented is based on region of interest (ROI), and is not 
voxel-based, as in the original paper22. Our method is based on automatically generated 
cold and hot regions in the plan. In this work, we demonstrate that such an iterative 
algorithm is applicable to clinical sites that are generally more challenging in IMRT 
planning. The method was applied to three clinical sites: head and neck, prostate with 
pelvic nodes, and anal canal cancers, where we evaluated its efficacies and time savings. 
In principal, this method can also be used for other sites to automate IMRT planning 
processes using planning scripts in treatment planning systems. 
 
A.2. Material and Methods  
A.2.1. Overview 
For each clinical site, a class solution was first developed manually based on a group of 
clinical cases. The class solution provides standard beam parameters such as number of 
beams, their energies, directions, collimator angles, jaw positions, and initial IMRT 
objectives and corresponding weights. After a class solution was developed for a clinical 
site, the entire optimization process was incorporated in a planning script. The planning 
script includes the major activities shown in Figure A-1. For the purpose of providing 
concrete methodologies, we will explain each of the optimization steps using the National 
Cancer Institute of Canada Clinical Trials Group head and neck clinical protocol (NCIC 
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CTG HN.6) as an example. This is a good clinical site to illustrate how to automate regional 
IMRT optimization with many OARs and multiple target volumes.  
 
Figure A 1. An overview of the steps completed by each script for a clinical site 
 
A.2.2. Check required regions of interest 
The IMRT scripts require basic regions of interests (ROIs) to be defined, such as all clinical 
target volumes (CTVs) and all organs at risk (OARs). For example, for the NCIC CTG 
HN.6, the following ROIs are required: CTV70, CTV63 and/or CTV56, where 70, 63, and 
56 are the prescription dose in units of Gray for each volume, with intended doses delivered 
in 35 fractions. Other required ROIs are: cord, brain_stem, right parotid (rt_parotid), left 
parotid (lt_parotid), larynx, mandible, rt_cochlea, lt_cochlea, oral_cavity, and one for the 
body contour (external). Standard nomenclature is required by the script. 
It is important to ensure all the required ROIs are present, so that the script can set proper 
IMRT objectives for these ROIs. The script will check for the required dose matrix and 
ROIs. If any of the ROIs are missing, it will display names of missing ROIs, in order for a 
user to add or correct the names of required ROIs. If all the required ROIs are present, the 
script will set standard colors for ROIs to facilitate quality assurance. 
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A.2.3. Generate additional contours  
After checking for the required ROIs, the iterative algorithm will generate various derived 
contours such as planning target volume (PTV) for each CTV, planning organ-at-risk 
volumes (PRVs) for required OARs, and various dose-limiting ring structures for IMRT 
optimization purpose. For the head and neck IMRT clinical trial, Table A-1 gives a 
summary of all the contours generated. 
Table A-1. Summary of all the contours generate for HN6 clinical trial 
Contour name Explanations Contour name Explanations 
PTV70 Planning target volumes for 
70, 63 and 56 Gy prescription 
doses 
TPTV Total sum of all PTVs 
PTV63 cord_prv Planning risk volumes for cord 
and brainstem with a 5 cm 
uniform margin 
PTV56 brainstem_prv 
modPTV70 PTVs that exclude cord_prv, 
brainstem_prv and not closer 
to the external contour by 5 
mm 
rt_parotid_opt Parotid volumes avoiding PTVs 
modPTV63 lt_parotid_opt 
modPTV56 external_5mm Body contour with a 5 mm margin  
optPTV63 Optimization PTVs, avoiding 
overlap volumes with higher 
prescription doses 
ring70 1 cm ring around PTV70 
optPTV56 ring63 1 cm ring around ring70, and 
PTV63 
optPTV63_m Optimization PTVs, avoiding 
overlap volumes with higher 
prescription doses with a 1 cm 
margin 
ring56 1 cm ring around ring63, and 
PTV56 
optPTV56_m ring50 1 cm ring around ring56 
The script generates derived ROIs for OARs, such as cord_prv and brainstem_prv with 5 
mm margin from cord and brain stem, respectively. Other generated PTVs are modPTV70, 
modPTV63, and/or modPTV56 that exclude cord_prv, brainstem_prv, and are away from 
skin by a 5 mm margin. Their purposes are to limit the dose to spinal cord and brain stem 
to within tolerance and reducing skin dose. Also, it generates optPTV63 and/or optPTV56 
that avoids overlapping with higher dose PTVs, such as optPTV63 = modPTV63 - 
modPTV70 for optimization purpose. Rings with 1 cm uniform margin around PTVs 
and/or other rings, such as ring70, ring63, and/or ring56, are created for creating a more 
conformal dose distribution by specifying a maximum dose in each ring structure. In order 
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to reduce dose to critical structures such as the parotids, rt_parotid_opt and lt_parotid_opt 
are generated that avoid the PTVs so that more realistic objectives for IMRT optimization 
can be set. Total sum of the PTVs, TPTV, is generated in order to help define optimal beam 
geometries. 
A.2.4. Add beams 
A summary of the six different fields used for HN.6 with their respective couch, gantry, 
and collimator angles is given in Table A-2. Beams are added according to the class 
solution with fixed jaw sizes based on the PTV coverage and OAR sparing to reduce local 
minimum problem in IMRT optimization and to improve delivery accuracy and efficiency. 
TPTV (defined previously) is used to adjust beam geometry that covers the desired 
volumes. Beam geometry is set by setting the collimator, gantry, and couch angles, and 
setting the jaw sizes. The jaw sizes for LAO and RAO fields in Table A-2 were set to cover 
the total PTV with 8 mm margin, but it is limited to less than 14.5 cm in order to avoid 
beam splitting on Varian linacs. Thus, only the side of TPTV where beam direction is along 
the boundary of TPTV and parotids is made sure to be covered by the fields so that the 
field edge can provide higher dose gradient between TPTV and parotids. This jaw size is 
also set to avoid junction of the multileaf collimator (MLC) inside the fields to reduce 
delivery uncertainty. However, two noncoplanar beams, LSAO and RSAO, are added to 
cover the whole TPTV with fixed jaw size to avoid beam splitting and to provide dose 
gradients required for both sides of TPTV. The use of noncoplanar beams is to cover lower 
neck nodes but avoid irradiation to shoulders. The advantage of using fixed jaw size for 
large IMRT target volumes in the head and neck was discussed in a recent publication23. 
As shown in Figure A-2, two posterior oblique fields cover the PTVs only from one side 
and shield part of the post neck region with only 2 cm jaw position from central axis for 
easier MLC segmentation to reduce dose to spinal cord and brain stem.  
After the beam geometry is defined, the proper dose prescription is set. In the case of HN.6, 
the prescription dose is 70 Gy in 35 fractions to a reference point at the center of GTV. The 
script will check for the position of the isocenter; this isocenter will be used in all beams. 
The isodose lines will also be set using standard percentages of prescription with standard 
colors.  
 147 
 
A similar procedure was carried out to implement class solutions for the high risk prostate 
cancer and anal canal cancer cases. 
Table A-2. Summary of beams generated for HN. 6 
 Gantry angle  Collimator 
angle 
Couch angle 
LSAO (left superior anterior oblique) 75 ˚ 0 ˚ 15 ˚ 
LAO (left anterior oblique) 15 ˚ 15 ˚ 0 ˚ 
LPO (left posterior oblique) 148 ˚ 350 ˚ 0 ˚ 
RPO (right posterior oblique) 218 ˚ 10 ˚ 0 ˚ 
RAO (right anterior oblique) 285 ˚ 0 ˚ 345 ˚ 
RSAO (right superior anterior 
oblique) 
345 ˚ 350 ˚ 0 ˚ 
 
Figure A 2. Jaw positions for IMRT fields are fixed in the scripts to reduce probability of 
local minimum to avoid beam splitting for more accurate and efficient radiation delivery 
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A.2.5. Initial optimization 
IMRT parameters are set in the script, including the maximum number of iterations, the 
maximum number of control points, minimum segment MU, and area. Then, IMRT 
objectives and their respective weights are set for the initial optimization using direct 
machine parameter optimization (DMPO) in Pinnacle. The IMRT objectives used for HN.6 
are given in Table A-3. Higher weights are given to minimum dose of CTVs and modified 
or optimization PTVs (modPTV70, optPTV63. and optPTV56) to ensure proper dose 
coverage of CTVs and PTVs that are away from skin by 5 mm. However, we specified 
lower maximum doses with low weights to the original PTVs to ensure that MLC will open 
around PTVs, since part of PTVs may be too close or outside patient skin. This will ensure 
sufficient skin flashing without unnecessary high skin dose. If any CTV is right on the skin, 
bolus will be used to make sure proper dose coverage. After IMRT objectives are specified, 
the dose is calculated and the first optimization is then started. 
Table A-3. Some of the IMRT objectives set for the first optimization for HN.6 
ROI name Objective type Dose (cGy) Weight 
CTV56 Minimum dose 5700 100 
CTV63 Minimum dose 6350 100 
CTV70 Minimum dose 7100 10 
modPTV70 Maximum dose 7690 100 
modPTV70 Minimum dose 7000 65 
optPTV63 Maximum dose 6720 70 
optPTV63 Minimum dose 6450 80 
optPTV63_m Uniform dose 6550 5 
optPTV56 Minimum dose 5700 100 
optPTV56_m Maximum dose 6125 100 
optPTV56_m Uniform dose 5650 1 
PTV56 Minimum dose 2800 1 
PTV63 Minimum dose 3200 1 
PTV70 Minimum dose 3000 30 
brainstem Maximum dose 5000 100 
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brainstem_prv Maximum dose 5500 33 
cord Maximum dose 4000 100 
cord_prv Maximum dose 4500 70 
mandible Maximum dose 7000 100 
lt_parotid_opt Maximum EUD 2350 20 
ring50 Maximum dose 5000 10 
ring56 Maximum dose 5600 100 
ring63 Maximum dose 6300 50 
ring70 Maximum dose 7000 100 
 
A.2.6. Regional optimization 
We implemented the regional optimization to reduce hot and cold spots in IMRT dose 
distributions automatically in a simple iterative manner.  
A.2.6.1. Generating regional cold and hot spots 
After initial IMRT optimization and the final dose calculation using collapsed cone 
convolution for the first pass, various isodose lines related to the minimum doses to PTVs, 
maximum doses inside or outside PTVs are converted to contours in the iterative algorithm. 
Then, the corresponding cold or hot spots in each region are generated, such as in HN.6, 
cold56, cold63, cold70 for cold spot in optTV56, optPTV63, and modPTV70, respectively. 
Each cold spot is automatically generated in the script by subtracting the required minimum 
isodose line (converted to contour) from the target volume. For example, cold70 = 
modPTV70 - 70 Gy isodose line. Similarly, hot56, hot63, hot70, hot_out_70 is the hot spot 
in optPTV56, optPTV63, PTV70, and outside PTV70, respectively, and they are generated 
automatically by the script. For example, hot63 = maximum isodose line allowed in PTV63 
- PTV70 - ring70. The reason to subtract higher dose ring ROIs is to avoid conflict with 
minimum dose coverage of higher dose PTVs. The regional cold and hot spots for HN.6 
clinical protocol are listed in Table A-4 with their relations to various ROIs and isodose 
lines. Similar cold and hot spots based on the prescription of each PTV are added for 
prostate with pelvic nodes and anal canal cases.  
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Table A-4. Summary of regional cold and hot spots for HN.6 clinical protocol. 
A.2.6.2. Iterative optimization with regional cold and hot spots 
IMRT objectives for these cold and hot spots are then added for regional optimization in 
the scripts — for example, objectives listed in Table A-5 for HN.6 protocol. The IMRT 
plan is then continually optimized with these added regional objectives based on previously 
optimized and segmented plan using DMPO. In this re-optimization, only MLC segment 
shape and weights are re-optimized. The HN.6 script uses 20 iterations. The generation of 
various hot or cold spots and re-optimization can be repeated multiple times until an 
optimal plan is achieved. 
Table A-5. Summary of objectives set for the regional optimization for HN.6 clinical 
protocol 
ROI name Objective type Dose (cGy) Weight 
hot_out_70 Maximum dose 6800 100 
hot63 Maximum dose 6650 50 
hot56 Maximum dose 5880 5 
hot70 Maximum dose 7350 1 
cold70 Minimum dose 700 100 
cold63 Minimum dose 6300 50 
cold56 Minimum dose 5600 10 
ROI name Relation to ROI of isodose lines 
hot_out_70 70 Gy isodose line – PTV70 – ring70 
hot63 69.3 Gy isodose line – PTV70 – ring70 
hot56 61.6 Gy isodose line – PTV70 – PTV63 – ring70 – ring 63 
hot70 75.6 Gy isodose line 
cold70 modPTV70 – 70 Gy isodose line 
cold63 optPTV63 -  63 Gy isodose line 
cold56 optPTV56 -  56 Gy isodose line 
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A.3. Results  
The method has been implemented and tested for three clinical sites: a clinical trial protocol 
for head and neck cancer, prostate cancer with pelvic nodes, and anal canal cancer. Figure 
A-3 shows DVH comparison for a head and neck case between a previously manually 
optimized clinical plan and the automatically optimized IMRT plan using the automatic 
iterative method. A manually optimized plan was used for comparison in this study and the 
plan was previously optimized by an experienced dosimetrist for clinical use. As shown in 
Figure A-3, the automatically generated plan has lower dose to the three most sensitive 
critical structures: brainstem, spinal cord, and the left and right parotids with similar PTV 
coverage. The comparison of dose distributions on an axial slice is shown in Figure A-4, 
showing fewer hot spots in the automatically optimized plan. 
As an example, the effect of regional optimization is shown in Figure A-5 for comparison 
of dose distributions before and after regional optimization using the cold and hot spots for 
a head and neck case.  
 
Figure A-3. DVH comparison for a head and neck case between manually (dashed line) 
and automatically generated plans (solid line). 
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Figure A-4. Comparison of dose distribution on a transverse slice for a head and neck case 
between manually generated IMRT plan and automatically generated IMRT plan using the 
iterative method. Red shaded volume is PTV70 covered by 70 Gy isodose line in blue, and 
green shaded volume is PTV63 covered by 63 Gy isodose line in black. 
 
Figure A-5. Comparison of dose distribution on the coronal slice for a head and neck case 
before (left) and after (right) automated regional optimization. Shaded volumes are PTV70 
(blue), PTV63 (green), and PTV56 (red), respectively. 
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Table A-6. Estimated time required to generate IMRT plans 
 Manual Planning Automated Planning 
Head and Neck > 4 hours ~ 8 minutes 
Anal Canal > 2 hours ~ 6 minutes 
Prostate with pelvic nodes > 1.5 hours ~ 6 minutes 
The time required to run the planning script on a Pinnacle thin client using computation 
server with 4 quad core 2.9 GHz CPU is listed in Table A-6. The estimated minimum time 
required for manual planning includes time needed to generate various derived contours, 
set up beams, dose prescription, manually and repeatedly adjust IMRT objectives, and 
running IMRT optimization. It shows that the iterative method implemented here as a script 
can save significant time in IMRT planning. These IMRT planning scripts are used 
clinically in our center for more than 500 clinical cases since they were implemented 
clinically in 2010. They include at least 300 head and neck cases, 180 prostate cases, and 
20 anal canal cases. It should be noted that after using automated planning scripts, most 
cases will be tweaked by dosimetrists to see if further improvements can be made. 
However, most tweaking just needs a few more passes of the continuous optimization that 
usually take less than an hour. The estimated time saved in planning for each case is at least 
2 hours for head and neck, and 1 hour for anal canal or prostate with pelvic nodes, 
depending on the experience of the planner. 
 
A.4. Discussion 
The present work implemented planning scripts for complex IMRT cases that automated 
most aspects of plan optimization which otherwise required continual manual input by a 
planner. We used Pinnacle planning script to automate the regional optimization in an 
iterative manner; however, the concept can be used in other planning systems, as well. 
Automated IMRT planning script was recently published for optimization of breast 
radiotherapy with tangential beams5. Here, we present an automated planning process for 
more complicated head and neck, prostate with pelvic nodes, and anal canal cases. It also 
includes the method to automatically reduce various cold and hot spots in the optimization 
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process. To our knowledge, such implementation for more complex IMRT cases has not 
been published before. Since the focus of this paper is on the methodology, we only present 
one example for each clinical site, even though the scripts have been used clinically for 
more than 500 cases. The thorough statistical analysis of these clinical cases will be 
presented in a separate paper. 
Since many IMRT planning steps are included in our IMRT planning scripts, they generally 
save many hours in the IMRT planning process. It also helps implement clinical protocols, 
in-house standards, using standard dose prescriptions, standard margin for PTVs, standard 
derived region of interests (ROIs), such as modPTVs, optPTVs, cord_prv, and 
brainstem_prv, as well as standard color scheme for ROIs and isodose lines. The planning 
script can reduce variations of plan quality due to different experience of planners. The 
planning scripts can be improved during clinical use, incorporating new techniques learned 
in practice.  
For many complicated cases, the IMRT planning scripts provide only a good starting point; 
an optimal plan still requires a planner to fine-tune the automatically generated plan to 
adapt the plan for individual situation. Also, the class solution does not consider geometry 
variations across patients; therefore, it requires fine-tuning for each individual patient. Such 
fine-tuning includes modifying IMRT objectives and their weights. Occasionally, beam 
parameters may also need to be modified, such as gantry or collimator angles. In future 
work we will investigate the impact of adjusting IMRT objectives and weights during the 
iterative optimization process. The regional optimization method presented in this paper 
may also be combined with priority-based IMRT optimization method24. 
A.5. Conclusions 
We have developed IMRT planning scripts for a few clinical sites to automate most of 
IMRT planning process. In particular, regional optimization has been implemented in an 
iterative algorithm to reduce hot or cold spots during the optimization process, especially 
important for complex cases. We demonstrated that this is particularly useful in IMRT 
planning for head and neck and prostate with pelvic nodes. We have shown that automated 
iterative inverse planning improves IMRT planning efficiency substantially. 
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B. Appendix B - Estimation of MV scatter contribution to kV 
detector  
The dose due to the scattered MV beam at a voxel of the kV detector was characterized 
based on theory from a paper titled “Compton scatter imaging of a transverse scatter and 
attenuations” by Battista JJ, Santon LW, and Bronskill MJ published in Physics in 
Medicine and Biology, 1977, vol. 22 (2), pp 229-2441. 
    
 
The dose scattered to 3 sample voxels (a,b,c) of the cesium iodide array scintillator on the  
amorphous silicon flat panel detector was calculated for a non-divergent beam incident on 
a cubic water phantom. The geometry of the setup mimics beam calibration of monitor 
Figure B.1. Schematic of Compton scattering to pixels (a, b, or c) of the on-board kV detector.  All 
symbols and parameter values are defined in the Table below. 
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units to dose at 100 cm source-to-axis distance (SAD), with a 10 cm x 10 cm field size at 
5 cm depth in water:  
𝐷𝑖𝑠𝑜 = 𝑀𝑈 × 
1.00 𝑐𝐺𝑦
𝑀𝑈
 
Voxel ‘P’, located at the center of the phantom, was used to represent a typical scattering 
element of the scattering volume (blue). The scattering contribution was calculated at 
voxels on the kV detector located in the center (a), top center (b), and bottom center (c), as 
shown in Figure B.1.  
The fluence of photons (i.e. per cm2) scattered by a voxel at P with area, a, and thickness, 
z, then arrive at a pixel area (d2) on the kV detector panel was deduced as follows:  
Φ𝑑𝑒𝑡
𝑣𝑜𝑥𝑒𝑙 =  
Φ𝑖𝑠𝑜 
𝑑𝜎
𝑑Ω 𝑑Ω  𝜌𝑒 𝑑𝑎 𝑑𝑧 𝑓2      
𝑑2
                                                                                    (1) 
where, assuming charge particle equilibrium (CPE), the isocentric fluence is:  
Φ𝑖𝑠𝑜 =
𝐷𝑖𝑠𝑜
𝐸0 (
𝜇𝑒𝑛
𝜌 )
𝐻2𝑂
⁄
                                                                                                             (2) 
The scattering Compton cross section is given by (Attix et al. 1986, equation 7.14)2:  
𝑑𝜎
𝑑Ω
=  
𝑟0
2
2
(
𝐸1
𝐸0
)
2
(
𝐸0
𝐸1
+  
𝐸1
𝐸0
−  𝑠𝑖𝑛2𝜙)                                                                                             (3)  
Where (Attix et al. 1986, equation 7.8)2: 
        𝐸1 =  
𝐸0
1+ (𝐸0 𝑚0𝑐2⁄ )(1−𝑐𝑜𝑠𝜙)
                                                                                                    (4) 
The solid angle subtended by a detector pixel of size d at distance L from isocentre is:  
        𝑑Ω =  (
𝑑2
𝐿2
)                                                                                                                               (5) 
The attenuation factor of the scattered photons is: 
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𝑓2 =  exp [− ∫ 𝜇(𝐸1, 𝑙) 𝑑𝑙]                                                                                                         (6) 
Next we consider the radiation scattered by all the voxels (like P) contained in the exposed 
region of the water phantom. We make the simplifying assumption that they are all well 
represented by the typical voxel at P. In reality, each scattering point has a different primary 
attenuation, scattering angle, solid angle, and secondary attenuation. We estimate the total 
scattered fluence reaching the detector pixel as follows: 
Φ𝑑𝑒𝑡
𝑣𝑜𝑙𝑢𝑚𝑒 =  Φ𝑑𝑒𝑡
𝑣𝑜𝑥𝑒𝑙  𝑑𝐴 𝑑𝑍
𝑑𝑎 𝑑𝑧
                                                                                                          (7) 
where dA is the non-divergent beam’s cross-sectional area and dZ is the phantom overall 
thickness. 
Assuming the detector material (det) is thick enough to achieve CPE, the absorbed dose at 
the detector voxel, related to pixel signal, is then given by: 
𝐷𝑑𝑒𝑡 =    (
𝜇𝑒𝑛
𝜌
)
𝑑𝑒𝑡
 Φ𝑑𝑒𝑡
𝑣𝑜𝑙𝑢𝑚𝑒  𝐸1                                                                                                  (8)                                                                   (1) 
Our ultimate step is to determine the “scatter-to-primary” ratio between the dose absorbed 
by pixels of the kV detector (assuming enough thickness to achieve CPE) and the isocentric 
reference dose: 
𝐷𝑑𝑒𝑡
𝐷𝑖𝑠𝑜
 =  𝐸1 (
𝜇𝑒𝑛
𝜌
)
𝑑𝑒𝑡
  
𝑑𝜎
𝑑Ω
 𝑑Ω 𝜌𝑒𝑓2 𝑑𝐴 𝑑𝑍  𝐸0 (
𝜇𝑒𝑛
𝜌
)
𝐻2𝑂
 𝑑2⁄                      (9)  
All parameters and units used in the calculation are summarized below:  
Φ𝑑𝑒𝑡
𝑣𝑜𝑥𝑒𝑙 Photon fluence due to scatter events originating in a small voxel at P (cm
-2).  
Φ𝑑𝑒𝑡
𝑣𝑜𝑙𝑢𝑚𝑒 Photon fluence due to scatter events originating from all P-like voxels in the 
exposed phantom volume (cm-2). 
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𝑑𝑎 Cross sectional area of the voxel P (cm2). Assumption:  Area 1 cm x 1 cm.    
𝑑𝑧 Thickness of the voxel P (cm). Assumption: 1 cm.   
𝑑𝐴 
Cross sectional area of the incident beam (cm2).  
Assumption: field size 10 cm x 10 cm of a non-divergent beam. 
𝑑𝑍 Thickness of the scattering phantom volume (cm). Assumption: 10 cm.   
Φ0 Photon fluence rate at isocenter of the incident beam (cm
-2). 
𝐷𝑖𝑠𝑜 Dose to water at isocenter (cGy). 
𝐸0 
Energy of incident photons. Assumption: 10 MV x-ray beam. Assumption: Effective 
monoenergetic source, with mean energy was calculated: 10 ×
1
3
= 3.333 𝑀𝑒𝑉 
(
𝜇
𝜌
)
𝐻2𝑂
 
Mass attenuation coefficient of water (cm2/g). 
𝐷𝑑𝑒𝑡 Dose at the kV detector voxel (cGy). 
𝐸1 Energy of scattered photon. 
(
𝜇𝑒𝑛
𝜌
)
𝑑𝑒𝑡
 
Mass energy absorption coefficient of the cesium iodide scintillator on the kV 
detector (cm2/g). 
𝑓2 Scattered beam attenuation factor.  
𝑙 Scattered photon path length in the phantom (cm). For the central voxel (a) of the 
detector, l = 5 cm, whereas for the top (b) and bottom (c) voxel, calculated based on 
the size of the kV detector, D, and scattering angle, 𝜙. 
𝑑𝜎
𝑑Ω
 
Klein-Nishina differential cross-section for the incident beam (cm2 e-1 sr-1).  
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𝑟0 Classical electron radius: 𝑟0 =  
𝑒2
𝑚0𝑐2
= 2.818 𝑥 10−13 cm.  
𝜙 Photon scattering angle (radians). For the central voxel (a) of the detector, 𝜙 = 
𝜋
2
 , 
whereas for the top (b) and bottom (c) voxel, calculated based on the size of the kV 
detector, D, and the distance from to kV detector, L:  𝜙 = 𝑡𝑎𝑛−1 (
𝐷/2
𝐿⁄ ) 
𝑚0𝑐
2 Rest energy of an electron is 0.511 MeV 
𝑑Ω Solid angle to the kV detector (sr). 
d Size of the height, width, or thickness of the voxel at the kV detector (cm) 
L Scattered photon path length to the voxel in the kV detector (cm). 
𝜌𝑒 
 
Electron density of water: 
𝜌𝑒 = 3.343 𝑥 10
−23(𝑒 𝑔−1)(𝑒 𝑔−1) × 0.9982  (𝑔 𝑐𝑚−3) 
                      = 3.337 𝑥 10−233370 (𝑒 𝑐𝑚−3)         
 
The dose scattered to the central voxel (a), top voxel (b), and bottom voxel (c) on the kV 
detector per unit isocentric dose was 1.74 x 10-4, 1.73 x 10-4, 1.54 x 10-4, respectively, or 
0.0174%, 0.0173%, and 0.0154%. This calculation provided for an estimation of the dose 
ratio to the kV detector. Intra-fractional imaging synchronous to the MV beam, as 
investigated in Chapters 3 and 4 of this thesis, is tarnished by the MV scatter acquired at 
the kV detector. Further analysis to characterize the MV scatter in the kV detector, as 
described in Section 6.2.2 of Chapter 6, can aid in improving image quality in during 
treatment imaging.  
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